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Benign prostatic hyperplasia (BPH) is a common disease of aging men and the
development of lower urinary tract symptoms (LUTS) secondary to BPH is believed
to be caused by both a static and dynamic component to bladder outflow obstruction
(BOO). The static component is attributed to the mass effect of the enlarged
adenoma, whereas the dynamic component is related to the smooth muscle tone
within the prostate. The prostate is a heterogeneous organ and comprises three
distinct anatomical "zones". The formation of stromal and glandular nodules is the
histological hallmarks of BPH and occurs in the transition zone. The mechanical
properties of benign prostate tissue obtained from transurethral resection (TURP)
have been shown to reflect the underlying morphology with respect to smooth
muscle content. To further investigate the structure-property relationship in benign
prostate tissue, specimens from TURP and whole prostates from cystoprostatectomy
were examined. The use of transverse sections of the whole gland allowed
morphometric and mechanical studies to be performed in all regions of the prostate.
A novel method of morphometric analysis representative of the local area of tissue
that was subjected to mechanical testing was developed. Significant correlations
were shown between the mechanical and morphological properties of glandular and
stromal nodules. Glandular nodules may contribute to the pathophysiology of BPH
by altering the dynamic characteristics of the prostate in addition to producing a mass
effect.
In parallel to the above aforementioned work in whole prostates, the effect of
quinazoline and non-quinazoline based alpha-blockers upon prostate tissue obtained
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Abstract
from TURP was examined. This work also investigated whether alpha blocker
therapy influenced the mechanical measurements by their action within the prostate
tissue. Significant correlations were shown between alpha blocker therapy and the
underlying morphology and this is reflected in the mechanical measurements.
These studies provide a greater understanding of the structure-property relationships
within prostate tissue and it is likely that assessment of the mechanical properties of
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The prostate gland is part of the male reproductive system. The prostate produces
alkaline fluid that is secreted into the urethra at the time of emission of semen,
providing an added medium for the life and motility of sperm.
1.1.1. Embryology and Development of the prostate
The prostate develops from the urogenital sinus, a subdivision of the cloaca. The
urogenital sinus arises during the 7th week of gestation but prostatic morphogenesis,
under the influence of circulating dihydrotestosterone (DHT), does not occur until
the 10th to 12th week. The initial event of prostatic morphogenesis is the outgrowth
and branching of epithelial buds from the urogenital epithelium into the surrounding
urogenital mesenchyme. The upper epithelial buds form the inner zone of the
prostate and are of mesodermal origin whereas the lower buds form the outer zone
and are of endodermal origin [1], The different zones are affected by differing
pathology later in life.
Throughout the development of the prostate, there are close interactions between the
stromal and the epithelial elements. Classic tissue recombination studies by Cunha et
al have demonstrated that the androgen receptors within the mesenchyme and not the
epithelium are required for normal prostate development [2, 3], Morphogenesis of
the epithelial cells and homeostasis is driven, in part, by the stromal cells in response
to DHT induction of several specific soluble growth factors in addition to alterations
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in the insoluble extracellular matrix [4, 5]. There are a wide variety of genes and
cellular pathways identified in the regulation of prostate development. These have
been recently reviewed by Leong et al [6] and Matusik et al [7].
1.1.2. Gross Anatomy of the prostate
The normal prostate weighs around 20g and resides in the pelvis. The prostate is
ovoid in shape and has anterior, posterior and lateral surfaces with a broad base
superiorly, which is continuous with the bladder neck and a narrowed apex
inferiorly, which is continuous with the urethral sphincter (see figure 1.1). The
prostate is enclosed by a thin capsule, which on the anterior and anterolateral aspects,
blends with the visceral continuation of the endopelvic fascia. At the apex of the
gland, this capsule is absent and superiorly, there is no capsule between the prostate
and bladder neck. The prostate is a relatively fixed organ with the puboprostatic
ligaments extending anteriorly to anchor the prostate to the pelvic bone. Microscopic
bands of smooth muscle extend from the posterior surface to fuse with Denonvilliers'
fascia.
The urethra traverses the whole length of the prostate and at the midpoint, the urethra
angles anteriorly by approximately 35 degrees. This angle divides the prostatic
urethra into proximal and distal segments where the majority of the glands within the
prostate open out into.
The arterial supply to the prostate arises from the inferior vesical artery and the
venous drainage from the periprostatic venous plexus. The prostate receives
16
Chapter One
































Figure 1.1: Saggital section through the prostatic and membranous urethra,
demonstrating the midline relations of the pelvic structures
1.1.3. Zonal anatomy of the prostate
The glandular elements of the prostate are tubuloalveolar epithelial glands showing
simple branching and lined with simple or columnar epithelium. The flattened basal
cells line each acinar and are the stem cells for the secretory epithelium. The stromal
elements consist predominantly of connective tissue, smooth muscle cells and
fibroblasts and serves as a structural support for the epithelial glands. The prostate
can be considered as three zones as described by McNeal [8]. Figure 1.2 shows a
graphical representation of the zonal anatomy of prostate. The transition zone (TZ)
surrounds the urethra proximal to the ejaculatory ducts and only accounts for 5-10%
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of the glandular tissue in a normal prostate. McNeal demonstrated that benign
prostatic hyperplasia (BPH) first develops in the periurethral transition zone of the
prostate [9], The central zone (CZ) surrounds the ejaculatory ducts and accounts for
20% of the prostate volume and peripheral zone (PZ) accounts for the majority of the
volume of the normal prostate in the apical, posterior and lateral aspects of the gland.
70% of prostate cancers arise within the peripheral zone. The anterior fibromuscular
stroma (AFS) is contiguous with the bladder neck to the striated external sphincter.
zone








1.1.4. Regulation of normal growth of the prostate
Once the normal prostate reaches its maximal adult size, it enters a maintenance
phase. During this phase, cell proliferation and programmed cell death (apoptosis)
occur continuously in a balanced fashion so that the size of the gland remains
constant [10]. The systems involved in this regulation of growth include steroid
hormones such as testosterone and oestrogen, growth factors, and their interactions
with the extracellular matrix. These are briefly considered below.
Steroid hormones
The testes produce 95% of the circulating serum androgen, testosterone. The
remaining 5% is from the conversion of adrenal steroids dehydroepiandrosterone and
androstenedione. With the majority of testosterone bound to sex hormone binding
globulin (SHBG), only the free testosterone is able to enter the prostate by diffusion.
Within the cell, it is converted to DHT by the enzyme, 5 a-reductase. DHT then
binds to the androgen receptor and stimulates, via a series of intracellular events, the
expression of specific genes and therefore, translation of proteins. These steps occur












Figure 1.3: Schematic diagram illustrating the intra-cellular effects of testosterone in
an epithelial cell.
Oestrogens are formed from the metabolism of circulating androgens within and out
with the cell. In canine prostate studies, oestrogens do not antagonise the androgen
effects upon the prostate, but instead have synergistic effects [11]. In human studies,
it has been shown that oestrogens have a stimulatory effect on prostatic stroma whilst
causing involution of the epithelial component [12]. Distribution of oestrogen
receptors (ER) and oestrogen binding are heterogeneous within the prostate. ER-a is
found predominantly within the stromal compartment and ER-(3 is mainly found
within the epithelial compartment and it seems that oestrogens have their main
effects upon the stromal compartment [13, 14]. However, the mechanisms of
androgen and oestrogen synergism are not well understood and it is not clear whether
anti-oestrogens could play a role in the treatment of abnormal prostate growth [15].
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Stromal and epithelial interactions
As discussed in section 1.1.1, the organogenesis of the prostate is dependent on the
important mesenchymal-epithelial interactions. The extracellular matrix, which itself
has growth factor-like properties, provides the necessary scaffolding for this two-way
flow of paracrine signals between the epithelial and stromal compartments. Cell to
cell and extracellular matrix interactions are increasingly studied to understand how
the phenotype of a cell is regulated. Getzenberg et al demonstrated that the
interactions of the extracellular matrix regulate many aspects of DNA functions
involved in cellular growth and differentiation [16].
Growth Factors
Growth factors are small polypeptides that promote or inhibit cellular proliferation
but also have other multifunctional roles in cellular regulation [17]. The cell is
prompted to synthesise a growth factor by signals such as paracrine communication
or hormonal levels. Figure 1.4 demonstrates a schematic diagram of the complex










Figure 1.4: Schematic diagram illustrating the complex interactions between
androgens and growth factors upon stroma and epithelial cells. The action of various
growth factors can be inhibited or stimulated by androgens.
There is no proven growth factor that is unique to the prostate but many growth
factors have been studied in detail. Table 1.1 summarises the growth factors that are




bFGF Basic fibroblast growth factor (prostate growth Present in normal prostate
factor, endothelial growth factor, FGF-2) Elevated in BPH
EGF Epidermal growth factor Over expression produces prostate
epithelial hyperplasia
TGF-a Transforming growth factor - a Low levels in human prostate
TGF-P Transforming growth factor - (3 Inhibitor of epithelial growth
MIS Mullerian-inhibiting substance Causes repression of mullerian
ducts
IGF Insulin-like growth factor 1 & 2 Related to proinsulin
PDGF Platelet-derived growth factor Mitogen for connective tissue cells
Table 1.1 - A summary of growth factors common to the prostate.
At least 22 family members of fibroblast growth factors (FGFs) have been
characterised and studied extensively [18]. There is recent evidence that FGF
pathways are involved in postnatal development of prostate ductal and branching
morphogenesis [19]. Androgens may work on epithelial cells via paracrine
stimulation from stromal cells [20], Sherwood et al reviewed the importance of
epidermal growth factor (EGF) in the development of normal and abnormal prostate
[21] and postulated that in conjunction with TGF-a , EGF maintains the structural
and functional integrity of BPH. Transforming growth factor [3 (TGF-[3) may
function as a braking system in negatively regulated normal prostate epithelial cell
growth while being a positive factor in stimulating normal stromal cell growth [22].
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Mtillerian-inhibiting substance is related to the TGF-[3 family and causes regression
of the mtillerian ducts. Insulin-like growth factors (IGFs), 1 and 2, are related in
sequence to insulin. IGFs exert a strong mitogenic effect on the growth of the
prostate [23], Platelet-derived growth factor (PDGF) is expressed in many tissues
and is mainly derived from platelets. PDGF has a strong mitogenic effect on
mesenchymal and connective tissue cells and cause cells to respond to other growth
factors. PDGF is postulated to be a mediator of the effects of inflammation upon
prostate growth [24]; however, these effects have not been fully elucidated.
1.2. Benign prostate hyperplasia
Benign prostate hyperplasia (BPH) is a benign pathologic process of the prostate that
is a common, but not exclusive cause, for lower urinary tract symptoms (LUTS) in
aging men.
1.2.1. Aetiology of benign prostate hyperplasia
The underlying aetiology of the development of BPH has not been clearly defined.
However, it is likely to involve several factors such as the disordered interactions
between stroma and epithelial elements and their response to androgens, oestrogens
and growth factors. The histopathologic process of enlargement of the gland is
characterised by cellular hyperplasia of epithelial and stromal cells which is a
process seen in the embryological development of the prostate. This observation
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suggests that stromal and epithelial hyperplasia in later life may be as a result of
"reawakening" of these early processes [25, 26], Cellular growth within the prostate
is dependent upon a fine balance between cellular proliferation and cellular death
(apoptosis) [27]. In the early phases of BPH, cellular proliferation may be seen but
in established disease, there is an increase in expression of anti-apoptotic pathway
genes such as bcl-2 [10, 28] rather than a increase in cellular proliferation. Also,
androgens are required for the normal development of the prostate but has also been
shown to actively inhibit apoptosis [29],
1.2.2. Pathophysiology of Benign prostatic hyperplasia
Histological features
Early work by Franks showed that the development of "fibromyoepithelial nodules"
is the morphological hallmark of BPH. The nodules were classified into 5 types
based on the morphological appearance and the relative amount of glandular and
smooth muscle content. His work highlighted, in detailed drawings, the
heterogeneity of histological composition of these nodules but concluded that the
most common type of large nodules were mainly epithelial in composition [30].
McNeal's autopsy studies demonstrated that BPH develops in the periurethral
transition zone of the prostate (see section 1 1.3). This work also noted that diffuse
enlargement of the transition zone, independent of nodule formation, was the most
common change noted with age [25]. These findings are confirmed in a later study
by Arenas et al [31]. The majority of early periurethral nodules were shown to be
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purely stromal nodules which were similar to embryonic mesenchyme. However, the
early transition zone nodules were mainly composed of glandular epithelium with a
reduction in stromal content. This is accompanied by hypertrophy of the epithelial
cells with an observed increase in height of the lining epithelium. This glandular
proliferative process leads to tight packing of epithelial glands within a given area
(see figure 1.5).
Figure 1.5: Photomicrograph of a glandular nodule (N) surrounded by stroma (S) at
x200 magnification
McNeal further described two chronological phases of nodular development. The
earlier and more common phase was characterised by an increase in small stromal
nodules within the periurethral and transitional zones. Decades later, many prostates
with BPH entered a second phase characterised by marked enlargement of glandular




Figure 1.6: Photograph depicting a transverse section of a whole prostate clearly
showing the nodular hyperplasia (N) which is a morphological hallmark of BPH.
The peripheral zone (PZ) of the prostate does not show nodular formation. The
urethra is highlighted on the image.
Following this work, many studies sought to quantitatively analyse the morphometric
composition of prostate tissue in both normal and in BPH prostates. Price et al
quantitatively examined the tissue composition from transurethral resection (TUR)
specimens and prostate enucleations. The weights of the TUR resections were
measured and it was observed that in the smaller resections (<10g in weight), bladder
neck and anterior fibromuscular tissue comprised more than half of the specimen.
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Non nodular prostatic tissue from the transition zone represented most of the resected
specimens that weighed less than 50g but greater than lOg. However, in the
specimens weighing greater than 50g, glandular nodules were found to be the
dominant component with a high epithelial to stromal (ET:SM) ratio with the purely
stromal nodules being poorly represented. The number of nodules with an ET:SM
ratio greater than one were more numerous than those with a lower ET:SM ratio,
and therefore it was suggested that these glandular nodules were more important than
stromal nodules in the pathogenesis of symptomatic BPH [32]. Work by Schuster et
al confirmed that resections of larger prostates are comprised mainly of epithelial
rather than stroma tissue [33], However, in other morphometric studies, resected
tissues from small glands were shown to be comprised of mainly stromal tissue [34,
35]. Chagas et al compared the histological components of the transition zone in
normal and BPH prostates. Smooth muscle, glandular acini and connective tissue
were quantified using computerised morphometric analysis. In BPH prostates, the
smooth muscle and connective tissue content were significantly increased compared
to the control prostates and concluded that BPH may be a predominantly stromal
disease process [36]. It is clearly evident that the prostate is a heterogeneous organ
and has anatomical regions with distinct embryological origins and specific
histological composition and these studies reflect this observation. Furthermore, an
increase in stromal to epithelial ratios may not necessarily suggest that this is a
predominantly "stromal disease". Stromal proliferation may well be due to
"epithelial disease" as a result of disordered stromal to epithelial interactions.
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The role ofprostatic smooth muscle
Historically, the mass effect of prostate enlargement was thought to be the main
cause for bothersome lower urinary tract symptoms, as this was based upon
epidemiological data suggesting that the prevalence of BPH and clinical BPH is age
dependent and therefore causally related [37]. This hypothesis was supported by the
clinical evidence that surgical removal of prostate bulk improved LUTS in many
patients [38], However, Caine et al, first postulated that adrenergic mediated tone
within the prostate musculature, may explain the variations in severity of obstructive
symptoms in patients with BPH [39], The level of sympathetic stimulation of
prostatic adrenergic receptors alters smooth muscle tone in the periurethral region
and therefore affects urethral resistance [40, 41]. In addition to the increase
stimulation of smooth muscle tone in the prostate, Shapiro et al have shown that
patients with symptomatic BPH have a higher stromal to epithelial ratio compared
with asymptomatic patients [35]. This group further demonstrated that the response
to alpha adrenergic blockers is proportional to the amount of smooth muscle within
the prostate [42], These early findings have led to the widespread use of alpha
adrenergic blockers to address the dynamic aspect of bladder outlet obstruction.
However, later studies have demonstrated that quinazoline-based alpha adrenergic
blockers increase apoptosis within the glandular and stromal elements of the prostate
and this mechanism has been suggested as an explanation for the durability of the
response in long term users of alpha adrenergic blockers [43]. The pharmacological
and functional aspects of adrenergic receptors and their blockade are considered
further in section 1.3.
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1.2.3. Epidemiology and natural history of BPH
The histological or autopsy prevalence of BPH was reported in a landmark study by
Berry et al [44], In this study the authors summarised the data from ten studies to
show that greater than 50% of men aged 50 years or over demonstrate histological
evidence of BPH, with this figure rising to 90% by the age of 85.
There is currently no universally accepted epidemiological definition of clinical
BPH. In the past decade, the definition of BPH has undergone several changes.
Historically, urinary symptoms associated with BPH were termed prostatism as it
was thought that the prostate was the sole cause. However, it was observed by Tage
Hald that there are at least three inter-related phenomena that can be assessed
independently. These are the symptoms, histological BPH and bladder outlet
obstruction (BOO) and in a given patient, all three, two of the three or only one of




Figure 1.7: Hald's rings depicting the relationship between histologic hyperplasia of
the prostate (BPH), lower urinary tract symptoms (LUTS) and bladder outlet
obstruction (BOO).
Paul Abrams coined the term lower urinary tract symptoms (LUTS) to replace the
inappropriate term ofprostatism [45], Therefore studies examining the prevalence of
clinical BPH may apply one or several of these terms in their definition of the disease
condition. The Olmsted County study showed a prevalence of moderate to severe
urinary symptoms in 13% of men aged 40-49 years and rising to 28% in men over
the age of 70 years [46], In the UK, a study by Garraway, defined clinical BPH as
the presence of an enlarged prostate (>20g) with symptoms or reduced urinary flow
rate (Qmax <15ml/s). The BPH prevalence in this study were 13.8% of men aged
40-49 years and 43% of men aged 60-69 years [47]. Despite the significantly
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different proportion ofmen with moderate to severe symptoms in many studies, there
is a clear trend toward an increase in symptom scores with increasing age.
The natural history of the disease refers to the prognosis of the disease over time.
The natural history of BPH can be obtained from two main sources, namely cross-
sectional longitudinal studies of community-dwelling men and the placebo arms of
several clinical trials. The most informative longitudinal study is the Olmsted
County Study. Recently, 92-month data which showed an annual AUA symptom
score deterioration of 0.34/year was observed across the study with the fastest rate of
deterioration in men aged 60-69 years. In addition, 6 year follow up data on
uroflowmetery measurements showed a median peak urinary flow rate decrease of -
2.1% per year. The peak flow declined more rapidly with an increasing baseline age,
prostate volume and symptom severity. The prostate growth (as measured with
transrectal ultrasound) in this cohort of men was estimated to be 0.6ml per year.
Prostate growth showed an exponential growth pattern with the growth rate of 0.4ml
per year in men aged 40-59 and of 1.2ml per year in men aged 60-79 years [48, 49],
Acute urinary retention (AUR) is a significant complication resulting from BPH,
The patient presents with the inability to void with increasing discomfort and the
requirement for catheterisation. The aetiology ofAUR is still poorly understood but
obstructive, myogenic and neurogenic causes may play a role [50]. Of the 2115 men
aged 40 to 79 years in the Olmsted County study, 57 had a first episode of AUR
during 8344 patient-years of follow up giving an incidence of 6.8/1000 patient-years
[51]. In the placebo arm of the PLESS trial, 1376 men with enlarged prostates and
moderate symptoms were followed up for four years. 99 of these men experienced a
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first episode of AUR giving an incidence rate of 1.8/1000 patient-years [52], In the
placebo arm of the MTOPS trial the incidence rate of AUR was 0.6/1000 patient-
years [53], In these two studies it was observed that the risk of AUR increases with
increasing serum PSA (PSA >1.4 ng/1 conferred an eightfold increase in risk) and
well as prostate volume (>40mls conferred a threefold increase in risk).
The need for BPH-related surgery has been studied in the Olmsted County cohort.
The overall incidence of this event is 16/1000 patient-years with a strong age-related
increase in patients 70 years old or older (rising to 30/1000 patient-years) [51]. From
the placebo arms of PLESS, the rates of surgery increased from 6.2% to 14.6% for
patients in the lowest (1.4-3.9 ng/1) to the highest PSA (>4.0 ng/1) tertile [52],
Many relevant parameters associated with BPH have been shown to worsen with
increasing age. The natural history of the disease suggests a worsening of LUTS and
BPH with time. However, there are several key baseline parameters allowing an
individual's patient's risk of progression to be stratified. Age, symptom severity,
prostate size and serum PSA are useful predictors of the risk of progression.
1.2.4. Assessment and diagnosis of clinical BPH
I
The assessment of LUTS in men leading to a diagnosis of clinical BPH is a challenge
for urologists as there are many non-prostatic causes of LUTS. Many tests and
investigations are available to the urologist for the assessment of these patients.
However, the correlation between the symptoms, clinical parameters and bladder
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outlet obstruction is variable and inconsistent [54, 55]. Taken own their own, these
assessment tools cannot be used to select the optimum therapy for a given patient and
they cannot predict the response to treatment. The investigations available to the
urologist are considered below.
Urinalysis
Urinalysis is considered to be a first line investigation and can be performed using
dipsticks. These can identify haematuria, glycosuria, proteinuria, pyuria, specific
gravity and the presence of urinary nitrites and leucocyte esterase. Abnormal
dipstick findings need to be confirmed by microscopy and culture of a mid stream
specimen of urine [56].
Structured questionnaires
Several structured symptom questionnaires have been developed but the most widely
used is the International Prostate Symptom Score (IPSS) [57]. The questionnaire
consists of seven questions relating to the symptoms of BPH and a final question to
assess the quality of life. By using this system, the patient's symptoms can be
classified as mild (0-7), moderate (8-19) or severe (20-35). However, many studies
have demonstrated a poor correlation between symptom score severity and other
indices of lower urinary tract dysfunction such as urodynamic parameters,




The recently published National Institute of Clinical Excellence (NICE) guidelines
on the management of LUTS do not recommend the routine measurement of serum
creatinine [59], If there are signs and symptoms suggestive of renal impairment such
as a palpable bladder, nocturnal enuresis and recurrent urinary tract infections, serum
creatinine measurements is appropriate. Patients with renal impairment have a
higher rate of post-operative complications following transurethral resection of the
prostate (TURP) [60], An elevated serum creatinine in a patient with BPH is an
indication for imaging of the upper urinary tracts.
Serum Prostate Specific Antigen (PSA)
Prostate cancer may arise in patients with LUTS suggestive ofBPH. NICE guideline
on the management of LUTS recommend a measurement of serum PSA in patients
with an abnormal rectal examination, symptoms suggestive of bladder outflow
obstruction and in patients concerned about prostate cancer [59].
Serum PSA is organ specific but not disease specific and may be elevated in men
with BPH. Serum PSA has been shown to be closely related to prostate volume (PV)
and this relationship is dependent on age [61]. Furthermore, several large scale
clinical trials such as Medical Therapy of Prostatic Symptoms (MTOPS), Proscar
Long-term Efficacy and Safety Study (PLESS) demonstrate that PSA is an
independent predictor of both prostate volume (PV) and BPH progression [53, 62,
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63]. Further analysis from the MTOPS study demonstrates that patients with a PSA
serum level of >1.6 ng/ml are at risk of clinically significant BPH progression.
These patients are more likely to have an enlarged prostate >30mls in volume and
therapy should be directed at reducing the size of the prostate [64].
Urinary flow rates
Uroflowmetery is the measurement of urinary flow rate with an electronic flowmeter.
The flow rate is measured in millilitres per second and peak flow rate (Qmax) has
been shown to identify patients with BPH more specifically than average flow rate
(Qave) [65]. Due to test-retest variability, there is not a specific rate of flow which
can be used to determine the course of therapy. Furthermore, flow rate cannot
distinguish between BOO and impaired detrusor contractility as the cause for a low
peak flow rate [66].
Post-void residual volume
Post-void residual volume (PVR) is the amount of urine remaining in the bladder
after micturition. This can be measured using ultrasound or, invasively by the
passage of a urinary catheter. Large variations in PVR measurements have been




The measurement of detrusor pressure whilst the bladder is filled and emptied is
made using a small suprapubic or urethral catheter. This investigation differentiates
patients with detrusor failure and those with BOO [69], Pressure flow studies should
be considered in complicated cases, such as young men with neurological disease or
those who have not responded favourably to treatment [59],
Urethrocystoscopy
Endoscopic evaluation of the lower urinary tract is recommended in patients in
whom other pathologies are suspected such as bladder cancer or urethral strictures.
Transrectal ultrasound ofthe prostate
Ultrasound examination of the prostate may be used to assess the size and shape of
the prostate. This may identify patients with large volume prostates who may be
treated effectively with an open procedure. However, the most common application




1.2.5. Non-surgical management of BPH
Watchful waiting
Watchful waiting is a strategy for monitoring for the progression of symptoms or
signs. Advice regarding decreasing fluid and caffeine intake late in the day may be
given and patients should be encouraged to promptly report any changes in
symptoms. Recent studies have shown that self-management, as part of watchful
waiting, reduces both symptoms and progression [70, 71].
Alpha adrenergic blockers
The use of alpha adrenergic blockers in the medical management of BPH is based
upon the hypothesis that the increase of smooth muscle tone in the prostate is
mediated by alpha adrenergic receptors (a ARs) [72]. Adrenergic receptors are
transmembrane glycoproteins that mediate catecholaminergic actions within the
sympathetic nervous system [73], This family of receptors are subdivided into oq, oq,
and P subtypes [74], It has been shown that the aia subtype predominates in the
prostate and is localised to the stromal compartment [75-77] and is the subtype that
mediates contraction of prostatic smooth muscle [41].
Three generations of alpha adrenergic antagonists have been used in the treatment of
LUTS suggestive of BPH. The first generation agents such as phenoxybenzamine,
antagonised both ai and cq receptors within the prostate and vasculature. As a
consequence of this non-selective blockade, this generation of agents were associated
38
Chapter One
with many dose-related adverse events such as first dose syncope, orthostatic
hypotension and reflex tachycardia [78, 79].
To improve the adverse events profile of these agents, the second generation of
agents selectively antagonised the ai AR subtype and not the 012 AR subtype in the
doses used in clinical practice. These agents include prazosin, terazosin and
doxasoin [80], Alfuzosin is considered a second generation agent as affinity studies
on human-cloned cp AR subtypes demonstrate that it does not show significant
receptor subtype specificity [81]. However, animals studies have shown that
receptor subtype selectivity does not correlate with functional selectivity of ai
adrenegic antagonists [82],
Third generation agents are pharmacologically selective for prostatic cxia AR subtype
receptors [83], Tamsulosin is a third generation agent and pharmacologic studies
have shown that tamsulosin has a 10-fold greater affinity for aiA AR subtype than for
the cob AR subtype [84], As tamsulosin has low affinity for aie AR subtypes, which
are predominantly found in the vasculature, cardiovascular adverse effects are
uncommon [85]. The clinical advantages of this pharmacologic selectivity are that
titration doses are not required and patients may begin at the usual treatment dose.
A recent meta-analysis of placebo-controlled and direct comparison studies of alpha
adrenergic blockers demonstrated that as a group, these agents are comparably




Alpha adrenergic receptor antagonists and the induction ofapoptosis in the prostate
The clinical efficacy for this group of agents has been attributed to their ability to
relax smooth muscle tone within the lower urinary tract via antagonism of op a AR
subtype receptors. However, Kyprianou el al. first reported the proapoptotic effects
of doxazosin as a potential mechanism for the long-term duration of efficacy for this
agent in patients with LUTS suggestive of BPH [87]. The authors demonstrated that
the apoptotic activity in the glandular and smooth muscle cells significantly
increased after 3 months of therapy and remained elevated for up to 12 months. This
increased in apoptosis correlated with degeneration of prostatic stroma and decreased
smooth muscle actin expression as assessed by immunohistochemical staining.
Further studies from this group assessed the proapoptotic effect of terazosin and
tamsulosin, demonstrating that terazosin therapy induced apoptosis in prostate
epithelial and smooth muscle cells in patients with BPH [88], In cell culture
experiments, tamsulosin did not exhibit proapoptotic effects against prostate cancer
cell growth [89], The proapoptotic activity of doxazosin and terazosin may be due to
their similarity in chemical structure as both agents possess a quinazoline nucleus
whereas tamsulosin is structurally different as it is a methoxybenzene sulphonamide
(see figure 1.8) [89].
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Figure 1.8: The chemical structure of alpha la antagonists. The quinazoline
structure is shared by doxazosin and terazosin, but not by the methoxysulphonamide-
derived alpha la antagonist, tamsulosin.
The pathways underlying the pro-apoptotic effect of quinazoline-based alpha
blockers have been studied. Treatment with terazosin and finasteride caused an
increase in the apoptotic index with increase expression of TGF - Pi [90]. Molecular
studies using prostate cancer cell lines demonstrated an induction of Caspase-3 and
an induction of several TGF - Pi signalling effectors in cells treated with doxazosin.
This effect was not seen with treatment with tamsulosin [91]. Doxazosin was found
to inhibit cell growth, adhesion and migration of human endothelial cells by
interfering with VEGF and FGF-2 action [92], These recent findings may suggest a
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potential therapeutic use of quinazoline-derived alpha 1 antagonist in the
management of malignant prostate disease [93].
5-a reductase inhibitors
The rationale for the use of these agents in the management of BPH is based on the
observation that the embryonic development of the prostate depends upon the
androgen, dihydrotestosterone (DHT). Conversely, suppression ofDHT removes the
stimulus for cell growth and induces apoptosis or prostate epithelial cells [94].
Testosterone physiology is discussed in section 1.1.4. The reduction in prostate
volume is thought to decrease the static component of BOO. However, it is
acknowledged that the pathophysiology of clinical BPH and LUTS are not directly
correlated to prostate size.
Two isoenzymes of 5-a reductase have been identified: type 1 and type 2. Type 1 is
found within the prostate but is the predominant enzyme in extra-prostatic tissue
such as skin and liver whereas type 2 is the predominant prostatic 5-a reductase [95].
The 5-a reductase inhibitors licensed for use in the treatment of BPH are finasteride,
which is a mono-inhibitor of type 2 isoenzyme, and dutasteride, a dual inhibitor of
both isomers.
The Proscar Long-Term Efficacy and Safety Study (PLESS) reported the unique
findings that the incidences of both AUR and BPH-related surgery were significantly
reduced with long term 5ARI therapy [52]. Finasteride conferred a relative risk
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reduction of 57% ofAUR and 55% of BPH-related surgery at 4 years. However, the
symptom score reduction of 2 points, and peak flow rate improvements 1.7ml/sec at
the end of the study were modest and comparable to prior finasteride studies [96].
The detection of cancer was not significantly different between the treatment and
placebo group implying that finasteride did not mask the diagnosis of prostate cancer
[97].
Dutasteride is a dual inhibitor of 5-a reductase types 1 and 2 and is shown to have a
greater impact on the suppression of serum DHT levels [98], Results from early
studies show similar results compared with finasteride. In a randomised controlled
trial of 4325 men, the symptom score was improved by 4.5 points and the peak flow
rate improved by 2.2ml/s at 24 months [99]. The relative risk reduction of AUR was
57% and the risk reduction of BPH-related surgery was 48% compared with placebo.
Combination therapy with alpha adrenergic blockers and 5-a reductase inhibitors
The Medical Therapy of Prostatic Symptoms (MTOPS) trial was established to
determine whether medical therapy can influence the progression of BPH in the long
term and what factors were associated with increased progression of the disease.
Patients were randomised to doxazosin, finasteride, a combination of both and to
placebo. The results of the trial show that the symptom score and peak flow rate
improved significantly in the combination group compared with the monotherapy
group. Patients on combination treatment experienced a relative risk reduction of
BPH progression of 67% compared with 39% for doxazosin and 34% for finasteride
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as monotherapy [53], Interestingly, in the doxazosin monotherapy group, the total
prostate volume increased from a baseline of 36.4 mis by 9.9mls by the end of the
four year study. This suggests that doxazosin, despite its pro-apoptotic effects, does
not interfere with the natural enlargement of the gland.
Combination versus Avodart or Tamsulosin (CombAT) trial recently reported the 4
year results. The results show that combination therapy with dutasteride and
tamsulosin reduced the relative risk of AUR or BPH-related surgery compared with
monotherapy with tamsulosin across all baseline subgroups by 43-77%. The
reduction was not significant in patients with a baseline prostate volume of <40 ml
[100],
Phosphodiesterase inhibitors
In 2002, the first clinical report was published documenting the improvement in
LUTS in men given sildenafil for erectile dysfunction [101]. There has been
significant interest in the role of phosphodiesterase inhibitors (PDEIs) as treatment
options for LUTS. There is level 1 evidence confirming improvement in LUTS after
treatment with PDEIs [102], In these studies, there are no significant changes in the
peak flow rate, which may suggest the mechanistic effects ofPDEIs may be focused
on detrusor function than on prostatic smooth muscle. The mechanisms by which





Phytotherapy is the use of plant extracts for medicinal purposes. The extract of the
American dwarf plant Serenoa repens is the most commonly used plant extract for
the treatment of BPH. These agents are currently more used in the USA, Germany
and France than in the UK. Permixon (Pierre Fabre Medicament, Boulogne, France),
the n-hexane liposterolic extract of Serenoa repens, is the product most rigorously
investigated of all the phytotherapeutic agents in use. However, the exact
mechanism of action is yet to be determined as these extracts are a composite of
several chemical molecules and display a wide range of pharmacological activity
[103], The postulated modes of action involve anti-androgenic action through
inhibition of 5-a reductase isoenzymes 1 and 2; anti-inflammatory effects mediated
via inhibition of cyclo-oxygenase and lipoxygenase enzymes and anti-proliferative
action through inhibition of bFGF [104], A recent systematic review by the
Cochrane Database concluded that Serenoa repens was not more effective than
placebo for the treatment of urinary symptoms consistent with BPH [105], However,
despite these studies, there is still a need for well designed, long term, randomised
placebo/comparative controlled studies with defined BPH symptom score endpoints
to determine the place of these agents in the medical treatment of BPH.
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1.2.6. Surgical management of BPH
Surgical treatment for symptomatic BPH was the accepted treatment before the
advent of medical therapies in the 1970s [39]. There are now many alternatives to
surgical treatment with less associated morbidity. More recent modalities of
treatment are compared to TURP as this is still considered the "gold standard" for the
treatment of symptomatic BPH.
Open prostatectomy
An open prostatectomy is open abdominal procedure in which the prostate adenoma
is enucleated through the bladder (transvescial prostatectomy) or through the prostate
capsule (Millin's prostatectomy). The open approach is usually reserved for patients
requiring the removal of very large prostates greater than lOOg [106],
TURP
TURP is considered the gold standard to which other invasive procedures are
compared. The efficacy of this procedure has been demonstrated in the many studies
and is the treatment of choice in patients with significant symptoms [107, 108]. A
recent review examining the changes in complication rates, indications and methods
for managing complications following TURP conclude that the morbidity of TURP




Minimally invasive therapies use high temperature to produce coagulation necrosis
of the prostate. Transurethral microwave therapy (TUMT) uses a combination of
heat delivered transurethrally and a water balloon to lower prostatic temperature to
prevent urethral damage. This technique has been assessed in a number of trials but
long term data is still lacking. It is however clear, that the TUMT offered less
morbidity than TURP but was not as effective as TURP in improving LUTS or
increasing peak flow rate as compared with TURP [110].
Transurethral needle ablation (TUNA) uses radiofrequency waves to deliver heat to
the prostate. A meta-analysis in 2004 reported that the effect of TUNA was to halve
the mean IPSS at 1 year. The peak flow rate increased by about 70% from baseline
to one year but tended again to decline over time. The main criticism was the
shortage of long term data [111].
Laser based therapies have been shown to achieve similar outcomes as TURP but the
cost of the laser and operation times seem to be the main drawbacks of this
procedure. Newer technologies have helped overcome some of the difficulties in
treating large prostates and the minimal invasiveness of the various laser
technologies has improved. A recent systematic literature review examining the
evidence for photoselective laser vapourisation and holmium laser enucleation of the
prostate has suggested that both these laser modalities are promising alternatives to
TURP. However, the quality of the trials examined in this review were not
completely robust and the follow up data was relatively short [112].
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1.3. Mechanical characteristics of biological tissues
Clinical assessment such as digital examination has been used for centuries to
qualitatively assess and diagnose the presence of tumours in accessible areas of the
human body as these pathological processes can alter the mechanical properties of
tissues. The mechanical properties of biological tissues are said to follow a
viscoelastic model and contain varying elastic and viscous elements and are
intrinsically related to their composition [113]. The understanding of the mechanical
properties of soft tissues is important in the fields of biomechanics and
bioengineering and its associated medical applications. There is significant interest
in the application of biomechanics to the diagnosis, planning and treatment of
various disease areas such as breast disease [114], vascular disease [115] and prostate
disease [116].
Biological soft tissues consist mainly of cells and extracellular substances such as
connective tissues such as collagen and myosin. These individual components have
been isolated and found to possess different mechanical properties [113]. Indeed,
there are significant variations in the proportion of cellular components at a given
area of the organ or tissue studied. Biological soft tissues may not show a linear
stress-strain relationship and therefore cannot be described or represented by a single
elastic modulus. The elastic modulus is a measure of the stiffness of a material and
this is gained from the application of stress to the material. Also, the mechanical
properties of the tissue may not be the same in different directions and are therefore
termed anisotropic materials. They often have a layered or very complex structure
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and the perfusion of the tissue or organ often plays an important role with regard to
the mechanical properties.
1.3.1. Mechanical measurements of the prostate
Despite the advancement of the field of biomechanics and bioengineering, there is
not a standard method for quantifying the mechanical properties of biological tissues.
Mechanical testing is usually conducted with tension or compression applied to the
tissue at a range of controlled strain rates. These tests are termed quasi-static as they
monotonically increase the displacement and measure the resulting load. There have
been many reports of quasi-static mechanical testing of biological tissues, but this
method of testing does not account for the viscous, or fluid, element of the tissue
[117-119J. Krouskop et a\ was the first to report quasi-static measurements of
prostate tissue and demonstrated differences between malignant and benign tissue
[120],
When ultrasound propagates through tissue, it causes a mechanical disturbance
which is related to the elastic properties of the tissue. This disturbance or distortion
can be detected in the pulse-echo (termed A-scan) ultrasonography to give a
graphical representation of the reflected ultrasonic wave. This development of
conventional ultrasound has been termed elastography, also called strain imaging,
and is recognised as a new diagnostic imaging modality. Higher-density tissues
allow less displacement with compression than soft tissue. Compression and
decompression of the prostate is generated by freehand during ultrasound. A
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comparison is made of the echo amplitudes through the tissue with and without
compression applied to the tissue and elastograms are generated demonstrating areas
of variation in stiffness. Several groups have utilised A-scan ultrasonography to
produce images depicting areas of varying stiffness in tissues [121, 122], This
technique has matured over the last decade and there is recent evidence within the
literature that this diagnostic tool may be useful in the detection of malignant lesions
within the prostate [123, 124], Sonoelastography utilises a device to introduce a
vibration into the target tissue whilst real-time Doppler techniques are used to the
image the resulting vibration pattern. A discrete hard inhomogeneity will cause a
decrease in the vibration amplitude at its location [125], Initial results seemed to
suggest that elastography yielded images of more clarity over the images produced
using sonoelastography. However, recent evidence suggests that sonoelastography is
proving to be an accurate tool in the detection of prostate lesions [126], However,
despite these results, elasticity imaging does not provide information of the
mechanical response of the tissue when subjected to a wide spectrum of strain
frequencies. This knowledge is essential to the development of an effective in vivo
measurement system.
To assess both the elastic and viscous components of a tissue, a dynamic mechanical
test of applying a compressive strain to the tissue, will enable the modulus of the two
components to be derived. The moduli commonly used to describe the two
components are the amplitude ratio (|E*|) and phase difference (tan 6) of the forces
applied to the tissue. Previous work from the Prostate Research Group has been
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focused on understanding the structure-property relationship of prostate tissue from
TURP chippings. The research utilised a load-compression probe to perform point
measurements of the mechanical properties of the target tissue. This technique
acknowledges the elastic and viscous properties of biological tissues and measures
the modulus dynamically (as the amplitude ratio and phase difference) between an
oscillating strain (probe displacement) and the resulting force. The amplitude ratio
and phase shift can therefore be used to determine the loss modulus and storage
modulus of the tissue, which is a more complete measure of tissue elastic and viscous
properties [127], Furthermore, Phipps et al demonstrated that malignant prostate
tissue can be differentiated from benign tissue on the basis of its mechanical
characteristics [128],
The mechanical properties of prostate tissue have been shown to be a function of the
underlying histological structure. Despite the number of tools available to the
urologist to assess a patient with LUTS secondary to BPH, there is a poor correlation
between the symptoms, clinical parameters and investigations. Also, these tests,
when considered on their own, are not able to guide treatment nor can they predict
the patient's response to a given treatment. From the results of the combination
studies of MTOPS and CombAT, patients with a prostate size >30 ml and a PSA of
1.4ng/ml or greater should benefit from a 5 a-reductase inhibitor than an alpha
blocker. However, studies have suggested that the severity of bladder outlet
obstruction is dependent upon the density of smooth muscle within the prostate and
the ratio of stroma to epithelium was the greatest in patients with clinical BPH [35,
42], As the mechanical properties of the prostate may reflect the underlying
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histology, this knowledge may be useful in guiding therapy and in predicting the
response to a given treatment.
1.4. Hypothesis and objectives of this thesis
Previous work from the prostate research group has demonstrated that there is a
relationship between the mechanical and histological properties of prostate tissue
from TURP chippings and that there are measureable differences between malignant
and benign prostate tissue. This work forms part of a project that has the ultimate
aim of developing an effective in vivo measurement system to assess the mechanical
properties of prostate tissue.
These samples were mainly stromal in composition than epithelial. We understand
from the work by Franks and McNeal that the prostate, taken as a whole, is a
heterogeneous organ with differing histological characteristics throughout its
structure (see section 1.2.2). Different patterns of tissue composition of the prostate
are seen when considering prostate size. In the smaller prostates the morphology of
pathological features, such as nodules, are comprised mainly of stromal tissue.
However, in the larger prostate, these nodules are comprised of mainly glandular
tissue. To fully understand the relationships between morphology and mechanical
characteristics in prostate tissue, the whole gland must be subject to assessment. The
heterogeneous nature of the prostate cannot be assessed simply from TURP
chippings. The aim of this thesis is to further explore the structure-property
relationship of prostate tissue in sections of whole prostate.
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In parallel to this work, studies will continue to utilise TURP chippings to
understand the relationship between alpha blocker therapy and the effect upon
prostate tissue. Studies have shown that quinazoline based alpha blockers, such as
doxazosin and terazosin were found to cause apoptosis in prostate cells whereas
tamsulosin, a sulphonamide based alpha blocker, did not have this effect (see section
1.2.5). The increase in prostate cellular apoptosis correlated with morphological
stromal regression. Alfuzosin, a quinazoline based alpha blocker, has not been
studied in relation to its effect upon prostate tissues. Therefore, this thesis also
seeks to explore the relationship between alpha blocker therapy and the effect upon








The project has two main objectives: Firstly to examine the mechanical and
morphological properties of prostate tissue harvested from radical
cystoprostatectomy specimens.
Protocol for first objective as follows:
Patients attending for Radical
Cystoprostectomy consented for tissue
donation for the study
A coronal slice of the prostate is
immediately cut by the pathologist
Specimen undergoes multiple point probing
with areas probed marled with Indian Ink
and an adjacently placed needle
Specimen is fixed in 10% Buffered
Formalin solution, embedded in wax,
sectioned and stained
Mosaic image created for the section, loco-
regional morphology selected from the
histology "map" and subject to quantitative
image analysis
Relationship between loco-regional




Secondly, to explore the relationship between alpha blocker therapy and the effects
upon the mechanical and morphological characteristics of prostate tissue in TURP
specimens.
Protocol for second objective:
Patients attending for TURP consented for
tissue donation for the study
TURP chips taken at time of resection
4
TURP specimens are subjected to
mechanical measurements
4^
Specimen is fixed in 10% Buffered
Formalin solution, embedded in wax,
sectioned and stained
Stained section is subject to quantitative
image analysis
4^
Relationship between alpha blocker therapy




2.1 Materials, Chemicals and Equipment
The materials, chemicals and equipment used in this project are described in detail.
2.1.1 Chemicals used
Concentrated hydrochloric acid (HC1) (Scientific & Chemical Ltd, Bilston, UK)
Tris[hydoxymethyl]aminomethane Trizma Base (Tris) (Sigma, Poole, UK)
Citric acid (Sigma, Poole, UK)
Tri-sodium citrate (Fisher Scientific, Loughborough, UK)
Sodium chloride (NaCl) (BDH, Poole, UK)
Sodium Hydroxide (NaOH) (BDH, Poole, UK)
Phosphate buffered saline tablets (PBS) (Oxoid, Basingstoke, UK)
Xylene - Analytical Grade (Fisher Scientific, Loughborough, UK)
Absolute ethanol - Analytical Grade (Fisher Scientific, Loughborough, UK)
Hydrogen peroxide (J.T. Baker, Deventer, Holland)
Depex mounting medium (BDH, Poole, UK)
Ethylenediaminetetraacetic acid (EDTA) (Sigma, Poole, UK)
DAB peroxidase substrate tablet set (Sigma, Poole, UK)
2.1.2 Solutions prepared
Tris-Buffered Saline, 0.05M pH 7.6 (TBS)
Dissolve 30.25g Tris in 400ml de-ionised water. Add 16.5ml concentrated HC1.
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Dissolve 40.5g NaCl in 4600ml de-ionised water.
Mix the two solutions to make up 51.
Adjust pH to 7.6 using either 4M HC1 or 1M NaOH.
Citrate Buffer 0.1M pH 6.0
Make up stock solution of 0.1M citric acid (21.01 g / litre).
Make up stock solution of 0.1 M sodium citrate (29.4lg / litre).
Mix 18ml of the citric acid with 82ml of the sodium citrate and make up to 1000ml
with de-ionised water.
Adjust to pH 6.0 using either 4M HC1 or 1M NaOH.
Phosphate Buffered Saline (PBS)
Make up using Oxoid PBS tablets, at one tablet per 100ml de-ionised water.
Tris-EDTA buffer (50X stock solution)
Dissolve 37g of EDTA with 40g of Tris in 2L of distilled water to make stock
solution.
To prepare a working solution, add 60mls of stock solution to 1.5L distilled water.
Adjust pH to 8.0 if necessary
Diaminobenzidine (DAB)
Make up with one diaminobenzidine (DAB) tablet and one urea hydrogen peroxide
tablet (both tablets supplied in the DAB peroxidase substrate kit),




Dissolve 12.14g of Tris in 1L of distilled water and adjust to pH 8.0 using
concentrated HC1 to give lOOmM Tris-HCl pH 8.0
Add 1.861g ofEDTA (50mM EDTA) to give a stock solution of Proteinase K buffer.
2.1.3 Immunohistochemical reagents
a) Primary Antibodies
Monoclonal mouse anti-human prostate specific antigen, clone ER-PR8 (Dako, Ely,
UK)
Monoclonal mouse anti-human smooth muscle myosin heavy chain, clone SMMS-1
(Dako, Ely, UK)
Polyclonal rabbit anti-human anti-active caspase-3 (Promega, Southampton, UK)
DeadEnd Colorimetric TUNEL system (Promega, Southampton, UK)
b) Secondary Antibodies
Biotin conjugated goat anti-mouse secondary antibody (Autogen Bioclear, Calne,
UK)
Biotin conjugated swine anti-rabbit secondary antibody (Dako, Ely, UK)
c) Blockers and visualisation agents
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Goat Serum (Diagnostics Scotland, Carluke, UK)
Swine Serum (Dako, Ely, UK)
Avidin/ Biotin blocking kit (Vector Laboratories, Peterborough, UK)
StreptABComplex streptavidin, horseradish peroxidase (Dako, Ely, UK)
Diaminobenzidine Tablets (Sigma, Poole, UK)
2.1.4 Equipment used
a) Mechanical Testing
A description of equipment used in the mechanical testing of prostate tissue is in
Section 2.3
b) Tissue processing
Tissue-Tek Vacuum Infiltration Processor (Model El50, Bayer Diagnostics,
Basingstoke, UK)
Tissue-Tek Tissue Embedding Console System (Model 4715, Bayer Diagnostics,
Basingstoke, UK)
Rotary Microtome (Model AS325, Shandon, Runcorn, UK)
Superfrost Plus 72x25x1mm Microscope Slides (BDH, Poole, UK)
Cover Glasses 18x18mm and 24x40mm, thickness no.l (BDH, Poole, UK)
60
Chapter Two
c) Image capture and analysis
Leica DMR light microscope with automated stage (Leica Microsystems,
Cambridge, UK)
Leica DC digital camera (Leica Microsystems, Cambridge, UK)
Qlmaging QICAM digital camera (Mediacybernetics, Berkshire, UK)
Pro-series Turboscan and Surveyor specimen scanning software (Mediacybernetics,
Berkshire, UK)
Leica Q550 imaging workstation personal computer with Leica Qwin image analysis
software (Leica Microsystems, Cambridge, UK)
Image-Pro Plus 5.1 image analysis software (Mediacybernetics, Berkshire, UK)
Panavue ImageAssembler - Trial Version (Panavue, Quebec, Canada)
2.2 Patients and Tissues
This section describes the source of the prostate tissue used in this project.
2.2.1 Ethical approval and consent
Full ethical approval for this project was granted by the Lothian Research Ethics
Committee (certificate reference LREC/2002/8/38). Written informed consent was
obtained from patients who agreed to donate a small proportion of their prostatic




2.2.2 Source and collection of tissue specimens
Radical cystoprostatectomy specimens
Prostate tissue was collected from attending for radical cystoprostatectomy for
bladder cancer at the Urology Department, Western General Hospital, Edinburgh.
Tissue was not collected from patients who had previous prostate surgery or prostate
biopsies as this may alter the morphology of the prostate tissue harvested.
Immediately following excision of the prostate and bladder, the specimen was
transported to the pathology department where a transverse slice of the whole
prostate was obtained. The specimen was taken close to the bladder neck to ensure
inclusion of the transitional zone of the prostate. The prostate specimen was then
subjected immediately to mechanical testing in the laboratory prior to fixation in
formalin and subsequent routine histopathological processing. Prepared histological
sections were studied to determine the morphology of the specimen and the protocols
are described in section 2.6
TURP specimens
Prostate tissue was collected from patients attending for TIJRP at the department of
Urology, Western General Hospital. Patients currently taking monotherapy of an
alpha blocker, alfuzosin or tamsulosin were selected. Tissue was not collected from
patients who were currently taking 5-alpha reductase inhibitor monotherapy or a
combination therapy of both alpha blocker and 5-alpha reductase inhibitor. It was
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felt that 5-alpha reductase inhibitors may alter the morphology or cellular properties
of the tissue examined. Patients were excluded if they had a diagnosis of prostate
cancer or had undergone previous prostate surgery. The TURP chippings were taken
at random and subjected immediately to mechanical testing in the laboratory.
Radical Prostatectomy specimens
A retrospective cohort of patients was identified to provide a comparison group to
the TURP group. This group comprised patients who were commenced on alpha
blocker therapy (alfuzosin or tamsulosin) for LUTS and were subsequently found to
have localised prostate cancer and radical prostatectomy was offered to these
patients. Paraffin-embedded archival tissue was used in this study. In an attempt to
ensure that the blocks represented a similar area of the prostate as represented by the
TURP specimens, tissue blocks were carefully selected (with the assistance of an
uro-pathologist) to reflect the transition zone of the prostate. Tissue blocks which
contained foci of prostate cancer were not utilised.
2.2.3 Clinical data
In this study, prostate specimens were acquired from patients undergoing two
different surgical procedures for urological disease. Specimens were obtained from
12 patients undergoing radical cystoprostatectomy, and from 16 patients undergoing
TURP and from 16 patients undergoing radical prostatectomy for localised prostate
cancer. Clinical data for the three groups are presented below.
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12 transverse slices were obtained from 12 patients undergoing radical
cystoprostatectomy for bladder cancer. In 5 patients, prostate cancer was
subsequently diagnosed. Each specimen that underwent mechanical testing was
subsequently examined by a histopathologist to ensure that there was no evidence of
prostate cancer. The 12 patients had a mean age of 72 years (range 62-80).
32 TURP chippings were obtained from 16 patients undergoing TURP for BPH. The
16 patients were stratified into 3 groups on the basis of medical therapy. Of the 16
patients, 6 patients received tamsulosin only and 4 patients received alfuzosin only.
6 patients formed the control group as these did not receive any pharmacotherapy.
The mean age for the tamsulosin group is 62 years (range 57-76), for the alfuzosin
group is 73 years (range 68-80) and for the control group is 67 years (range 60-72).
The mean PSA for the tamsulosin group is 5.3 (range 2.6-7.6), alfuzosin group is 4.7
(range 1.8-8.9) and for the control group is 5.3 (range 1.2-6.3).
16 patients who experienced LUTS related to BPH were identified retrospectively.
These patients underwent radical prostatectomy for localised small volume prostate
cancer. Of these 16 patients, 5 patients received tamsulosin only and 5 patients
received alfuzosin only prior to radical prostatectomy. A control group for this
cohort comprised 6 patients who did not receive alpha blocker therapy. The mean
age for the tamsulosin group is 64 years (range 58-68), for the alfuzosin group is 60
years (range 50-67) and for the control group is 63 years (range 56-68). The mean
PSA for the tamsulosin group is 6.4 (range 4.9-7.8), alfuzosin group is 5.9 (range
1.2-15) and for the control group is 9.1 (range 6.4-12.5).
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Full clinical details of the patients from whom tissue taken for analysis are presented
in Appendix I.
2.3 The measurement ofmechanical properties of prostatic tissue
2.3.1 Equipment
The mechanical measurements were obtained from a test rig developed by a research
associate from the School of Engineering and Physical Sciences (Mechanical
Engineering) Heriot Watt University, Edinburgh. The development of this rig was
the subject of a PhD thesis by the research associate. During this project,









Figure 2.2 - Modified mechanical test rig for the dynamic measurement of prostate
tissue. Electromechanical shaker has been replaced by a stepper motor controlled
base plate.
The mechanical test rig originally consisted of an electro-mechanical shaker (LDS
V201 with amplifier PA-25E) capable of inducing cyclic load between 1Hz and





with signal conditioning unit (Measurements Group 2311) was used to measure the
load resulting from the cyclic loading, and a proximity sensor (Bentley Nevada
3300XL) was used to measure the displacement of the induced cyclic strain at the
shaker system. A schematic diagram of the arrangement of the test rig is shown in
figure 2.1. The data acquisition system consisted of a National Instrument 6036E
card, and Labview was used to generate the actuation frequencies at the shaker
system and to acquire the analogue signals of cyclic displacement (s) and cyclic load
(a) from the proximity sensor and load cell respectively. The dynamic testing system
and its calibration using phantom tissues has been described in [129].
A number a modifications was made to the test rig prior to the testing of whole
prostate slices. The electro-mechanical shaker was replaced with a stepper motor
(shown in Fig 2.2) to allow finer control of the cyclic load to the tissue. The probe
size measures 2mm in diameter. In order to understand the effect that probe size has
on the mechanical measurements, the probe was exchanged for a micro-indenter
measuring 400pm x 500pm. Experiments utilising the 2mm diameter probe were
termed macro-probing experiments whereas the experiments utilising the 400pm x
500pm probe were termed micro-probing experiments. The overall aim of this work
is to develop an in vivo measurement system to assess the mechanical properties of
prostate tissue. In a collaborative project with a micro-engineering facility, the
Rutherford Appleton Laboratory, the development and assembly of a micro-
engineered palpation device for measuring mechanical properties of biological
tissues was in progress. Understanding the structure-property relationship of
biological tissue at the micro level is crucial in the development of this device.
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2.3.2 Mechanical testing protocol
Following collection of the specimen at cystoprostatectomy, the bladder and prostate
were transported to the pathology laboratory and a transverse slice of the whole
prostate was obtained. The slice measured at least 5mm in thickness. The specimen
underwent immediate mechanical cyclic probing. The area subjected to mechanical
testing was marked with Indian ink and a needle was embedded into the tissue
adjacent to the test point to aid localisation of the test point. Following collection of
the TURP specimens, the individual TURP chippings were subjected to immediate
mechanical testing.
A controlled compressive cyclic strain is applied to the tissue specimen through the
movement of the base plate by the electro-mechanical shaker or stepper motor. The
displacement of the plate is measured by the proximity sensor, and the force arising
from the specimen is measured by the load cell via the probe which is in contact with
the specimen surface. Each specimen was probed at actuation frequencies (co)
between 5Hz and 50Hz at an increment of 5FIz with the pre-strain to ensure that the
probe did not lift off the specimen during cyclic loading. The dynamic modulus was
determined by two components, the amplitude ratio (|E*|) and phase difference (tan
5).
|E*| is the ratio of the amplitudes of the waveforms of these two forces. The phase
difference between these two waveforms is tan 5. Previous work from the Prostate
Research Group has demonstrated that the mechanical properties of prostate tissue
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from TURP chippings follow a viscoelastic model, analogous to the suspension of a
car. The stromal component is likened to the springs and the epithelial content is
likened to the dampers of the vehicle, and these components are described
mathematically by |E*| and tan 8, respectively [127, 128],
2.4 Tissue processing, embedding and sectioning
Once the prostate specimens obtained from TURP or radical cystoprostatectomy had
been subjected to mechanical testing, the tissue was fixed in 10% formalin for 48
hours and processed and paraffin embedded. Both types of specimens were
processed by infiltration with paraffin wax using a Tissue- Tek Vacuum Infiltration
Processor (Model El50, Bayer Diagnostics, Basingstoke, UK) employing a protocol
used in the Department of Histopathology at the Western General Hospital,
Edinburgh, before being embedded in paraffin wax cassettes using a Tissue-Tek
Tissue Embedding Console System (Model 4715, Bayer Diagnostics, Basingstoke,
UK). As the whole prostate slices were too large to mount on a standard 75 x 25 mm
glass slide, the specimen was divided into individual right and left lobes and then
further divided again to yield four specimens that fit into standard embedding
cassettes. The TURP specimens were mounted singly on each glass slide. The
blocks were cooled on ice before histological sections were cut from the paraffin
blocks. Consecutive 4pm-thick sections were cut from each paraffin block using a
Rotary Microtome (Model AS325, Shandon, Runcorn, UK). Individual sections
were mounted on 75 x 25 x 1mm Superfrost Plus microscope slides (BDH, UK)
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which were allowed to stand until dry and then incubated overnight in an oven at
37°C.
2.5 Immunohistochemical Staining
2.5.1 Antibodies for morphological analysis
Primary antibodies to smooth muscle (clone SMMS-1, Dako, Ely UK) and PSA
(clone ER-PR8, Dako, Ely, UK) were chosen as these have been demonstrated to
represent the tissue components which have an effect upon the mechanical
characteristics [130, 131]. The working dilutions of both antibodies were 1:100.
Connective tissue proteins such as Collagen Type I and Type III have not been
shown to affect the mechanical properties of the tissue [130], Preliminary studies
with anti-fibroblast antibodies did not yield encouraging results as the staining was
sub-optimal. Additionally, it was difficult to choose an appropriate antibody which
targeted the correct stage of fibroblast development.
The immunohistochemical staining protocol used has been proven by previous work
within the group. Essentially, unwanted antibody sites were blocked with serum
from the species in which the secondary antibody was raised. Endogenous
peroxidase activity was quenched with hydrogen peroxide and endogenous biotin
sites were blocked with avidin. The section was then incubated with the primary
antibody overnight at 4°C and then incubated with the appropriate biotin conjugated
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secondary antibody. Visualisation of staining employed a biotin-streptavidin-
peroxidase technique in conjunction with a Diaminobenzidine (DAB) chromogen.
The section was fixed with a xylene based fixative.
The full protocol is described below.
2.5.2 Protocol for Immunohistochemical staining of formalin-fixed, paraffin
embedded sections
Immunohistochemical staining was carried out as follows:
1 Prepare 4pm-thick sections mounted on superfrost slides as described in section 2.4
2 Place sections in staining rack and incubate at 60°C for 15 minutes
3 Two washes in xylene for 10 minutes.
4 Two washes in absolute ethanol for 2 minutes.
5 Two washes in 90% ethanol for 2 minutes.
6 Two washes in 70% ethanol for 2 minutes.
7 Two washes in 30% ethanol for 2 minutes.
8 Two washes in TBS for 2 minutes.
9 Heat Induced Epitope Retrieval consists of:
a) In the microwave oven, bring 1000ml of citrate buffer or EDTA to the boil by
heating for 15 minutes.
b) Add sections and boil for 5 min. Add de-ionised water after boiling to
replace water lost as steam. Repeat this step 3 more times.
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c) Allow to stand for 20min, then cool dish and sections in sink of cold water
for 15-30min, wash once in de-ionised water for 3 min and twice in TBS for
3 min.
10 If blocking serum is frozen, defrost at this point.
11 Wash sections in 3% H202 for 10 min.
12 Make up solution of 20% serum in TBS.
13 Separate the 20% serum solution into two portions: to the 1st add 4 drops/ml of
avidin. To the other add 4 drops/ ml biotin and then add primary antibody at
recommended concentration.
14 Place sections in sequenza using distilled water, then run TBS over each
slide.
15 When the TBS has run through, run lOOpl serum/ avidin solution over
each section. Leave for 30 min.
16 Prepare solution for -ve controls: biotin in 20% serum solution (ie no primary
antibody).
17 Run lOOpl control solution over the -ve controls.
18 Run lOOpl serum/ primary antibody solution over remaining sections.
Leave overnight at 4°C.
19 Run TBS over sections twice.
20 Make up a 1 in 200 solution of biotinylated secondary antibody of the appropriate
species.
21 Make up streptavidin solution in 5ml of TBS by adding 1 drop of reagent A with
1 drop of reagent B from the supplied kit. Must made up at least 30 min before use.
22 Run lOOpl secondary antibody solution over each section. Leave for 30min.
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23 Run TBS over each section twice.
24 Run lOOpl Streptavidin/TBS solution over each section. Leave 30 min.
25 Run TBS over sections twice.
26 Make up solution ofDAB.
27 Treating 10 sections at a time, add lOOpl DAB to each for 5 min.
28 Pour DAB back into tube and add DAB neutralising solution.
39 Rinse each slide with tap water.
30 Two washes in TBS for 2 min.
31 Two washes in 30% ethanol for 2 min.
32 Two washes in 70% ethanol for 2 min.
33 Two washes in 90% ethanol for 2 min.
34 Two washes in absolute ethanol for 2 min.
35 Two washes in xylene for 2 min.
36 Mount coverglasses using Depex mounting medium in fume cupboard.
2.5.3 The detection of apoptosis
There are a variety of methods used in the detection of apoptosis with the two most
common approaches cited in the literature are observation of cell morphology and
detection of DNA fragmentation [132], Despite the usefulness of these techniques,
both techniques have problems with interpretation and artefacts. The specific
changes in the cell nucleus, such as segmentation of the nucleus, are cytological
hallmarks of apoptosis but are difficult to interpret in paraffin embedded sections.
The detection of fragmented DNA strands using TUNEL assays has been used to
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detect apoptosis but this method is not specific to apoptosis per se as cell necrosis
also generates fragmented DNA [133],
Recent understanding of the events in the apoptosis cascade have highlighted that
caspase activation (the cleavage of procaspase to active caspase) is a specific
indicator of cell suicide mechanism. Caspase 3 is a central effector of caspase and
mediates the cleavage of itself and other caspases downstream. The development of
antibodies to the neoepitopes of caspases has been shown to detect apoptotic events
with high specificity and sensitivity [134], Therefore the studies of apoptosis in BPH
tissue are conducted using two methods of detection, namely, TUNEL assay
(Promega, Southampton, UK) and Anti-active Caspase-3 (Promega, Southampton,
UK).
2.5.4 Protocol for the detection of apoptosis using Colorimetric TUNEL kit in
paraffin embedded sections
Supplied with the 40 reactions TUNEL assay kit from Promega, UK are:
9.6ml ofEquilibration Buffer
40pl Biotinylated Nucleotide Mix (2 x 20 pi)
40pl Terminal Deoxynucleotidyl Transferase, Recombinant (2 x 20 pi)
70ml SSC Buffer (20x concentration)
lOmg Proteinase K
40pl Streptavidin HRP (0.5mg/ml)
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200|il DAB 20x Chromogen
200pl DAB Substrate 20x Buffer Solution
The following protocol describes the steps necessary for the detection of apoptosis
using the Colorimetric TUNEL assay:
1 Prepare 4pm-thick sections mounted on superfrost slides as described in section
2.4.2.
2 Two washes in xylene for 5 minutes.
3 One wash in absolute ethanol for 5 minutes.
4 One wash in absolute ethanol for 3 minutes.
5 Two washes in 90% ethanol for 3 minutes.
6 Two washes in 70% ethanol for 3 minutes.
7 Two washes in 30% ethanol for 3 minutes.
8 Two washes in PBS for 3 minutes.
9 Remove the liquid from the tissue and place the slides on a flat surface. Prepare a
20pg/ml Proteinase K working solution from the lOmg/ml Proteinase K stock
solution (lOmg Proteinase K reconstituted with 1ml of Proteinase K buffer detailed
in section 2.1.2.) by diluting 1:500 in PBS. Add lOOpl of the 20pg/ml Proteinase K
solution to each slide to cover the tissue section and incubate slides for 10 minutes at
room temperature.
10 Two washes in PBS for 5 minutes.
11 Remove excess liquid by tapping the slides. Cover section with lOOpl of
Equilibration Buffer. Equilibrate at room temperature for 5-10 minutes.
76
Chapter Two
12 While the sections are equilibrating, thaw the Biotinylated Nucleotide Mix on ice
and prepare sufficient rTdT reaction mix. lOOpl of reaction mix is used to cover
each section. 1 OOpl of Reaction mix is composed of 98pl of Equilibration Buffer
and lpl of Biotinylated Nucleotide Mix and lpl of rTdT Enzyme. For negative
controls, omit rTdT enzyme from the reaction mix.
13 Blot around the equilibrated areas and add lOOpl of the reaction mix to the
sections.
14 Cover with plastic coverslips to ensure even distribution of the reagent. Incubate
slides at 37oC for 60 minutes inside a humidified chamber to allow end-labelling to
occur.
15 Dilute the 20X SCC 1:10 with deionised water. Remove plastic coverslips and
terminate reactions by immersing slides in 2X SCC for 15 minutes.
16 Two washes in PBS for 5 minutes.
17 Block endogenous peroxidases by immersing slides in 0.3% hydrogen peroxide in
PBS for 3 minutes.
18 Two washes in PBS for 5 minutes.
19 Dilute the Streptavidin HRP solution 1:500 with PBS. Add lOOpl to each slide
and incubate for 30 minutes at room temperature.
20 Two washes in PBS for 5 minutes.
21 Combine the DAB components just prior to use. Add 50pl of the DAB
Substrate 20X Buffer to 950pl deionized water. Then add 50pl of the DAB
20X Chromogen and 50pl of Hydrogen Peroxide 20X. Add 100f.il of DAB
solution to each slide and develop until there is a light brown background
22 Rinse several times in deionised water.
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23 Counterstain with Haematoxylin and develop with ammonia water.
24 Two washes in 30% ethanol for 2 min.
25 Two washes in 70% ethanol for 2 min.
26 Two washes in 90% ethanol for 2 min.
27 Two washes in absolute ethanol for 2 min.
28 Two washes in xylene for 2 min.
29 Mount coverglasses using Depex mounting medium in fume cupboard.
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2.6 Quantitative image analysis of a transverse section of prostate tissue
2.6.1 Introduction
Quantitative image analysis was performed using an upgraded Leica image analysis
system (Leica Microsystems, Cambridge, UK). In addition to the Leica DMR light
microscope with an automated stage, the original digital camera was upgraded to a
Qlmaging QICAM digital camera (Mediacybernetics, Berkshire, UK) and the
software upgraded to Image Pro Plus 5.1 with Pro-series Turboscan and Surveyor
specimen scanning software ((Mediacybernetics, Berkshire, UK). The Turboscan
and Surveyor software allows for accurate mosaics (stitched composite images) of
the specimen to be captured and created.
The protocol for morphometric analysis of TURP specimens has been established by
Phipps et al [135], Briefly, at x200 magnification, the whole section, mounted on a
motorised stage, was scanned by the microscope and the images written to the hard
disk. Quantitative image analysis was performed on each image and a percentage
area occupied by the target histological component was calculated and exported to an
excel file (see section 2.6.3).
This protocol was adopted for the analysis of whole transverse sections of prostate.
As described in section 2.4, the specimen was divided into four sections to allow for
mounting of the specimens to standard glass microscope slides. This protocol
generated a significant increase in the number of images captures per section. An
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average of 60 to 100 images would represent one TURP specimen. Application of
this protocol to sections of mounted whole prostate resulted in 800-1000 images per
section. Lower magnifications (x50 and xlOO) of image capture were considered but
did not provide the image resolution needed for accurate morphometric analysis.
The following section describes the methodology used to analyse the morphology of
transverse sections of prostate tissue.
2.6.2 Methods
Multiple mechanical test points were made on transverse sections of whole prostates.
The areas tested were marked with Indian ink and a pin-hole was created by
embedding a needle adjacent to the test point prior to the formalin fixation process.
These measures were used to enable accurate localisation of the test points after the
section was fixed, processed and stained. A transverse slice of prostate was fixed
and processed as described in section 2.4. Each prostate lobe was halved to yield
four blocks which were embedded in wax, cut and mounted on a standard
microscope glass slide. The morphometric analysis protocol to analyse TURP
specimens (see section 2.6.1) was used to capture images of the transverse slice of
prostate. To locate the individual areas of tissue that were subjected to mechanical
analysis, a composite histological "map" of the whole specimen was generated.
Panavue Assembler (Panavue, Quebec, Canada) software was used to manually
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stitch individual rows of images to then form a mosaic or composite image of the
whole section (see figure 2.3).
Figure 2.3 - Composite image or mosaic of a section stained with anti-smooth
muscle antibody on the left and anti-PSA on the right. The image on the left is
composed of 759 individual images taken at x200 magnification. Solid lined red box
corresponds to an area of interest corresponding to a glandular nodule, and dashed
line box highlights a predominantly stromal area.
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The individual images are numbered according to the sequence of capture. Therefore
a numerical matrix corresponding to the individual images could be created for the
whole section (see figure 2.4).
Figure 2.4 - The numerical "map" on the right corresponds to the group of individual
images that comprise the whole section of prostate tissue (stained with anti-smooth
muscle antibody). The dashed lined box corresponds to an area of stroma and solid
lined box corresponds with a nodular area as seen in figure 2.3
Two main groups of tissue were of interest. Glandular nodules are defined as having
an expansile border with glandular tissue branching into stroma. In nodules with
high epithelial content, the stroma is usually reduced to a narrow band in between
glands. Included in this definition were cystic glandular nodules which were
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composed of distended, enlarged lumens with flattened epithelium (see figure 2.5).
Stromal hyperplasia was defined as stroma with a predominant fibroblastic
component with evenly dispersed smooth muscle cells [32], Using these definitions,
a group of images representing glandular nodules and stromal hyperplasia were
selected and the morphology compared with each other.
Figure 2.5 - Micrograph (x 200 magnification) showing hyperplastic nodules stained
with anti-PSA antibody. The intervening stroma between the glands is not stained.
However, it can be seem that the stroma is compressed between the glandular
elements. Top left of the image shows a nodule with a normal branching glandular
pattern and bottom right of the image shows a nodule with a cystic pattern.
As each image comprising the mosaic corresponded to a value on the numerical
matrix, areas of interest were delineated, selected and subjected to quantitative image
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analysis. The solid red box in figure 2.3 delineates an area of interest corresponding
to a glandular nodule. Individual images that comprise this nodule are highlighted in
a solid red box in the numerical matrix or map of the section. Once the groups of
images are selected, the percentage area of smooth muscle and epithelial tissue
within each individual image are measured using quantitative image analysis
software using the protocols and methods described in section 2.6.3.
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2.6.3 Quantitative morphometric analysis of nodular and stromal areas
Using Leica Qwin image analysis software (Leica Microsystems, Cambridge, UK),
colour detection thresholds were used to identify the brown colour of the DAB
chromogen within an image. An example of an image demonstrating the brown
DAB chromogen and the subsequent software colour detection is seen in Figure. 2.6
Figure 2.6 - Top left hand image demonstrates an image stained with anti-PSA (x200
magnification). Top right hand image demonstrates the same image with the brown
colour detected by the software - signified by the blue colouring. Bottom left hand
image is an image stained with anti-smooth muscle antibody. Bottom left
demonstrates the brown chromogen detected by the software.
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The simple detection and calculation of the percentage area of brown colour within
an image was suitable for images stained with anti-smooth muscle antibody.
Calculation of the area occupied by the epithelial gland, stained with anti-PSA
antibody, requires the software to calculate the percentage area of the lumen. The
"fill" parameter of the software is used to "fill in" the area bordered by brown colour.
Figure. 2.7 demonstrates the software "filling-in" the luminal area of epithelial
tissue. These measurements are performed for each image and data is exported into
an excel spreadsheet. Calculation of the overall percentage of brown staining within
a group of images, the mean values of the measurements of the individual images
was used. Percentage of smooth muscle (%SM), percentage of epithelial tissue
(%ET) and the mean acinar area were calculated.
Figure 2.7 - The green colour shows the software "filling-in" the luminal area of the




2.6.4 Results of the comparative studies of nodular and stromal areas
This study examines the relationships between histological areas classified as
glandular nodules or stromal hyperplasia in a whole transverse section of a prostate.
The methodology of morphometric analysis is described in section 2.6.2 and 2.6.3.
The whole section of prostate is divided into four sections and subjected to
immunohistochemical staining for anti-smooth muscle myosin and anti-PSA. From
each section, an area representative of a nodule and of an area of stromal hyperplasia
was selected for analysis. The %SM and %ET was calculated from the individual
images representing this area of interest and the mean values are presented in tables
2.1 and 2.2. These values are presented with the mean %SM and %ET of the whole
section.
Section 1 Section 2 Section 3 Section 4
(Mean ±SD) (Mean ±SD) (Mean ±SD) (Mean ±SD)
18 ± 11 15 ± 7 20 ± 11 23 ± 18
42 ± 8 30 ± 5 37 ± 5 35 ±4
34 ± 16 19 ± 9 27 ± 11 30±13
ANOVA <0.005 <0.005 <0.005 <0.005
Table 2.1 - Morphology of areas classified as nodules, stroma and the whole section.
%SM is presented as a mean of the group of images selected to represent these areas
















Nodule 58 ±23 51 ±27 36 ±22 49 ±22
Stroma 24 ±21 19 ± 16 24 ±20 18 ± 15
ANOVA <0.005 <0.005 <0.005 <0.005
Table 2.2 - Morphology of areas classified as nodules and stroma. %PSA is
presented as a mean of the group of images selected to represent these areas of
interest.
The results presented in tables 2.1 and 2.2 are a summary of the morphometric
analysis of a whole prostate section at x 200 magnification. The mean number of
images used to "describe" a whole section is 332 (range is 252 - 437). Comparisons
of the %SM and %ET between areas classified as nodules and stroma were made
using single factor analysis of variance (ANOVA). This statistical test provides an
analysis of variance of the data for two or more samples. This tests the hypothesis
that the mean for each sample considered are drawn from the same underlying
probability distribution. The ANOVA demonstrates that there were significant
differences between the morphology of nodules and stroma with respect to the




In this study, the complex architecture from a transverse slice of prostate is examined
in great detail at x 200 magnification. The ability to create a histological map of the
whole section allows areas of histological interest to be identified, and in association
with the numerical map, quantified. The results presented in this section show that
areas of histological interest such as glandular nodules or predominantly stromal
areas can be represented in a quantitative manner and are found to be significantly
different to each other and to the section area taken as a whole. The description of
the histological hallmarks of BPH, nodular hyperplasia of both glandular and stromal
elements, has been reported by Price et al [32], Their work highlights the
heterogeneity of tissue composition in BPH and with increasing gland size; the
epithelial-rich nodules were the most rapidly evolving tissue component. The results
presented here confirm that there are discrete areas in the prostate with different
morphological characteristics. Within the four sections, that represent a transverse
section of a whole prostate, there is significant heterogeneity in the morphology.
There are easily recognisable histological hallmarks of BPH such as glandular
nodules and stroma hyperplasia. The results from this work are in agreement with
the studies of Price et al.
This methodology of morphometric analysis is a very labour intensive process and
places great demands on both the computer hardware and software and also the
researcher. The number of images used to represent just a quarter of a whole slice is
between 600-800 images. These images require significant computation resources to
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allow for the stitching of images together to form a mosaic. This process also
demands a significant amount of time from the researcher to manually stitch the
images together. Therefore, section 2.7 reports on the modification of the above
methodology to decrease the time involved in quantitative image analysis. It was
important not to compromise the unique opportunities that this methodology offers in
the analysis of discrete histological areas of interest within a whole transverse section
of prostate.
2.7 Quantitative image analysis of loco-regional morphology
This section describes the modifications to the methodology used in section 2.6 to
allow for the rapid and accurate location of histological areas of interest to be subject
to computerised morphometric analysis.
2.7.1 Introduction
In the methodology described above for the image capture of prepared sections of
whole prostates, the manual creation of histological maps of the sections to allow
analysis of regional areas of interest is very demanding of resources. The
development of a less demanding methodology for generating a histological map of a




The addition of the Turboscan and Surveyor software (Mediacybernetics, Berkshire,
UK) to the morphometric analysis workstation allows the user to capture the whole
section at lower magnification (x5 magnification) to create a low-resolution mosaic.
As the microscope is calibrated accurately to an automated motorised stage, the user
can use the software to pinpoint an area of interest on the lower magnification
mosaic. A new "origin" point (that is, a point on the mosaic from which the
microscope will begin scanning at again) can be placed over an area of interest, and a
user defined area can be captured at higher magnification to give images of higher
resolution suitable for quantitative image analysis.
2.7.2 Methods
In order to localise the position of the area of prostate tissue subjected to mechanical
testing, the probe tip was covered in Indian ink. The probe was applied to the tissue
surface and subjected to cyclic compressive strain to obtain the mechanical
measurements. Once the probe was removed, a small pin, measuring 0.7mm in
diameter was inserted into the tissue adjacent to the marked point. Each prostate
lobe is halved to enable mounting onto a standard 75 x 25 x 1mm Superfrost Plus
microscope slide (BDH, UK) as described in section 2.4. The prostate specimen was
processed and paraffin-embedded with the pin in situ and removed prior to
sectioning the specimen. Once the section had undergone immunohistochemical
staining, the area subjected to mechanical testing could be identified easily on the





Figure 2.8 - Mosaic image demonstrates the relationship between the number of
images corresponding to the macro probe size which is 2mm in diameter (red box)
and the selected 7x7 matrix of images for morphometric studies of loco-regional
morphology (blue box).
The mechanical measurements were conducted via a circular probe size of 2mm in
diameter (see section 2.3.1), and the area under the probe was calculated using the
•2 *2mathematical formula of 7ir (n equals 3.14 and r denotes the radius) to be 3.14mm .
The equivalent number of frames at *200 magnification is roughly 3 x 3 frames with
one frame measuring 0.7mm x 0.5mm. However, there is the issue of uncertainty of
the area of histology considered corresponding to the area subjected to mechanical
point probing. A self-similarity exercise was performed to determine the optimum




The protocol used 49 images in a 7 x 7 matrix to analyse loco-regional areas of
interest. An assessment was made as to the suitability of this arbitrarily chosen
matrix size. Within this 7x7 matrix, the image could be divided into various
smaller matrix ofwhich, 3x3 matrix would correspond to the macro probe size (see
figure 2.8). In mathematics, self-similarity describes an object that is exactly or
approximately similar to a part of itself. In this "self-similarity" test, the aim is to
assess which matrix pattern is most similar to itself. Using the framework of the 49
images, a "self-similarity" test was used to determine the pattern of results obtained
from using a 3 x 3 matrix, a 4 x 4 matrix and then a 5 x 5 matrix of images to assess
the morphology. This study quantifies the observed variability within the
histological values when considering different sizes of matrix that represent the areas
of interest studied.
Initially, a 3 x 3 matrix or "mask" was applied to the grid of 49 individual images
that contains the area of interest. A matrix of 3 x 3 yields 9 images. Within the
overall framework of the 7 x 7 matrix, it is possible to describe 25 unique groups of
9 images.
This represents the uncertainty of the actual position of the macro indenter probe on
the tissue. Using single factor analysis of variance (ANOVA), the variability and
difference within these 25 groups of 9 images was analysed. The p values from this
analysis are tabulated in the columns labelled "3 x 3" in Table 2.3. The non-
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significant analyses, i.e. p>0.05, are highlighted in bold in table. That is, there is no
significant variability between the 25 groups of 9 images. In other words, the area of
interest examined is very homogenous.
A larger matrix of 4 x 4 was applied to the 7x7 matrix frame which gave a possible
16 groups of 16 individual images. The variability and difference was analysed
between these groups using ANOVA. The p values of these analyses are tabulated in
the "4 x 4" columns. Non-significant variability between groups is highlighted in
bold. Finally a 5 x 5 matrix was applied to the 49 images which gave a possible 9
groups of 25 images. Again the same ANOVA test was applied to these groups.
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Point 3x3 (M) 4x4 (M) 5x5 (M) 3x3 (P) 4x4 (P) 5x5(P)
P70 Q1 Pt1 0.001 0.635 0.965 0.077 0.393 0.789
P70 Q1 Pt2 0.016 0.227 0.961 0.000 0.001 0.222
P70 Q1 Pt3 0.068 0.583 0.710 0.531 0.753 0.430
P70 Q1 Pt4 0.002 0.017 0.158 0.013 0.092 0.487
P70 Q1 Pt5 0.762 0.734 0.745 0.009 0.055 0.583
P70 Q2 Pt1 0.002 0.033 0.382 0.000 0.008 0.493
P70 Q2 Pt2 0.059 0.262 0.977 0.004 0.175 0.884
P70 Q2 Ot3 0.213 0.951 0.812 0.000 0.000 0.002
P70 Q2 Pt4 0.012 0.086 0.498 0.072 0.422 0.775
P70 Q2Pt 5 0.643 0.714 0.080 0.001 0.025 0.285
P70 Q3 Pt1 0.000 0.070 0.564 0.000 0.016 0.406
P70 Q3 Pt2 0.000 0.000 0.002 0.678 0.968 0.906
P70 Q3 Pt3 0.004 0.563 0.741 0.000 0.000 0.043
P70 Q3 Pt4 0.581 1.000 0.971 0.000 0.000 0.000
P70 Q4 Pt1 0.000 0.000 0.000 0.000 0.006 0.795
P70 Q4 Pt2 0.000 0.002 0.009 0.001 0.002 0.145
P70 Q4 Pt3 0.902 0.974 0.884 0.010 0.132 0.668
P70 Q4 Pt4 0.000 0.012 0.437 0.990 1.000 0.993
Table 2.3 - Results of a self-similarity test ofmorphometric analysis in loco-regional
areas of histological interest. (M) denotes sections stained for smooth muscle and
(P) denotes sections stained for epithelial tissue. 3 x 3, 4 x 4 and 5x5 denote the
different sizes of areas of interest composed of the respective number of image
frames. The bold highlights non-significant ANOVA results within the groups.
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2.7.3 Discussion and conclusions
The protocol described in Section 2.7.2 allows for a smaller area to be captured for
morphometric analysis. This protocol enables resources to be saved and less time is
required to process images. The use of a matrix of 49 individual images to analyse
an area which is morphologically different to adjacent areas has been addressed in
the "self-similarity" study summarised in Table 2.3. With respect to the column "3 x
3", a significant proportion of the ANOVA results confirm that there are significant
variability between the images captured using the 3 x 3 matrix. Considering the "4 x
4" column, the number of non-significant ANOVA results increase but the majority
of the results demonstrate significant variability between images captured. The 5x5
column shows the majority of results are non-significant in the variability within the
groups of images represented with this matrix. This implies that the area considered
by these varying matrices are not significantly different from each other and
therefore, using a matrix this size will give an "average" of the histology considered
in this small area - whilst still acknowledging the heterogeneity of the histology from
each individual microscope frame to the next. The pattern that is demonstrated is
that in the 3x3 matrix group, the variability within each of the 25 groups is
significantly different from each other. In other words, if using a matrix of 3 x 3, the
difference in histology considered in this matrix will be significantly different to the
next group. However, if using a 5 x 5 matrix, the incidence of non-significant
analysis increases in this group. This indicates that the histology considered within
the 9 groups of 25 individual images is likely not to be significantly different to the
adjacent 5x5 matrix. This observation holds true for sections stained with anti-PSA
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and anti-smooth muscle. The conclusion to this study is that a matrix of 7 x 7 is the
optimum size for the capture of an area of loco-regional morphology that will yield
sufficient detail to demonstrate the difference between areas classified as nodules and
stroma.
2.8 Quantitative image analysis of apoptotic index
This section describes the methodology used to quantitatively assess the apoptotic
index within prostate tissue. As discussed in section 2.5.3, two methods of assessing
apoptosis are required to adequately assess the apoptotic activity in tissue. The two
methods utilised in this study produce different images which have to be analysed in
a different manner.
2.8.1 Caspase-3 Immunostaining
For quantitative analysis of immunohistochemical staining, an overall score was
calculated by multiplying the intensity of the staining by the percentage of positive
cells which exhibited the staining (overall score=percentage of positive cells
multiplied by intensity). The percentages of positive cells were counted using the




The validity of the automated counting of cells was confirmed by comparing results
obtained manually by counting cells showing staining and counting the overall
number of cells within a x400 magnification image. The intensity was recorded on
an ordinal scale of 0-3. 0 indicating absent staining and 3 indicating intense staining.
The sections were evaluated independently by 2 observers and during the evaluation,
each observer had reference images indicating the different grades of intensity.
Figure 2.9 shows the reference images indicating intensity of staining.
10 randomly selected images at x400 magnification were used to quantify the
immunoreactivity of caspase-3 within prostate epithelial tissue. A mean apoptotic
score was used in the analysis. Due to the small sample size, two blocks of tissue




Control Image - Score 0
Mild staining - Score 1
Moderate staining - Score 2
Strong staining - Score 3





Deoxyribonucleic acid (DNA) fragmentation within prostate epithelial cell nuclei
was evaluated using terminal deoxynucleotidyl transferase dUTP nick end labelling
(TUNEL). The protocol for Immunostaining sections with the TUNEL kit (Promega,
Southampton, UK) is described in section 2.5.4. A reference slide was used as a
positive control which demonstrated positive staining of the nuclei. Using this slide,
the automated image analysis system was programmed to count the total number of
nuclei per microscope image captured (at x400 magnification) and then counted only
nuclei that was stained brown. The result was expressed as a percentage of positive
cells stained over the total number of cells in the section. 10 random fields were
selected per section and a mean score was calculated per section. As the sample size
was small, two blocks of tissue per patient were evaluated.





This section describes the statistical methods used in analysis of the data generated.
2.9.1 Introduction
There are two main aims of this project. Firstly, to explore the relationship between
the morphology and mechanical properties of the prostate as analysed as a whole
section. Secondly, to explore the relationship between alpha blocker therapy the
effects upon apoptotic indices and the mechanical and morphological characteristics
of prostate tissue. All statistical analysis of data was performed using Microsoft
Excel (Microsoft, USA) with the Statplus Version 2.5 add-in. In all analysis, a p-
value of 0.05 or less was considered to be statistically significant.
2.9.2 Single Factor Analysis of Variance
Single factor analysis of variance (ANOVA) was used to analyse the significance of
the data when performing multiple comparisons between the morphological and
mechanical measurements from different prostates. This test provides a simple
analysis of variance on data for two or more samples. This tests the hypothesis that
the mean for each sample considered are drawn from the same underlying probability




2.9.3 Simple linear regression analysis
Simple linear regression analysis was used to assess the strengths of the correlations
between the morphological and mechanical properties between prostates. When
using this test, it is assumed that the relationship between the two variables is linear.
The Pearson co-efficient is a measure of the strength of this relationship with a value
ranging from +1 to -1. R2 is the square of the Pearson co-efficient and describes the
percentage of the variation in the dependent variable that is influenced by changes in
the independent variable.
2.9.4 Multiple linear regression analysis
Multiple linear regression analysis was used to assess the strengths of the
correlations between the morphological and mechanical properties between prostates.
The relationships are assumed to be linear. Multiple linear regression analysis allows
for the assessment of relationships between the "response" variable and multiple
• 9
predictor or "independent" variables. The process generates a multiple R which
describes the percentage of variation in the dependent variable that is influenced by
changes in the multiple independent variables.
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2.9.5 Artificial Neural Networks
Artificial neural networks (ANN) are mathematical models based upon the physical
low-level structure of the brain. The term "artificial" in ANN is used to differentiate
the computer based system from the biological systems. ANNs have been used in
widely diverse areas such as financial, industrial and medical applications. Within
the realm of urology, Djavan et al. demonstrated the use ofANN in the diagnosis and
prognosis of prostate cancer. [136]. There are different types of ANN that are used
to assess various different types of problem areas. However, the "standard" type of
ANN used in general practice is termed a "feed-forward" network which is the type
used in this study.
The basic data structure in the human brain is the neuron which numbers
approximately 1011. The neuron has branching cell receivers called dendrites and a
projection called an axon which propagates the nerve signal. At the end of the axon,
the axon terminal transmits the electro-chemical signal across a synapse to the
receiving cell. ANNs are computer programmes that mimic some of the features of
this biological system. Neurons and synapses are modelled with various connection
strengths, termed "weights", for each pair of connected neurons. Unlike the human
brain, there are a specific set of input and output neurons, along with the synapses
and weights of the system, which correspond to instructions from a computer






Figure 2.11. Schematic diagram depicting a multilayer feedforward neural network.
This network has 7 input neurons, 2 hidden layers, 9 hidden neurons and 63
synapes/weights. These synaptic weights contain the "intelligence" of this system.
Neurons within a biological system are physically limited in the signal magnitude
that can be passed onto the next neuron. Similarly, ANNs have a need to operate
with signals restricted to a finite range usually between values of 1 and -1. Within
ANN, there are a number of mathematical functions that take incoming signals with
very large ranges and transform them into a smaller manageable range. This ensures
an internal operating range consistency within the network.
A traditional computer program consists of a set of instructions which are explicitly
carried out. ANNs are fundamentally different in that the program is told what to
know rather than what to do. This is accomplished by training the ANN to recognise
the behaviour or pattern of the desired system or dataset by repeatedly exposing the
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network to historical data which characterise the effect of interest. The initial
configuration of the network in terms of number of input neurons, hidden layers and
output neurons are chosen by the ANN designer. There are no rules or standards to
determine optimal parameter settings and trial and error based on experience seems
to be the best method.
Initially, the network synaptic weights (the "intelligence" of the system) are
randomised so that the system consists of "white noise". Training of the network
consists of entering the training dataset through the network and calculating how
many cases the system can process correctly. A correct case is defined as a result
from the ANN which is sufficiently close to the established output from the training
database. At first, the number of correct cases will be small. At the end of one
training cycle, the network training module will examine the errors and adjusts the
synaptic weights in attempt to increase the number of correct cases identified by the
system. Once the adjustments have been made, the training data is inserted into the
ANN again and this process repeats itself until the number of correct cases reaches a
maximum.
Once the training phase of the system is complete, the system must be validated with
more data from the original dataset. Usually 10-20% of the dataset is set aside to
then be analysed by the trained system and therefore assess the system's ability to
correctly process data that it has not seen before. If the validation data is assessed
and deemed similar to the training data, then the network is ready for use in this
particular application. However, if the validation data is not assessed to the same
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accuracy, then the network must be adjusted by the programmer and the training and
validation procedures repeated until the results are deemed acceptable. Once ANNs
have been constructed, trained and then validated, they are usually encased in a user-
friendly "shell" program so that data entry into the ANN is easier and the output
from the system can be displayed in a form suitable for a specific application.
In Rodvold et al., the output from an ANN is compared to the statistical model of
linear regression [137]. This was shown to illustrate how ANN is comparable to
commonly used statistical techniques in medical literature. The authors show that
when ANNs are restricted in certain ways, they behave as linear regression models.
Figure. 2.9 demonstrates the statistical equivalents of various configurations ofANN.
However, when restrictions are not placed upon ANNs, a wider range of applications
of the system can be used. ANNs are able to recognise more complex relationships
within a given dataset in which regression analysis may not identify as ANNs can
adapt to recognise non-linear relationships. Most linear regression models require
some prior assumptions about the distribution of the dataset but in using ANN,
predictive models can be created without specifying such information.
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ANN model Statistical Equivalent
Single linear perceptron Linear regression
Simple linear perceptron Multivariate multiple linear
regression
Simple nonlinear perceptrcin Logistic regression
Adaline network Linear discriminant
function
Functional link network Polynomial regression
Multilayer perceptron Simple nonlinear regression
or multivariate multiple
nonlinear regression
Figure 2.12 - Statistical equivalents of various configurations of ANN. The single
linear perceptron is the equivalent of linear regression analysis but this is a very
restricted ANN model. The multilayer perceptron ANN is the network demonstrated
above in figure 2.11
However, even though ANNs are powerful analytical tools, there are criticisms from
those who claim that scientific discipline is lacking in the application of ANNs. It
can be true that the automated processes by which many ANNs operate can lull users
into a sense of complacency when creating, training and validating a network. It can
seem as if users input the data into the network and unquestioningly accept whatever
output is given. The most difficult task when assessing an ANN is to know when the
system is finished with its analysis. The architecture of the system is an important
factor in the performance of the network. If the number of neurons and layers is too
small, there is a risk that the network will be overwhelmed and performance will
suffer. Also if the number of neurons and layers is too great, then there is a risk of
the network simply memorising the data instead of identifying trends. Determining
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this balance between under and over performance is a difficult task and usually
involves repetitive runs of the system.
In some instances, the network can be "over-trained". During the training phase of
optimising the network, the number of correct cases detected increases dramatically
in the early stages but as the data is then recognised, the gains decrease. "Over¬
training" refers to the situation when the number of correct cases identified
diminishes and the network is simply memorising the "noise" inherent in the data
presented to it. One additional concern of ANN is that once it has been trained, the
network will give an answer to any question posed even though it is not "qualified"
or suitable to answer such a question. So if a completely dissimilar set of data from
the training data is given to the ANN, it will output an answer. Therefore caution
must be used in deploying ANN for situations clearly out with its area of expertise.
The way to achieve this is to ensure that the prospective data to be analysed is not out
with the ranges present in the training dataset.
In summary, ANNs are complex mathematical tools but not dissimilar to other
commonly used statistical and analytical tools used in the medical and scientific
literature. They can be easy to use and providing that safeguards and rigorous design
and validation methodology is adhered to, ANNs offer a powerful and effective
means to solve difficult problems.
ANN is used to assess the correlations between multiple morphological and





and macro-probe point probing
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3. Loco-regional morphology and macro-probe point probing
In this chapter, the results of the loco-regional morphometric studies are presented in
context with corresponding mechanical measurements which were made using a
2mm diameter ball end probe (macro-sized probe). The methodology used to
analyse loco-regional morphology is described in section 2.7.
3.1. Loco-regional morphometric studies
Sixty two morphological and mechanical measurements were obtained from random
areas of transverse slices of whole prostate tissue from five radical
cystoprostatectomy patients. The morphology was classified as predominantly
glandular nodules or stromal hyperplasia. The percentage of smooth muscle,
epithelial tissue and the mean acinar size of the glands for both histological groups
are presented in table 3.1.
Mean %ET ± SE Mean %SM ± SE Mean Acinar Area (p2) ± SE
Nodule (n=37) 47.63 ±2.56 21.20 ± 1.38 189646 ±26530
Stroma (n=25) 30.07 ±3.91 25.62 ± 1.87 121349 ±24440
p-value <0.001 0.05 0.32
Table 3.1 - Summary of results of morphological characteristics of the glandular
nodular group and stromal group.
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The results show that there is a significant difference in the mean percentages of the
epithelial tissue and of the smooth muscle content between glandular nodules
compared to areas comprised mainly of stroma. The mean acinar areas between the
two groups do not demonstrate any significant difference.
The relationship between the smooth muscle content and the epithelial content of
glandular nodules were examined with simple linear regression analysis. The
correlation between these histological components shows a strong negative
correlation. This is shown in figure. 3.1
%ET




The relationship between %SM and %ET within the stromal group were examined
using simple linear regression analysis. See Figure 3.2 This demonstrates a strong
negative correlation compared with the relationship seen within the nodular group.
Figure 3.2 - The correlation between %ET and %SM within the stromal group
(n=25).
The distribution of areas classified as glandular nodules and stroma, according to the
calculated epithelial to stroma ratio, is presented in the histogram shown in figure
3.3. Stromal areas predominate in areas with an epithelial to stroma ratio <1.
However, there are areas classified as stroma that have a higher epithelial content
than expected. Upon review of the morphology, these points represent areas adjacent
to glandular nodules and therefore, the epithelial to stroma ratio is higher.
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I li I I.
>1 and <2 >2 and <3 >3 and <4 >4
Epithelial to Stromal ratio
■ Nodular areas ■ Stromal areas
Figure 3.3 - The distribution of epithelial to stroma ratios within nodular and stromal
areas.
The mean acinar areas of the epithelial glands in both the stromal and glandular
nodular areas are presented in figure 3.4. The mean acinar area in the glandular
nodule group is numerically greater than that of the stromal group. However, this
observation is not statistically significant. This can be attributed to a small number


























Figure 3.4 - Mean acinar area of glands within nodules and stroma.
3.2. Mechanical studies
For each test point classified as nodules or stroma, there are corresponding
mechanical measurements. The mean |E*| (a measure of tissue stiffness) and tan 8 (a
measure of tissue viscosity) are measured. The results of the mechanical studies are
presented in this section. In figure 3.5, the nodular areas are shown to be
significantly stiffer than stromal areas. In figure 3.6, the stromal areas are





Figure 3.5 - Mean |E*| in areas classified as nodules and stroma.
p=0.03
■Nodule ■Stroma
Figure 3.6 - Mean tan 5 in areas classified as nodules and stroma.
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3.3. Correlations between the morphometric studies and the mechanical
measurements in the nodular group
The morphometric studies demonstrate significant differences in smooth muscle and
epithelial tissue content between areas classified as glandular nodules and stromal
areas. The mechanical studies confirm that nodules exhibit significantly different
mechanical characteristics to stromal areas. Linear and multiple regression analysis
were used to examine the relationships between the morphometric and mechanical
parameters. The results of these studies, in the nodular group, are presented in this
section.
Correlations between smooth muscle content and mechanical measurements
The relationships between %SM and the mechanical measurements, E* and tan 8
are presented in tables 3.2 and 3.3. The results of linear regression analysis of%SM
9 9
vs. |E*| and tan 8 are presented as R values. R is the square of the Pearson co¬
efficient and describes the percentage of the variation in the dependent variable that
is influenced by changes in the independent variable. The p value of the analysis is
given if the R2 is greater than 0.5. The morphological parameters, %SM and %ET,
are stratified according to varying % content. All test points are considered initially,
and then the data is stratified into tests points containing an increasing amount of
smooth muscle or epithelial tissue. The corresponding number of test points
associated with that grouping is noted in the table.
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SM content Number of points R2 %SM vs |E*| R2 %SM vs tan 6
~
AH 37 0.063 0.004
>10% 29 0.088 0.002
>20% 20 0.116 0.020
Table 3.2 - Correlations between %SM and |E*| and tan 8 within the nodular group.
%SM is stratified according to increasing SM content.
SM Number of Multiple R2 %SM, Mean Multiple R2 %SM, Mean
content points acinar area vs |E*| acinar area vs tan 8
All 37 0.250 0.097
>10% 29 0.300 0.085
>20% 20 0.340 0.149
Table 3.3 - Multiple linear regression analysis with predictor variables of %SM and
mean acinar area, and response variables of either |E*| or tan 8 in the nodular group.
The results in table 3.2 shows that there are no strong correlations between %SM and
|E*| and tan 8 using linear regression analysis. Multiple regression analysis was used
to assess the impact of including mean acinar area into the analysis. No strong
correlations were seen in Table 3.3.
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Correlations between epithelial tissue content and mechanical measurements
ET content Number of points R2 %ET vs |E*| Rn %ET vs tan 8
All 37 0.016 0.097
>20% 35 0.011 0.095
>30% 32 0.024 0.152
>40% 27 0.020 0.182
>50% 17 0.004 0.168
>60% 8 0.338 0.325
Table 3.4 - Correlations between %ET and E*| and tan 8 within the nodular group.
%ET is stratified according to increasing ET content.
ET Number of Multiple R2 %ET, Mean Multiple R2 %ET, Mean
content points acinar area vs |E*| acinar area vs tan 8
All 37 0.130 0.332
>20% 35 0.117 0.335
>30% 32 0.170 0.404
>40% 27 0.152 0.435
>50% 17 0.181 0.417
>60% 8 0.753 (p=0.12) 0.897 (p=0.017)
Table 3.5 - Multiple linear regression analysis with predictor variables of %ET and
Mean acinar area, and response variables of either |E*| or tan 8 in the nodular group.
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In Table 3.4, there are weak correlations between %ET and |E*| and tan 8. Using
multiple linear regression analysis, the additional variable of mean acinar area was
considered in the analysis. The correlations strengthen when areas containing a
higher amount of ET (>60%) were considered (see table 3.5). In the analysis with
|E*|, there is a strong correlation seen (R2 = 0.753) but the result does not reach
significance. However, in the analysis with tan 8, there is a strong and significant
relationship with %ET >60 and mean acinar area (R2= 0.897 p=0.017).
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3.4. Correlations between the morphometric studies and the mechanical
measurements in the stromal group
In this section, the results of the correlation analyses in the stromal group are
presented. Linear and multiple regression analysis were used to examine the
relationships between the morphometric and mechanical parameters.
Correlations between smooth muscle content and mechanical measurements
SM content Number of points R7 %SMvs|E*| R2 %SM vs tan 5
All 25 0.038 0.118
>10% 24 0.020 0.127
>20% 19 0.036 0.135
>30% 9 0.002 0.075
Table 3.6 - Correlations between %SM and |E*| and tan 5 within the stromal group.
%SM is stratified according to increasing SM content.
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SM Number of Multiple R2 %SM, Mean Multiple R2 %SM, Mean
content points acinar area vs |E*| acinar area vs tan 8
All 25 0.083 0.422
>10% 24 0.080 0.377
>20% 19 0.164 0.387
>30% 9 0.187 0.673 (p=0.06)
Table 3.7 - Multiple linear regression analysis with predictor variables of %SM and
Mean acinar area, and response variables of either |E*| or tan 8 in the stromal group.
Table 3.6 shows the correlation between %SM and |E*| and tan 8 in stromal areas
containing an increasing SM content. There are no significant correlations shown.
In Table 3.7, multiple linear regression analysis was used to assess the relationship
between the predictor variables of %SM and mean acinar area with the response
variables of |E*| and tan 8. There are weak correlations with %SM, mean acinar area
and |E*|. There are stronger correlations between stromal areas with >20% smooth




Correlations between epithelial tissue content and mechanical measurements
ET content Number of points R2 %ET vs |E*| R2 %ET vs tan 8
All 25 0.003 0.068
>10% 19 0.007 0.081
>20% 14 0.138 0.019
>30% 27 0.294 0.013
>40% 5 0.024 0.013
Table 3.8 - Correlations between %ET and |E*| and tan 5 within the stromal group.





Multiple R2 %ET, Mean
acinar area vs |E*|
Multiple R2 %ET, Mean
acinar area vs tan 8
All 25 0.218 0.128
>10% 19 0.415 0.449
>20% 14 0.376 0.210
>30% 11 0.422 0.397
>40% 5 0.985 (p=0.172) 0.993 (p=0.116)
Table 3.9 - Multiple linear regression analysis with predictor variables of %ET and
Mean acinar area, and response variables of either |E*| or tan 8 in the stromal group.
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Table 3.8 shows weak correlations between %ET and |E*| and tan 8. In Table 3.9,
multiple regression analysis, demonstrates a strong correlation with %ET, mean
acinar area and the mechanical measurements |E*| and tan 5 in stromal areas with
>40% epithelial content. However these relationships do not achieve statistical
significance as a result of the diminished numbers in this group (n=5).
The results presented in sections 3.3 to 3.4 demonstrate that linear regression
analysis is unable to discern meaningful relationships between morphometric
parameters, %SM and %ET, and the associated mechanical measurements. It would
appear that there are other factors unaccounted for. The morphometric parameter of
acinar size of the glandular epithelium may have an impact upon the mechanical
measurements. Multiple regression analysis was used to assess the impact of this
additional morphometric parameter upon the relationships with the mechanical
studies. There were stronger correlations seen in the epithelial studies in both the
nodular and stromal groups when considering tissues with an increasing epithelial
content (see tables 3.5 and 3.9). In the smooth muscle studies, a stronger correlation
was seen in the analysis of%SM, mean acinar area vs. tan 8 in the stromal group (see
table 3.7). However, a significant number of test points are composed of a varying
amount of smooth muscle and epithelial tissue and do not have a strong relationship
with the mechanical parameters. Artificial neural networks are able to recognise
more complex relationships within a given dataset in which regression analysis may
not identify as ANNs can adapt to recognise non-linear relationships. The results of




3.5. The assessment of the impact of the morphology upon the mechanical
properties using Artificial Neural Networks
A brief overview of artificial neural networks is presented in section 2.9.5. One of
the many important applications of neural networks is pattern recognition. The
analysis of any dataset by ANNs can be considered in three stages. The initial stage
is the training phase or cycle of the network whereby a proportion of the raw data
(input data), about 70%, is analysed in a cyclical manner until the maximum number
of correct cases (output data) is reached. A correct case is defined as a result from
the ANN which is close to the established output from the training database or input
data. In effect, the network is trained to associate its outputs with input patterns.
The dataset is organised differently from the previous studies. In this study, each
parameter, whether it is morphometric or mechanical data, is represented by a
column of raw numerical data. No attempt is made to stratify or classify the data.
Once the training phase of the system is complete, the system must be validated with
more unseen data from the original dataset. Usually 10-20% of the dataset is set
aside to be analysed to assess the system's ability to correctly process the original
data. Validation is when the network identifies the input pattern (the unseen data)
and tries to output the associated target pattern. Once the system is validated, the
network can be used to identify groups or patterns of data within any given dataset.
In this case, the network gives the output that corresponds to the learned input pattern
from the training phase (the target output). This is the final "test" phase of the ANN.
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The relationships between the morphometric, %ET and %SM, and the mechanical
parameters, |E*| and tan 5 were assessed using an ANN. The ANN generates an
output plot comprising three graphs representing the three stages of analysis. This
output plot is a regression plot which shows the relationship between the outputs of
the network and the targets. The ANN assigns a calculated value to both output and
target values during the analysis. The dashed line in each axis represents the perfect
result: output = targets. The solid coloured lines represent the best fit linear
regression line between outputs and targets. The R value is an indication of the
relationship between output and target.
Figure 3.7 shows the ANN analysis between %ET and |E*|. The training plot shows
that the ANN is identifying a strong positive correlation between the two variables.
The plot of the validation phase confirms that there is still a strong correlation
between %ET and |E*| dataset. The reduction in data points reflect the process that
10-20% of the overall dataset is used in this phase (n=8). The final plot shows the
output from the test phase. There remains a strong positive relationship between
these two parameters despite a reduced dataset (n=8). In figure 3.8, there are similar
conclusions drawn from the regression plots of the ANN analysis of%ET and tan 8.
125
Chapter Three
Validation Outputs vs. Targets, R=0.64326
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Figure 3.7 - Regression plot of the ANN analysis of the parameters %ET and |E*|. A
strong and positive relationship is observed between these two variables.
Training Outputs vs. Targets. R=0.65225 Validation Outputs vs. Targets. FM) 853S5 Test Outputs vs Targets. R=073805
Targets TTargets T Targets T
O Test Data Points
Best UnearFit
O Validation Data Points
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Figure 3.8 - Regression plot of the ANN analysis of the parameters tan 8 and %ET.
A strong and positive relationship is seen between these two variables.
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The ANN was used to examine the relationship between all four parameters, %ET
and %SM and |E*| and tan 8. Figure 3.9 shows the regression plot from this analysis.
Examining the regression analysis of the training data plot, the ANN has found
strong and significant relationships between the datasets of all four variables
(R=0.806). The regression analysis of the validation and test plots show that the
output (the testing of unseen data) corresponds strongly to the targets (the
relationships learned during the training phase). This suggests that there are
meaningful relationships between the morphometric and mechanical parameters
which have not been identified using linear regression tools.
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Figure 3.9 - Regression plot of the ANN analysis of the parameters %SM, %ET, |E*|




3.6. Loco-regional morphology and macro-probe point: summary of findings
The main findings from the study of loco-regional morphology and the mechanical
measurements are summarised below:
1. There are significant histological differences between areas of loco-regional
morphology classified as nodules and as stroma. The epithelial to stroma ratio is
greater in the nodular areas compared with stromal areas.
2. The mean acinar area of glandular epithelium is greater in nodules than in
stroma.
3. Areas classified as glandular nodules have a significantly higher mean |E*| than
areas classified as stromal areas.
4. Areas classified as stromal areas have a significantly higher tan 8 than areas
classified as nodules.
5. Weak correlations were found between the morphological and mechanical
measurements as assessed using linear and multiple linear regression analysis.
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6. Within the nodular group, there are strong correlations between %ET, mean
acinar area and the mechanical parameters of |E*| and tan 5 in areas composed
predominantly of epithelial tissue.
7. Artificial neural network analysis demonstrated strong relationships between the




The results from Table 3.1 demonstrate that discrete areas of histological interest that
have been classified as either nodular or stromal areas are significantly different in
their composition with respect to %SM and %ET. This forms the basis of the
concept that loco-regional morphology can be qualitatively classified and
quantitatively assessed. In figure 3.4, the mean acinar area of the glandular
epithelium in areas classified as nodules is greater than that of stromal areas.
However, this is observation does not reach statistical significance and can be
explained with reference to figure 3.3. The composition of each nodule stromal area
can be represented by the epithelial to smooth muscle ratio (ET:SM). The histogram
in figure 3.3 shows the distribution of nodular and stromal areas as a ratio of
epithelial and smooth muscle. A significant proportion of stromal areas (n=15) have
a ET:SM of less than one. However several areas classified as stroma are shown to
contain a greater epithelial composition than expected. The morphology was
reviewed and these areas were found to be adjacent to areas containing glandular
nodules. The protocol for image capture and analysis dictates that an area of interest
is represented by 49 images (arranged in a 7 x 7 matrix). The histological
measurements can therefore partly represent areas that do not reflect the type of
tissue tested. In areas adjacent to glands that may contain predominantly epithelial
tissue, the morphometric measurements may be incorrectly skewed towards a tissue
type. These pitfalls area acknowledged in the methodology presented in section 2.7,
where the issue of the size of image capture and the rationale for using a larger
matrix size is discussed.
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Macroscopic examination of the slice of a whole prostate clearly reveals areas of
nodular formation (see figure 1.6) which were found only in the transition zone of
the prostate. Morphometric analysis of these nodules revealed that they were mainly
composed of glandular epithelium with corresponding lower amounts of smooth
muscle. Table 3.1 summaries the histological differences between nodules and
stroma. The mean %ET composition of nodules is significantly greater than in
stroma. However, the %SM content in stromal areas is significantly greater than that
in nodules. The histogram in figure 3.3 demonstrates the distribution of the
histological composition of nodules. There are a greater proportion of nodules that
have an epithelial to smooth muscle ratio greater than two. In McNeal's original
work, he demonstrated that there is diffuse enlargement of the transition zone with
increasing age. Initially there is an increase in small nodules, mainly stromal, in the
transition zone. However, subsequently there is an increase in nodule size which is
associated with an increase in the epithelium to stroma ratio [25]. These nodules are
considered a morphologic hallmark of BPH. Subsequent work from Price et al
showed that small volume TURP resections were comprised mainly of smooth
muscle with glandular tissue only comprising approximately 5% of the resected
tissue. However in larger TURP resections and in whole prostate specimens from
enucleations, nodules with an epithelial to smooth muscle ratio greater than one,
predominated in the transition zone [32], Schuster et al examined the tissue
composition of TURP chippings according to the resection weight and found that as
resection weight increased, there was a four-fold increase in the amount of the
epithelial component [33]. The morphometric characteristics of these nodules are in
agreement with the work noted above.
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Nodule exhibit significantly different morphology compared with stromal areas. The
mechanical studies demonstrate that nodules exhibit significantly different
characteristics to stromal areas. In figure 3.5 and 3.6, nodules are shown to be stiffer
and less viscous that stromal areas respectively. Using linear and multivariate
regression analysis, relationships were sought between the mechanical and
morphological characteristics of nodules. No correlation was seen between %SM
and the mechanical properties (see tables 3.2 and 3.3). Figure 3.1 demonstrates the
spread of histological composition of ET and SM within the nodule group. Within
the nodular group, the mean %SM was only 21.2% which may explain the lack of
correlation seen. The relationship between %ET and the mechanical properties was
found to be weak. The impact of mean acinar area was assessed using multivariate
regression analysis and strong relationship was seen only in nodules containing
greater than 60% ET. These results are non-significant due to the very small sample
size of the group. These findings suggest that in nodules mainly composed of
epithelial glands with large acini, there is a significant impact upon the mechanical
measurements. In nodules composed of less than 60% ET, weak correlations are
seen and this may represent the heterogeneity of the morphology dataset as
illustrated in figure 3.1. There is wide variation in the composition of nodules.
Artificial neural networks are used in situations whereby linear statistical tools are
unable to recognise a relationship or patterns within a dataset. In section 3.5 the
results of the ANN analysis show that there are significant relationships between the
morphometric and mechanical parameters. The ANN can recognise non-linear
patterns that linear statistical tools may fail to understand. However, the ANN is
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unable to define precisely the relationship between the parameters. Instead, the ANN
will train itself to look for patterns within a given dataset, apply the learnt pattern to
an unseen set of data, and output a correlation between the new data and the
previously learnt relationship. Adding further parameters may strengthen or weaken
the output of the network. In figure 3.9, the impact of adding both the mechanical
and morphometric parameters results in a stronger correlation between the variables.
These findings suggest that the structure-property relationship in nodules may be
dependent upon more than one variable or factor. A significant proportion of the
composition is unaccounted for and it may be that other morphological components
may exert an effect on the mechanical properties. The prostate stroma is composed
of smooth muscle and associated connective tissue such as collagen, elastic fibres,
fibroblasts, vessels and nerves. It is possible that these components may be a
significant determinant of the mechanical properties of the tissue. However, based
on work by Phipps et al, smooth muscle and epithelial tissue were the main
determinants of the mechanical properties of prostate tissue from TURP chippings
[127, 128], Collagen III did not demonstrate any significant relationship to the
mechanical characteristics of TURP tissue. Several immunohistochemical stains
were evaluated for identifying fibroblasts but the results were weak. At present, the
influence that collagen types and other components of the stroma have upon the
mechanical properties of prostate tissue is currently unknown.
It appears that nodules display a mechanical property that does not correspond to the
structure-property relationship identified in TURP tissues. Phipps et al demonstrated
that prostate tissues from TURP containing a greater proportion of SM are stiffer
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irrespective of their epithelial tissue content [127]. In this relationship the histology
from TURP chippings is considered homogenous based upon morphometric studies
of several TURP chippings [138], It was also assumed that the TURP chippings
were isotropic, that is their mechanical characteristics were the same irrespective of
the direction of mechanical testing. In the study of transverse sections of whole
prostates one must acknowledge the heterogeneity of the tissue composition found in
such a specimen. Even within specific and discrete histological structures such as
glandular nodules, there remains a significant degree of variability of tissue
composition. One must also consider such a specimen to be anisotropic. Differing
mechanical measurements were obtained from testing of a single nodule in two
separate but adjacent locations. This may simply be a function of the underlying
heterogeneous morphology of the nodule (the morphology was slightly different at
the individual test points). However, it may also be a reflection of the 3-dimensional
configuration of the structure, which may not be uniform in shape. Further studies
will be required to explore these issues.
The mechanical properties of nodules clearly demonstrate that these structures are
significantly stiffer than stromal areas (see figure 3.5) and are significantly less
viscous than stromal areas (see figure 3.6). The observations and descriptions of
glandular nodules given by McNeal may explain these findings [25], The glandular
proliferative process leads to tight packing of epithelial glands within a given area
(see figure 1.5). The nodule is usually surrounded by a thin band of smooth muscle
or stroma. One may postulate that fluid filled glands that are constricted by
surrounding connective tissue bands may exhibit increased pressure within the
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glands. This may explain the almost exponential rise in |E*| of nodules compared to
surrounding stroma. A further explanation may relate to work performed by
Watanabe et al. His group developed the concept of prostatic pressure coefficient
(PPC). This is a measure of the pressure within the prostatic urethra using a balloon
and a pressure transducer to measure the change in pressure from the balloon. The
basis of this concept is that when a nodule develops, this exerts an outwards pressure
on the surgical capsule of the prostate. The capsule also pushes back on the nodule.
The elastic qualities of the surgical capsule may play a role in whether a nodule
causes bladder outflow obstruction. If the capsule is sufficiently elastic, then the
outward push from the nodule is accommodated. However, if the capsule is
inelastic, then very little pressure within a nodule could cause clinical symptoms of
obstruction. The raised [E*| values associated with nodules may be a function of the
constrictive force of the prostatic surgical capsule. Further studies to assess the
elasticity of the surgical capsule are required to understand these issues.
The results presented in this chapter demonstrate that there are significant differences
with respect to the morphological and mechanical properties of loco-regional areas
within a transverse slice of whole prostates. The inherent heterogeneity of the
morphology and non-linear distribution of the data has posed a significant challenge
to understanding the structure -property relationship of glandular nodules and
stromal areas. However, the use of ANN has confirmed that there are strong
correlations between the morphology and the mechanical properties. Further
morphological studies to characterise the remaining components of the stroma may








4. Loco-regional morphology and micro-point probing
In collaboration with a micro-engineering facility, a parallel aim of this overall
project is to develop a micro-engineered palpation device for the measurement of
mechanical properties of prostate tissue. The rationale for the reduction in size of the
device is that it should be able to be deployed via the working channel of a flexible
cystoscope. In the design brief of the engineering department, the micro-engineered
probe is designed around a hydraulic system with a piston at the operating end to
apply the compressive strain to the tissue. The dynamic compressive force applied to
the tissue will then allow for the measurement of the mechanical properties to be
made. The compressive force is transmitted via a silicone diaphragm measuring
200pm x 500pm. This diaphragm is significantly smaller in cross-sectional area than
the macro probe. The aim of this study presented in this section, is to investigate the
mechanical measurements that are made with a micro-indenter measuring 400pm x
500pm. The area covered by the macro probe is 9.86mm2 compared with 0.2mm2 of
the micro probe. The reduction in size of the indenter allows for the study of
mechanical properties at a scale that approaches microscopic feature size.
Figure 4.2 illustrates the significant reduction in size of the indenter in relation to the
morphology as represented by a mosaic image. The area occupied by the macro
indenter is represented by 3 x 3 microscope frames at x200 magnification and the










t Hydraulic fluid to p__p , ■ , ^actuate the piston ' —' o' w 0'
Figure 4.1 - Schematic diagram of the design of the micro-engineered probe. The
piston (coloured red) acts upon a silicone diaphragm which measures 200pm x
500pm in size. This diaphragm will be in contact with the prostate tissue.
This presents the challenge of capturing loco-regional areas of interest that have been
subjected to mechanical testing using the micro probe. The protocol outlined in
section 2.7.3 captures an area represented by 49 images (a matrix of 7 x 7 frames) of
histological data. Using this method of selecting points of interest, there is
confidence that this area will include the point of mechanical measurement.
However, the trade off is increasing the uncertainty that the histological
measurement calculated from a large area will truly represent the underlying
morphology that was subjected to mechanical testing. It is acknowledged that
improvement is required to increase the precision of localising the test point
subjected to mechanical testing. However, the current protocol for the analysis of
loco-regional morphology is a balance of the workload burden of analysis ofmultiple
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images with the goal of as accurate as possible , localisation of the histology
subjected to testing.
Figure 4.2 - Mosaic image showing the relative difference in sizes of the macro and
micro probe indenters. The area outlined by the dashed line is the area of
morphology captured using a matrix of 7 x 7 frames.
4.1. Loco-regional morphometric studies
7 radical prostatectomy specimens were used for this study and 71 individual point
probing measurements were obtained from the fresh tissue specimens.
Morphological studies were performed on the tissue after preparation as described in
sections 2.4 to 2.7.
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Morphological areas of interest corresponding to the tissue area subjected to
mechanical testing were classified into two groups in accordance with their
histological appearance. The area of morphological interest is represented by 49
individual images (taken at x 200 magnification) configured in a 7 x 7 matrix as
described in section 2.7. The %ET and %SM for each individual image were
determined by computerised morphometric analysis. The mean values of%SM and
%ET of each individual 7x7 matrix were used. The mean acinar area of epithelial
glands was measured. The methodology is described in depth in section 2.7.
The results described in table 4.1 show that there are significant morphological
differences between areas classified as stroma and nodular areas. Nodules are shown
to compose of predominately epithelial glands whereas stromal areas are shown to
have a significantly increased smooth muscle composition. The mean acinar areas of
the glands are significantly larger in nodules than in stromal areas.
Mean %ET ± SE Mean %SM ± SE Mean Acinar Area (p2) ± SE
Nodule (n=38) 50.08 ±2.23 21.26 ± 1.23 137953 ± 10986
Stroma (n=33) 29.37 ±2.14 26.27 ± 1.16 82063 ±6378
p-value <0.001 <0.01 <0.005




Figure 4.3 demonstrate the relationship between %ET and %SM within the nodule
group. There is a significant negative relationship between the %ET and %SM. This
is a reflection of greater ET content within areas classified as nodules than in stromal
areas.
%ET
Figure 4.3 - Correlation between %ET and %SM in the nodule group (n=38)
The relationship between %ET and %SM within the stroma group is shown in figure
4.4. There is a significant negative relationship between %ET and %SM within the





Figure 4.4 - Correlation between %ET and %SM in the stroma group (n=33)
Figures 4.3 and 4.4 demonstrate that there are significant relationships between these
variables; however the correlations are weak within both the nodular (R2 = 0.183)
and stromal groups (R2 = 0.183). This may reflect the heterogeneity and variability
seen within both groups. A study of the distribution ofmorphology represented as a
ratio of epithelial to smooth muscle components highlight the significant overlap in
describing areas of interest using values of %ET and %SM. The calculated ratio of
%ET to %SM for each area of interest is shown in the distribution histogram in
figure 4.5. Moving from left to right, the greater the epithelial to smooth muscle
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Figure 4.5 - Histogram of the distribution of areas of interest represented as a ratio of
epithelial to stromal tissue. The number above the columns corresponds to the
number of points within the stratified group.
In the nodule group, 12 areas have an epithelial to stromal ratio greater than 3.
Stromal areas have an epithelial to smooth muscle (ET:SM) ratio less than 3.
Between an ET:SM ratio of greater than 1 and less than 3, there is a significant
overlap of both nodular (24 areas) and stromal (20 areas) areas represented. The
dataset for both the nodule and stroma groups were reorganised to with respect to
ET:SM ratio. The relationships between %ET and %SM were re-examined using
linear regression analysis, but the correlations were found to be weak. The use of
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epithelial to smooth muscle ratio did not sufficiently differentiate between stroma
and nodular areas.
The mean acinar area of the epithelial glands in the stroma and nodular groups are
shown in figure 4.6. There is a significant difference between the mean acinar area
of the epithelial glands in areas designated as nodules (137953 p.2) compared with
stroma (82063 p2). The architecture of epithelial glands themselves within the

























Figure 4.7 - Correlation between mean acinar area and %ET of epithelial glands
within nodules (n=38).
Figure 4.7 shows the strong and significant relationship between %ET and the mean
acinar area of epithelial glands within nodular areas (R2=0.25 p<0.005). In nodules
with increasing %ET, the size of the acini increases. However, the correlations
between %SM and mean acinar area were weak in the nodule group.
The morphological data for the nodule group was again represented as epithelial to
smooth muscle ratio (see figure 4.5) to explore whether stratification of the data
would improve the correlations with the parameter, mean acinar area. The %ET data
was sorted according to the ratio of epithelium to smooth muscle. Table 4.2
demonstrate no significant relationships between %ET and mean acinar are when the
dataset is represented in this way.
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The relationship between mean acinar area and the %ET and %SM in the stroma
group were examined using linear regression analysis. The correlations between the
morphological parameters %ET, %SM and mean acinar area were weak.
ET:SM ratio Number of points R2 mean acinar area vs %ET
All (0-9) 38 0.25 (p<0.005)
<2 16 0.11
>2 and <3 10 0.05
>3 and 4< 7 0.34 (p=0.13)
>4 5 0.10
Table 4.2 - Correlation between mean acinar area and %ET in the nodule group
according to increasing ET:SM ratio
146
Chapter Four
4.2. Summary of loco-regional morphometric studies
1. There are significant differences in the composition of nodules and stromal areas
with respect to %ET, %SM and mean acinar area.
2. There is a significant overlap of tissue composition represented by ET:SM ratio
in both nodules and stromal groups.
3. There is a strong relationship between mean acinar area and %ET within the
nodule group.
4. These studies show that the measured individual morphometric parameters, %ET





71 individual point probing measurements were obtained from the fresh tissue
specimens ex vivo. For each test point classified as nodules or stroma, there are
corresponding mechanical measurements. The probe used in the application of a
compressive cyclic strain to the tissue is micro-engineered to a size measuring
400pm x 500pm as described in section 2.3. The mean |E*| (a measure of tissue
stiffness) and tan 5 (a measure of tissue viscosity) are measured. The results of the













Figure 4.8 - Mean |E*| in areas classified as nodules and stroma. There is a





Figure 4.9 - Mean tan 8 in areas classified as nodules and stroma. No difference was
found between groups.
In figure 4.8, there is a significant difference between |E*| within nodules compared
with stromal areas. Nodules were found to be significantly stiffer than stromal areas.
However, tan 5 was not found to be significantly different between the two groups as
shown in figure 4.9.
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4.4. Correlations between the morphometric studies and the mechanical
measurement in the nodule group
The morphometric studies demonstrate that there are significant differences in
smooth muscle content, epithelial content and mean acinar area between areas
classified as glandular nodules and stromal areas. The mechanical studies show that
there is a significant difference in |E*| between nodules and stroma. However, there
is no difference found in tan 8 between the groups. Linear and multiple regression
analysis were used to examine the relationships between the morphology and
mechanical measurements. The results are presented as R2 values and the values
highlighted in bold are significant correlations with the corresponding p value noted.
In addition to the analysis of multiple variables, the data is stratified into different
groups defined by percentage of epithelial or smooth muscle content to understand
the impact this may have on the analysis. The results of these studies, in the nodular
group, are presented in this section.
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Correlations between smooth muscle andmechanical measurements
SM content i(%) Number of points R2 %SMvs|E*| R2 %SM vs tan 8
All 38 0.02 0.02
>10% 35 0.007 0.007
>20% 20 0.15 0.01
>30% 6 0.11 0.10
Table 4.3 - Correlations between %SM and |E*| and tan 8 within the nodular group.
%SM is stratified according to increasing SM content.
SM content
(%)
Number of Multiple R2 %ET, Mean
points acinar area vs |E*|
Multiple R2 %ET, Mean
acinar area vs tan 8
All 38 0.306 0.166
>10 and <20 18 0.245 0.128
>20 and <30 14 0.301 0.618
>30% 6 0.945 (p=0.035) 0.869
Table 4.4 - Multiple linear regression analysis with predictor variables of%SM and
mean acinar area, and response variables of |E*| and tan 8 in the nodule group.
The results in table 4.3 do not show significant relationships between %SM and |E*|
and tan 8 using linear regression analysis. Multiple regression analysis was used to
assess the impact of including mean acinar area into the analysis. The results shown
in table 4.4 demonstrate a significant positive relationship between %SM, mean
acinar area and the |E*| in tissues containing >30% SM. This observation perhaps
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reflects the finding that in tissues with a greater amount of SM content, the higher the
|E*|. There is a positive relationship between %SM content of >30% with %ET,
mean acinar area and tan 8, but this does not reach statistical significance. In
stratifying the data according to %SM, there are fewer points within each group and
therefore, this correlation is based only on a small number of data points. Despite
incorporating additional measurements of morphology, the correlations between
morphological and mechanical measurements are still weak.
Correlations between epithelial tissue andmechanical measurements
ET content (%) Number of points R2 %ET vs |E*| R2 %ET vs tan 8
All 38 0.06 0.04
>20% 37 0.02 0.03
>30% 35 0.04 0.002
>40% 30 0.06 0.001
>50% 19 0.12 0.01
>60% 9 0.13 0.07
Table 4.5 - Correlations between %ET and |E*| and tan 8 within the nodular group.







Multiple R2 %SM, Mean
acinar area vs |E*|
Multiple R2 %SM, Mean
acinar area vs tan 5
All 38 0.276 0.231
>18 and <40 8 0.545 0.947 (p=0.003)
>40 and <50 10 0.479 0.681
>50 and 60 11 0.650 0.543
>60 and <80 9 0.672 0.316
Table 4.6 - Multiple linear regression analysis with predictor variables of %SM and
mean acinar area, and response variables of |E*| and tan 8 in the nodule group
The results shown in table 4.5, there are no significant relationships between %ET
and |E*| and tan 5 using linear regression analysis. In table 4.6, there is a significant
relationship between %SM, mean acinar area and tan 5 within the group of points
with low ET content (>18% and <40%). However, there are no significant
correlations seen in the analysis between %ET with %SM, mean acinar area and |E*|.
Correlations between mean acinar size and mechanical measurements
Using simple linear regression analysis, the morphological measurements of %SM,
%ET, mean acinar area and ET:SM ratio were compared with |E*| and tan 8 within
the nodule group. A significant positive correlation was seen in the relationship
between mean acinar area and tan 8 as shown in figure 4.10. As mean acinar size
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increases, the phase lag, measured by tan 8 increases. Tan 8, in the viscoelastic
model, is considered the damping force of the model. This correlation suggests that
tan 8 is sensitive to gland size and the greater the gland acini size, the higher the
measured viscosity.
Mean acinar area (micron2)
Figure 4.10 - Correlation between mean acinar area and tan 8 (n=38) in the nodule
group.
The correlation between mean acinar area and tan 8 shown in figure 4.10 is
strengthened when the data is stratified by ET:SM ratio. In nodular areas with an
ET:SM ratio of <2, the relationship between mean acinar area and tan 8 is
















Figure 4.11 - Correlation between mean acinar area and tan 5 (n=16) within the
nodule group in areas where the ET:SM ratio is <2.
There is a significant positive relationship between mean acinar area and tan 8. From
these results, it appears that mean acinar area is an important morphometric
measurement that is shown to have strong relationships with the mechanical
measurements within the nodule group.
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4.5. Correlations between the morphometric studies and the mechanical
measurement in the stroma group
Correlations between smooth muscle and mechanical measurements
SM content Number of points R2 %SMvs|E*| R2 %SM vs tan 8
AH 33 003 0.20 (p=0.01)
>20% 28 0.02 0.01
>30% 12 0.001 0.01
Table 4.7 - Correlations between %SM and |E*| and tan 8 within the stroma group.
%SM is stratified according to increasing SM content (n=33). There is a significant
correlation between %SM and tan 8 (see figure 4.12)
Number of Multiple R %SM, Mean Multiple R~ %SM, Mean
content . ... ' , . f '
points Acinar Area vs |E*| Acinar Area vs tan o
All 33 0221 0.406
>20% 18 0.195 0.165
>30% 9 0.514 0.131
Table 4.8 - Multiple linear regression analysis with predictor variables of %ET and




Figure 4.12 - Correlation between %SM and tan 5 (n=33) within the stroma group.
Table 4.7 demonstrate a significant correlations between %SM and tan 5 (R =0.2;
p=0.01). In figure 4.12, the correlation graph shows a negative relationship between
increasing %SM and tan §. Stromal areas are shown in table 4.1 to comprise of
significantly greater %SM compared with nodular areas. The correlation between
%SM and tan 8 suggest that as %SM increases, the glandular composition of the
tissue decreases, and this is reflected in the lower viscosity of the tissue.
Table 4.8 show the correlation results using multiple regression analysis. No
significant correlations are seen within %SM, mean acinar area and E*| or tan 8.
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Correlations between epithelial tissue and mechanical measurements
ET content Number of points R2 %ET vs |E*| R2 %ET vs tan 8
All 33 0.002 0.007
>20% 23 0.014 0.005
>30% 16 0.050 0.054
>40% 7 0.174 0.102
Table 4.9 - Correlations between %ET and |E*| and tan 8 within the stroma group.
%ET is stratified according to increasing ET content.
ET content Number of Multiple R2 %SM, Mean Multiple R2 %SM, Mean
(%) points acinar area vs |E*| acinar area vs tan 8
All 33 0.065 0.133
>20 21 0.105 0.227
>30 15 0.258 0.341
>40 7 0.898 (p=0.037) 0.645
Table 4.10 - Multiple linear regression analysis with predictor variables of %SM and
mean acinar area, and response variables of |E*| and tan 8 in the stroma group
Table 4.9 shows the correlations between %ET and |E*| and tan 8 in the stroma
group. No significant correlations are seen. Table 4.10 shows the results using
multiple regression analysis with %ET and Mean acinar area, and the response
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variables of either |E*| or tan 8. There is a significant correlation between %ET,
%SM, mean acinar area vs |E*| in stromal areas containing >40% of ET. The
relationship between %ET, %SM, mean acinar area vs tan 8 do not reach statistical
significance.
4.6. The assessment of the impact of the morphology upon the mechanical
properties using Artificial Neural Networks
In section 4.4 and 4.5, it has been shown that there are very few significant
correlations between the morphometric and mechanical parameters. Linear
regression and multiple regression analysis has failed to identify strong relationships
between the groups. The significant correlations observed within sub-group data-sets
however, cannot completely explain the complex interactions and relationships
between the morphology and mechanical properties seen in a whole section of
prostate tissue. Artificial neural networks are able to recognise complex
relationships that regression analysis may not be able to identify.
As in the work presented in section 3.5, the use and the results of ANN are reported
in this section. The organisation of the dataset is similar to the method explained in
section 3.5. Briefly, in this study, each parameter whether it related to morphometric
or mechanical data, is represented by a column of raw numerical data. The ANN
analyses the data in three stages; the training, validation and finally the output phase.
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ANN analysis of%ET and %SMwith £*
Training Outputs vs. Targets, R=0.44017
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Figure 4.13 - Regression plot ofANN analysis of the parameters %ET and |E*
There is no relationship between |E*| and %ET (R2=0.088).
Training Outputs vs. Targets. R=0.24455 Validation Outputs vs. Targets, R=0.6725















O Validation Data Points
Best Linear Fit
A= T










Test Outputs vs. Targets, R=0.10153
15 20 25 30 35 40
Targets T
Figure 4.14 - Regression plot ofANN analysis of the parameters %SM and |E*|.
There is no relationship seen between |E*| and %SM (R2=0.101).
From this analysis shown in figures 4.13 and 4.14, the morphometric variables, %SM
and %ET do not show a strong relationship with the mechanical variable, |E*|.
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ANN analysis of%ET and %SMwith tan 5
Training Outputs vs. Targets, R=0.49503
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Best Linear Fit
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Figure 4.15 - Regression plot ofANN analysis of the parameters %ET and tan 8.
There is a significant relationship between these variables (R2=0.625)
Training Outputs vs. Targets, R=0.2854 Validation Outputs vs. Targets, 6=0 39668
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Figure 4.16 - Regression plot ofANN analysis of the parameters %SM and tan 8.
There is no significant relationship between these two variables (R2=0.226).
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In figures 4.15, there is a significant positive relationship between tan and %ET. No
relationships were seen between %SM and tan 8. However, in table 4.7 and in figure
4.12, there is a weak but significant negative relationship between %SM and tan 8.
The observations calculated using linear regression analysis is based upon
classification of the dataset into stroma and nodular groups. In the ANN analysis,
the dataset is not classified, and the ANN performs the analysis on the dataset as a
whole. These results are not directly comparable, but the findings highlight
difficulty in identifying strong relationships within a heterogeneous dataset.
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Figure 4.17 - Regression plot of ANN analysis of the parameters %SM, %ET and
|E*| and tan 8. There is a strong relationship between the morphometric parameters




The ANN analysis of both the morphometric and mechanical parameters in figure
4.17 demonstrate that there are significant positive relationships between all four
parameters. It can be inferred that the neural network is seeing patterns and
variations that are not possible when assessed in a linear fashion. The drawback of
the ANN analysis is that the system does not declare the path it took to arrive at these
conclusions. The raw data that is entered into the Neural Network is not shown in
any original form at the end of the analysis. The graphical points do not indicate
numerical values of morphological or mechanical data. Instead they are markers of
how close the output points are to the validation data points or training data points.
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4.7. Loco-regional morphology and micro-probe point: summary of findings
The main findings from the study of loco-regional morphology and the mechanical
measurements are summarised below:
1. There are significant histological differences between areas of loco-regional
morphology classified as nodules and as stroma.
2. Mean |E*| in nodular areas are significantly higher than in stromal areas.
3. Mean acinar area is an important morphological parameter. There are significant
correlations between mean acinar area and the mechanical measurements.
4. Multiple linear regression analysis yielded mixed results in analysis of the impact
ofmultiple morphometric variables upon the mechanical measurements.
5. Artificial neural networks analysis demonstrate that there are significant
correlations between all the morphological parameters (%ET and %SM) and




The results in Table 4.1 demonstrate that there are measurable differences between
loco-regional areas classified as nodules and stroma. The mean acinar area of
nodules is significantly greater than that of stroma. Figure 4.5 demonstrate the
distribution of the epithelial to stroma ratio within all examined areas of histology.
The majority of nodules have an epithelial to stroma ratio >1. These morphometric
results are in accordance with the results from the previous work in Chapter 3.
The morphometric and mechanical measurements show that |E*| is significantly
greater in nodules than in stroma. Mean acinar size is significantly greater in nodules
than in stromal areas. However, it appears that tan 5, used alone, is a poor
discriminator between stromal and nodular areas regardless of acinar size (figure
4.9).
The results presented in section 4.4 and 4.5 examine the relationships between the
morphology and the mechanical properties of nodule and stroma groups. Within the
nodule group, there are poor correlations between %SM content with the mechanical
measurements. The addition of mean acinar area to the analysis, seen in table 4.4,
shows a strengthening of the relationship but only in areas containing >30% smooth
muscle. These areas area predominantly smooth muscle in composition and appears
to exhibit different mechanical properties to areas composed of less smooth muscle.
As the tissue studied comprised of mainly smooth muscle, it may be that the tissue
behaves according to the viscoelastic model shown in TURP chippings. In this
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model, there is a direct relationship between %SM and |E*|. However, these
conclusions cannot be made with certainty as the number of points tested in this sub-
selected group is 6 compared with 38 for the whole nodule group.
Examining the relationships between %ET and the mechanical properties, there are
no significant correlations seen despite stratifying the dataset in increasing % content
of ET (see table 4.5). In the multiple regression analysis, the addition ofmean acinar
area to the analysis strengthens the relationships between the morphology and
mechanical properties. The positive effect of mean acinar area is seen in the
relationships between both |E*| and tan 5, but do not reach statistical significant due
to reduced numbers of data points (see table 4.6).
In the linear regression studies of morphological and mechanical properties of the
prostate, mean acinar area appeared to be highly discriminative of nodular and
stroma classification. There were significant correlations between mean acinar area
and tan 5 within the nodular group (figure 4.10). The relationship improves further
in areas of the nodule with an ET to SM ratio is less than 2 (fig 4.11). It appears that
mean acinar area is shown to have an important relationship with tan 5 within
nodular areas. As the gland size increases, there is a linear increase in the viscosity
of the tissues. This relationship maintains this strong relationship in areas that area
have a low ET:SM ratio. This suggests that the mechanical properties of nodules
with increased ET:SM content (i.e. nodules comprised of mainly epithelial tissue)
exhibit different mechanical properties. There may be other histological parameters
166
Chapter Four
that are not considered in this study, that may be influencing the mechanical
properties of nodules with varying ET content.
The results of the ANN analysis in figures 4.13 and 4.14, demonstrates that there are
poor relationships between %ET and %SM with |E*|. It appears that taken
individually, these parameters do not influence |E*|. In figure 4.15 demonstrate a
significant relationship between %ET and tan 5. However, this relationship is not
seen between %SM and tan 8 (figure 4.16). As an individual morphometric
parameter, %ET has most influence on tan 8. Considering all morphometric
parameters, the analysis presented in figure 4.17 show a strong and positive
relationship between |E*| and tan 8. The advantage of the ANN is that analysis of the
data in a non-linear fashion can identify correlations that are difficult to elucidate.
ANN confirms that there are measureable relationships between morphology and
mechanical properties of the prostate. It does not suggest that there are simple, linear
and strong relationships between the morphometric variables and mechanical
measurements employed in this study.
The results shown from these studies of prostate morphology and mechanical
properties using a micro-probe indenter suggest that the structure property
relationship of the prostate does not appear to follow the simple viscoelastic model
described in previous work by Phipps et al [127]. Briefly, Phipps et al have shown
that in tissues taken at time of TURP, there was a strong correlation between the SM
content of the tissue and |E*|. However, in this study, the tissue studied comprised
mainly SM and very little epithelial tissue. In this study of whole prostates, the main
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tissue composition for most of the specimens have high epithelial to stroma ratio.
Therefore our studies cannot be closely compared. The studies suggest that the
amplitude ratio, |E*|, maybe a more sensitive discriminator between hyperplastic
nodules or stroma with an increasing SM or ET content. Relationships strengthen
when mean acinar area and %ET content is considered in multiple regression
analysis. As %ET and mean acinar area increases, the most likely structure to be
described is a glandular nodule with tightly bound acini (see figure 4.18).
Figure 4.18 - Mosaic photomicrograph depicting a large glandular nodule within a
transverse slice ofwhole prostate stained with anti-PSA
The morphometric analysis of this nodule show a fairly homogenous dataset. A
cyclic compressive forced is applied to the tissue with a micro indenter measuring
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400pm x 500pm (0.2mm2) yet the histology area captured as the area of interest
measures 42mm2. Therefore, if a large glandular nodule is the area of interest, the
histology represented by each 49 image could be relatively homogenous. In contrast,
figure 4.19 shows an area of interest (represented by 7 x 7 matrix of images) and the
heterogeneity of % smooth muscle content per image captured is significant. Several
frames lie on predominately stromal areas and others on glandular areas.
Figure 4.19 - Mosaic photomicrograph. On the left is a whole section of prostate
stained with anti-SM myosin. A large glandular nodule can be seen within the
stromal framework seen. On the right is the area of histological interest represented
by 7 x 7 images. In several frames, the amount of SM can clearly be seen to be very
different between adjacent frames.
169
Chapter Four
This study demonstrates the difficulties in comparing the histological features with
the mechanical data generated from a micro-sized indenter. The initial approach to
assessing loco-regional morphology was to use the protocol described in section
2.7.3. A "self-similarity" exercise was performed and results are seen in Table 2.5
and the discussion is in section 2.7.4. Using a smaller matrix of captured images,
such as 3 x 3 size, has possible advantages. However, due to the small size of the
indenter, it was no longer possible to mark accurately the area of tissue subjected to
point probing. Therefore using a smaller area of interest would increase the
uncertainty of using histological data that was not subjected to mechanical testing.
Therefore the aim was to use a 7 x 7 matrix as the assumption is that the area
examined should contain the test point. Several attempts were made to analyse data
with respect to individual histological values from each single microscopic frame
taken at x200 magnification. However, these analyses yielded very poor result with
no correlations found. Despite the use of multiple linear regression analysis and
using ANN, no significant relationships were found between the core variables such
as %ET, %SM, |E*| and tan 5. The heterogeneity of the histological results
hampered analysis. A mean value of the histological results per point probed was
used in all calculations within this chapter. In using the mean of all 49 images
describing one point, there were measurable differences with significant correlations
between tan 5, mean acinar area and %SM.
The lack of correlations may be as a result of other histological structures
contributing to the mechanical properties of the prostate which are measured in this
study. Collagen III (CIII) was studied along with smooth muscle and glandular
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tissue by Schuster et al. This group showed that CIII composition remained roughly
at 30-35% in all sizes of prostates examined [33]. Phipps et al demonstrated that
CIII estimation did not affect mechanical properties within TURP chippings despite
comprising 15-44% of the composition [127, 128]. It was based upon this finding
that, in this study, Collagen III was not studied as a histological parameter.
Fibroblasts are thought to comprise a significant proportion of the stroma but
identification of fibroblasts is often difficult due to the lack of suitable markers
[139], However, recent availability of a suitable antibody, TE-7, has been shown to
positively identify human fibroblasts within formalin fixed tissue [140],
The prostate is considered as a heterogonous organ, and based upon the studies of
McNeal, different zones of the prostate exhibit different pathological processes and
tissue composition [9]. In this study, the use of transverse sections of whole
prostates allow for the examination and appreciation of the heterogeneous
architecture of the prostate. TURP chippings are composed of mainly stromal tissue




Figure 4.20 - A composite "map" showing histological and mechanical variation
across a whole transverse slice of prostate.
In figure 4.20, a composite image of a whole section of prostate, stained with anti-
smooth muscle antibody, demonstrates the variability of histology as well as
mechanical measurements across this specimen. It may be too simplistic to describe
or quantify loco-regional areas of morphology that are so distinct from each other
with just two components of prostate tissue, namely smooth muscle and epithelial
tissue. As the mechanical properties are functions of the morphology of the gland,
further characterisation of the components of the stromal area within the prostate
may lead to further development and understanding of the relationship between
morphology and the mechanical properties of the gland.
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The limitations ofthe present study
1. Morphological examination does not take into account of the various components
that are in addition to the smooth muscle and glandular components of the gland.
2. The mechanical measurements are a function of the morphology and if the
morphology is incomplete, the mechanical measurements cannot reflect the
morphological map.
3. Micro-probe may give better discrimination on histological components but
placement precision is needed to be improved to accurately assess the loco-
regional morphology subjected to testing.
4. Artificial neural network is a useful tool to understand the possible relationships
between various, seemingly unconnected variables. There is a requirement for




The relationship between alpha blocker





Studies have shown the pro-apoptotic effects of quinazoline-based alpha blockers,
terazosin and doxazosin, upon BPH tissues [43, 87, 88], An increase in the apoptotic
index (AI) correlated with a decrease in smooth muscle content of the tissue.
However, no study to date has examined the apoptotic effects of alfuzosin, a
quinazoline-based alpha blocker, upon prostate tissues and whether there is a
relationship with morphology.
Previous work from Phipps et al have shown that the mechanical properties of TURP
tissue are a function of smooth muscle content when measurements are made using a
macro-probe [127], Therefore, this study was conducted on patients undergoing
TURP and were selected based upon the type of alpha blocker therapy used in the
initial stages of treatment of LUTS secondary to BOO. The TURP patients were
classified into treatment groups based upon quinazoline (alfuzosin) or non-
quinazoline-based (tamsulosin) alpha blocker therapy and a control group of patients
with no medical therapy. The clinical characteristics of this group are presented in
Table 5.1.
The prostate tissue was subjected to mechanical testing using the 2mm diameter ball
end macro-probe. The tissue is subsequently processed, fixed and morphometric
studies are carried out to determine the %SM and %ET composition. The
assessment of the AI of the tissues was performed using TUNEL specific staining
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and immunostaining using anti-Caspase-3 antibodies (see Section 2.8 for
methodology).
Recruitment into this prospective group of patients resulted in a small number of
patients within the alfuzosin and tamsulosin groups. Excluded were patients on
combination therapy of an alpha blocker and a 5ARI as the latter is shown to
decrease ET content of prostate tissue and may affect the mechanical characteristics
of the tissue. Obtaining tissue from men undergoing TURP who were currently
taking a single alpha blocking agent was challenging due to small number of patients
fitting this criteria.
Therefore a second cohort of patients were sought to allow further studies on the
effects of alfuzosin and tamsulosin upon the morphology and AI of prostate tissue.
This cohort of patients was retrospectively chosen from the database of patients who
have undergone radical retropubic prostatectomy (RRP) for localised prostate cancer.
These patients had initially presented to the clinic with LUTS and several were
commenced on alpha blocker therapy. All patients in this group responded to
medical therapy but underwent RRP upon the diagnosis of localised prostate cancer.
The patients were stratified into treatment groups based upon their alpha blocker
therapy with a control group of patients in whom no medication was taken.
Particular attention was given to the selection of tissue blocks from these patients.
The histo-pathologist ensured that the blocks selected reflect the transitional zone of
the prostate so that meaningful comparisons can be made with the morphometric
176
Chapter Five
studies from the TURP group. Unfortunately, due to the retrospective nature of this
cohort, no mechanical measurements could be taken from the tissue as it was
processed and fixed. Therefore this group of patients, who have shown response to
alpha blocker therapy, will provide information regarding the effect of alpha blocker
therapy upon the morphology and how this relates to the apoptotic indices of the
tissue. The clinical characteristics of this group are presented in Table 5.2.
The aim, therefore, of this study is to examine the inter-relationship between
apoptotic effects of alpha blocker therapy with the mechanical and morphological
characteristics of the BPH tissue.
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5.1. Clinical materials employed
Prostate tissue was obtained from 16 patients who underwent TURP. Morphometric
and mechanical measurements were performed as previously described. In this
group, 6 patients were on Tamsulosin, 4 patients were on Alfuzosin and 6 patients
did not take any medications. Clinical characteristics of this group are provided in
Table 5.1
Patient No Age PSA Duration ofmedication (months)
Tamsulosin Group
25 61 3.4 6
28 57 6.5 8
31 59 2.6 12
54 58 5.5 3
55 76 7.6 6
67 61 6 12
Alfuzosin Group
3 71 3 6
30 75 5 12
74 80 1.8 36
76 68 8.9 3
Control Group
24 68 2.3 No medication
51 71 6.3 No medication
53 71 5.6 No medication
56 60 1.2 No medication
63 62 6.2 No medication
75 72 10 No medication
Table 5.1 - Clinical characteristics of the TURP group.
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Prostate tissue from patients who underwent RRP was used as a comparison group in
the apoptotic experiments with TURP tissues. In this group, 5 patients were treated
with tamsulosin, 5 with alfuzosin and 6 without medication. The patients on
treatment continued their treatment until they underwent RRP for localised prostate
cancer. The tissue blocks were examined by a pathologist to ensure that the
transitional zone of the prostate was studied. Clinical characteristics of this group
are provided in Table 5.2
Patient No Age PSA Duration of medication (months)
Tamsulosin Group
12907 76 4.9 12
3800 76 n/a 10
799 68 7 8
1070 69 7.8 6
8324 77 6 14
Alfuzosin Group
524 76 4.7 10
105719 72 1.2 7
17962 65 5 15
13566 69 15 9
3574 56 3.5 18
Control Group
8489 64 n/a No medication
5359 74 8.9 No medication
4559 64 12.3 No medication
2153 78 n/a No medication
16921 71 n/a No medication
11442 74 6.4 No medication
Table 5.2 - Clinical characteristics of the RRP control group
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5.2. The measurement of apoptotic indices in the TURP group
The study of apoptotic events with in the TURP tissues are conducted using two
methods of detection as outlined in Section 2.5.3. Briefly, immunohistochemistry is
used to assess Caspase-3 activity within the tissue. The overall apoptotic score was
calculated by multiplying the intensity of the staining by the percentage of positive
cells which exhibited the staining as outlined in section 2.8.1
TUNEL is a specific stain to detect DNA fragmentation by labelling the terminal end
of nucleic acids. The apoptotic score was calculated as the percentage of positive

























Tamsulosin * p=0 q2 Alfuzosin + p=o.05 Control
Fig 5.1 - The apoptotic index in TURP tissues using Caspase-3 assay.
The results of the study of apoptotic activity as assessed by the Caspase-3 assay in
TURP tissues are presented in Figure 5.1. The results show that there is a significant
increase in apoptotic activity within the TURP group treated with Alfuzosin
compared with the group treated with Tamsulosin (* p=0.02). There is a significant
increase in apoptotic activity within the Alfuzosin group compared with the control
(+ p=0.05). There was no significant difference between tamsulosin and the control
(p>0.05). The raw data for this experiment is contained in Appendix III.
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Figure 5.2 - The apoptotic index in TURP tissues using TUNEL assay.
The results of the study of apoptotic activity as assessed by TUNEL assay in TURP
tissues are presented in Figure 5.2. The results show that there is a significant
increase in apoptotic activity within the TURP group treated with Alfuzosin
compared with the group treated with Tamsulosin (* p<0.01). There is a significant
increase in apoptotic activity within the Alfuzosin group compared with the control
(+ p<0.01). There was no significant difference between tamsulosin and the control
(p=0.07).
The raw data for this experiment is contained in Appendix IV.
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5.3. Morphometric and mechanical measurements in TURP tissues
To assess the morphology of the TURP tissues, prepared sections of tissue are
subjected to immunohistochemical staining for anti-PSA and anti-smooth muscle
antibodies to characterise the %ET and %SM within the tissue respectively. The
quantitative analysis is described in section 2.5.3. The results of these experiments
are presented in figures 5.3 and 5.4.
Prior to fixation and embedding in paraffin, the ex vivo prostate tissue resected at
TURP is subjected to mechanical testing by applying a cyclic strain to the tissue
using a 2mm macro-probe. The mechanical properties of the tissue are expressed by
two values, |E*| and tan 8. |E*| represents tissue elasticity whereas tan 8 represents























Figure 5.3 - %SM in TURP patients treated with tamsulosin, alfuzosin and control
Tamsulosin Alfuzosin Control
Figure 5.4 - %ET in TURP patients treated with tamsulosin, alfuzosin and control
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The results of the morphometric studies are presented in figures 5.3 and 5.4. The
%SM of the prostate tissue is shown in figure 5.3. These results show that the %SM
in the alfuzosin group is significantly less than the tamsulosin (p<0.03) and control
groups (p<0.05). There was no significant difference between the %SM content in
the tamsulosin group and the control (p=0.08). The reduction in %SM can be
attributed to the increase in apoptotic indices in the group treated with alfuzosin.
Studies have confirmed the pro-apoptotic class effect of quinazoline-based alpha
blockers but the literature is lacking in studies on alfuzosin. Therefore this work
represents the first evidence for the pro-apoptotic effects of alfuzosin.
In figure 5.4, the %ET of the TURP tissue is shown. There are no significant
differences in the epithelial content between the treatment groups and control group
(p>0.05 for all groups). This may be a reflection of the low apoptotic rates within
the epithelial compartment (which will be discussed later in this chapter).
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Figure 5.6 - Tan 8 in TURP patients treated with tamsulosin, alfuzosin and control
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The results of the mechanical testing in TURP tissues are shown in figures 5.5 and
5.6. In figure 5.5, there is a significant reduction in |E*|, tissue elasticity, in the
group treated with alfuzosin compared with tamsulosin (p<0.05) and the control
(p<0.05). There was no significant difference between tamsulosin and the control
group (p=0.2). These results confirm that the effect of alfuzosin on prostate tissue
has a significant and measureable difference in mechanical properties of the tissue.
In Figure 5.6, there are no significant differences in the mechanical measurement of
tan 5 between the tamsulosin and alfuzosin group (p=0.07), alfuzosin and control
group (p=0.22) and tamsulosin and control group (p=3.1). This may be a reflection
of the low rates of apoptotic activity within the epithelial areas.
5.4 Measurement of apoptosis indices in RRP tissues
RRP tissues were used as a comparative cohort to the TURP group. The apoptotic



























Figure 5.7 - Apoptotic index in RRP tissues assessed using Caspase-3.
Figure 5.7 demonstrates the apoptotic index measured using the Caspase-3 assay in
RRP tissues in treated and non-treated patients. There was no significant difference
between in the apoptotic index between the tamsulosin and alfuzosin group (p=0.32).
No significant differences were found between tamsulosin and the control group
(p=0.35) and alfuzosin and the control group (p=0.48).
188
Chapter Five















Figure 5.8 - Apoptotic index in RRP tissues assessed using TUNEL.
Figure 5.8 demonstrates the apoptotic index as measured using the TUNEL assay in
RRP tissues in treated and non-treated patients. There was no significant difference
between in the apoptotic index between the tamsulosin and alfuzosin group (p=0.41).
No significant differences were found between tamsulosin and the control group





5.5. Morphometric measurements in RRP tissues
The methodology for morphometric analysis ofRRP tissues is identical to that of the
TURP group. In the RRP group, no mechanical measurements are available due to




















Figure 5.9 - %ET in RRP patients treated with tamsulosin, alfuzosin and control
Figure 5.9 demonstrates the mean epithelial content within treated and non-treated
RRP patients. There was no significant difference in %ET between the tamsulosin
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and alfuzosin group (p=0.21). No significant differences were found between

















Figure 5.10 - %SM in RRP patients treated with tamsulosin, alfuzosin and control
Figure 5.10 demonstrates the mean %SM content in treated and non-treated RRP
patients. There are no significant differences between the groups. The
morphometric studies examining the %SM and %ET within RRP tissues do not show
any significant difference between the treated groups and the control groups. There
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was no significant difference in %SM between the tamsulosin and alfuzosin group
(p=0.09). No significant differences were found between tamsulosin and the control
group (p=0.13) and alfuzosin and the control group (p=0.35).
5.6. Discussion
The aim of this study is to examine the inter-relationship between apoptotic effects of
alpha blocker therapy with the mechanical and morphological characteristics of the
BPH tissue.
Two groups of patients were used to assess the relationship between alpha blocker
therapy and its effect upon tissue composition and the rate of apoptotic events. The
TURP group had come to surgery as medical therapy had failed whereas the RRP
group had surgery for prostate cancer, but were responding to medical therapy at the
time of their surgery. Patients in the TURP group were collected prospectively and
underwent mechanical measurements prior to processing of the tissue. The RRP
group lack mechanical measurements as these patients were selected retrospectively
based upon their medical treatment.
TURP tissues
In section 5.2, the results show that within the TURP group, medical treatment with
alfuzosin is associated with a significant increase in apoptotic activity within the
tissues as assessed using both Caspase-3 assay and the TUNEL assay. In section
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5.3.1, the morphometric analysis demonstrate that there is a significant reduction in
%SM in the patients treated with alfuzosin. However, there were no significant
differences seen in %ET between the groups. Within section 5.3.2, the mechanical
measurements from the prostate tissue show that there was a significant reduction in
|E*|, tissue elasticity, in patients treated with alfuzosin. There were no differences
seen in tan 8, tissue viscosity, between the groups.
These sets of experiments confirm that in patients treated with alfuzosin, there is an
increase in apoptotic activity which is associated with a reduction in smooth muscle
composition of the tissue. The reduction in %SM is reflected in the mechanical
measurements and a lower |E*| value is seen in the alfuzosin group.
Several studies have confirmed the pro-apoptotic effects of quinazoline-based alpha
blockers, Doxazosin and Terazosin, in BPH tissues [87, 88, 141]. These studies
show that an increase in apoptotic activity is associated with smooth muscle
regression. However to date, there are no studies examining the pro-apoptotic effects
of alfuzosin, a quinazoline-based alpha blocker. The work presented here supports
the observation that alfuzosin appears to have similar pro-apoptotic effects as other
quinazoline-based alpha blockers. The increase in apoptotic activity is seen
primarily in the stroma and is associated with smooth muscle regression. This is in
accordance with the findings from studies examining the agents, doxazosin and
terazosin [43, 141], Phipps et al have shown that the mechanical properties of TURP
tissue are a function of smooth muscle content when measurements are made using a
macro-probe [127]. The mechanical measurements (which were made using a
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macro-probe indenter) presented in section 5.3.2 demonstrate the strong association
with %SM and |E*|. Therefore, treatment with alfuzosin is shown to have a
significant impact upon the mechanical properties of prostate tissue.
Despite a significant increase in apoptotic indices in patients treated with alfuzosin,
no significant differences in %ET were observed in treated and non-treated prostates.
In the TURP group, the mean %ET in all groups was 16% and the mean %SM was
35%. The TURP tissues were comprised mainly of smooth muscle. The remaining
50% comprise of the other constituents of the stroma such as fibroblasts, collagen
and ground substance. Based upon previous work from this group, the epithelial and
smooth muscle components of prostate tissue were found to be the most important
determinants of the mechanical properties of the tissue. Therefore the remaining
cellular constituents were not quantified in any manner.
Morphometric studies demonstrate that the %ET in patients (see figure 5.4) treated
with alfuzosin is not significantly different to the tamsulosin and control group.
Subsequently, there are no observed differences in tan 8, within all groups. This may
be explained by the observation that apoptotic activity is much lower in the epithelial
compartment. It was observed in the initial studies with doxazosin, that apoptotic
activity within the glandular epithelium peaked at 4-5 months of treatment and
returned to baseline after 11-13 months [87]. Subsequent studies have shown that




Patients treated with alpha blocker therapy with low grade and low volume prostate
cancers were identified from the local prostate cancer database. These patients had
undergone RRP and the archival prostate tissue from this cohort provided a
comparison group to the TURP group. Tissue blocks were taken from the base of the
prostate to ensure adequate representation of the transitional zone of the prostate.
From the microscopic and macroscopic histopathology report, blocks with known
prostate cancer were avoided. The aim of using RRP tissue was two-fold. One was
to increase our study numbers as the TURP cohort had only 4 patients treated with
alfuzosin. Secondly, it was to assess whether there were differences in apoptotic
indices in patients who have responded to or failed medical therapy.
The results from the apoptotic experiments shown in figures 5.7 and 5.8, demonstrate
no significant difference in the apoptotic indices of treated and non-treated prostates.
The apoptotic indices in all groups within the RRP cohort are comparable to the
baseline apoptotic index of the control group in the TURP patients. The
morphometric studies do not demonstrate significant differences in %ET and %SM
composition between all groups as shown in figures 5.9 and 5.10.
The low apoptotic activity that is shown across all 3 groups may be explained by the
differences in tissue composition. The mean %ET in the RRP cohort is 57%
compared with 16% in the TURP group and the mean %SM is 17% in the RRP
group compared with 37% in the TURP group. The histological composition ofmost
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areas studied in the RRP group comprise mainly of glandular epithelium consisting
of large acini separated by stroma containing tightly packed smooth muscle fibres.
These sections were taken from the base of the prostate, close to the bladder neck, to
ensure that the transitional zone was studied. However, despite this, the tissue
architecture was significantly different to the morphology of tissue from TURP. This
may be a reflection of prostate size, as proportions of ET and SM within specimens
vary significantly depending upon the resected weight at TURP (which is a surrogate
for prostate size) [33]. However, there is no data on the size of the prostates that
underwent TURP. Histological reports for the RRP group confirm that the prostates
weighed greater than 30g and this may explain the greater composition of ET in the
RRP group.
The low rate of apoptosis within both smooth muscle and epithelial compartments
may be explained by different cellular kinetics, i.e. the rate of cell death versus
proliferation, exhibited by the RRP group. The morphology of tissue obtained from
the RRP group show low smooth muscle content (mean %SM is 17%) and high
epithelial content (mean %ET is 57%) as shown in figures 5.9 and 5.10. Several
studies have observed increased expression of the anti-apoptotic factor bcl-2 in BPH
epithelial cells. Bcl-2 is a proto-oncogene that plays a role in blocking programmed
cell death [142]. These studies observed a significant increase in bcl-2 expression in
basal epithelial and secretory cells but not stromal cells in BPH tissues [28, 143-145].
The increase in bcl-2 expression may result in a reduction in apoptosis within
epithelial cells and thereby maintain the cell population despite the pro-apoptotic
effects of alfuzosin. A further cellular mechanism that may explain low apoptotic
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activity is cellular senescence. Senescence describes the process by which somatic
cells lose their ability to proliferate or to undergo apoptosis. The senescent cell
remains metabolically active but in a growth arrested state. Studies have shown that
larger prostates exhibit increased biomarkers of senescence and that these biomarkers
were only expressed in the epithelial cells [146, 147], Therefore, understanding the
cell kinetics of this group may explain the observation of low apoptotic activity seen
in mainly epithelial tissue.
Summary
Despite the small sample size of this study, the findings suggest that alfuzosin shares
the same class effect of pro-apoptotic activity as doxazosin and terazosin. The results
clearly show that treatment with alfuzosin is associated with an increase in apoptotic
activity in BPH tissues. The increase in apoptotic activity is associated with a
significant reduction in smooth muscle. The mechanical properties are a function of
the underlying morphology and the work presented here show that alfuzosin therapy
can have a significant impact upon the mechanical measurements. These
measurements taken in vivo, may have great potential in aiding the urologist in the
assessment and management of patients with prostatic disease.
These experiments are the first evidence that alfuzosin shares the class effect of other
quinazoline-based agents. Over the last few years, the focus has been on elucidating
the exact molecular mechanisms that underpin the pro-apoptotic properties of these
agents. Much interest has been placed upon their potential role in the treatment of
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prostate cancer [148, 149], The work presented here is the first step in understanding
the pro-apoptotic effects of alfuzosin. Understanding the apoptotic activity in the
prostate tells only half the story. Further work is required in characterising the
cellular kinetics with respect to proliferation markers such as bcl-2, TGF-1(3, ki-67 to
name a few will allow for a more complete picture of the dynamics within the tissue.
Biomarkers of senescence should be examined, especially in samples composed
mainly of epithelial tissue, to understand why there are such low levels of apoptosis




General discussion and Conclusions
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6.1. Development of the viscoelastic model of the prostate
This thesis builds upon the previous studies in the characterisation of the structure-
property relationship of prostate tissue. The mechanical properties of prostate tissue
from TURP have been shown to be a function of the underlying morphology [127,
128], The structure-property relationship of TURP chippings follow a viscoelastic
model with the smooth muscle component acting as springs (|E*| or amplitude ratio)
and the epithelial component acting as dampers (tan 8 or phase lag).
The main body of this work examines the morphological and mechanical properties
of prostate tissue from radical cystoprostatectomy patients. TURP chippings mainly
originate from the transitional zone of the prostate or from around the bladder neck.
The use of transverse slices of whole prostates allow for the examination of the
morphology of the whole prostate rather than restricting morphological analysis to a
single zone of the prostate. The understanding of the morphological and mechanical
characteristics of different areas within the whole prostate will further our knowledge
of the structure-property relationship of prostatic tissue in respect of the whole gland.
Morphometric analysis
Protocols for the morphometric analysis of TURP chippings yielded on average 60-
100 individual images per TURP chipping for computerised analysis. In the
morphometric analysis of a section of a whole prostate, the processed and embedded
specimen was required to be divided into four sections so that it can be mounted on
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standard 25 x 75 mm glass slides as described in section 2.4. Subsequent application
of these protocols to the analysis of whole prostates resulted in 3600 - 4000 images
per section of a whole prostate at x200 magnification. Composite images were
reconstructed using image stitching software to create a "histological map" of the
section. Discrete histological areas such as nodules comprising mainly of epithelial
or stromal tissue were identified on the "histological map". Price et al, described
these areas in a quantitative manner in their work with prostate tissue from both
TURP and enucleations [32], The work presented in section 2.1 show that there are
significant histological differences in %ET and %SM between nodular and stromal
areas. Nodular areas are comprised mainly of epithelial tissue whereas in stromal
areas, smooth muscle is the main constituent (see section 2.6.4). Also in accordance
to the work by Price et al, there are significant differences between the histological
information from TURP chippings and from a transverse section of a whole prostate.
This is most apparent in the data presented in Chapter 5. In section 5.3.1 the
morphometric results from TURP tissues differ significantly from that ofRRP tissues
shown in section 5.5.
The volume of information generated from the morphometric analysis of a section of
a whole prostate is 40-fold greater than from a single TURP chipping. The work
with the whole prostates required modification of the original protocol used in the
analysis of TURP chippings. Using a motorised stage and specialist scanning and
stitching software, as detailed in Section 2.2, a mosaic or "map" of a section of
prostate is captured at low magnification. The user can then pinpoint areas of
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interest, such as areas subjected to mechanical testing, and capture histological
information at high magnification. Marking of the area using ink and a pin
embedded into the tissue allowed the area subjected to mechanical testing to be
localised. This methodology enabled the study of loco-regional morphology and its
associated mechanical properties. Recent studies by Ahn et al examined the
mechanical properties of malignant prostate tissue from RRP patients [150, 151].
The methodology employed in the analysis of histology and the associated
mechanical measurement was acknowledged to be flawed as a result of uncertainty
in the localisation of the area subjected to mechanical testing. The authors arbitrarily
divided the prostate into zones and subjected these areas of mechanical testing
without employing any means to accurately mark the areas tested. However, in
comparison, the methodology presented in this work enables a more accurate
localisation of the area of tissue subjected to mechanical testing and provides a
means to perform loco-regional morphometric analysis upon these areas.
Macro-point probing
Initial studies examining the relationship between the loco-regional morphology and
the underlying mechanical properties used a macro sized 2mm diameter ball end
probe for the mechanical testing. The loco-regional morphology was classified into
nodular or stromal areas without prior knowledge of the associated mechanical
measurements. The results presented in Section 3.2 show that the amplitude ratio,
|E*|, is significantly higher (>150 kPa) in the nodular group compared with the
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stromal group. The phase lag, tan 8, was found to be significantly lower in the
nodular group compared with the stromal group. That is, nodules are "stiffer" and
less "viscous" than stromal areas respectively.
Despite these strong observations between these two morphologically distinct
groups, individual correlations between morphological and mechanical parameters
were found to be weak, as shown in sections 3.3 to 3.4. Initial statistical analysis
utilised linear regression analysis which yielded weak correlations. Multiple linear
regression analysis was employed to assess the impact of mean acinar area upon the
relationships between the morphological and mechanical variables but these
relationships did not follow a simple regression model. However, the correlations
are strengthened when mean acinar area is considered in the multivariate analysis
which suggests that taken individually, %SM and %ET values seem to be poor
discriminators between stromal and nodular areas. However, the majority of the areas
tested comprised of mixed epithelial and smooth muscle content of varying
proportions. In figure 3.3, a histogram depicts the distribution of points according to
the epithelial to smooth muscle ratio. The majority of nodular areas were comprised
of tissue containing a higher epithelial to smooth muscle ratio. However, when the
data was stratified according to epithelial and smooth muscle ratio, the relationships
were still weak. Artificial neural networks are able to recognise complex
relationships which a regression analysis may not be able to identify.
Artificial neural networks require a training stage and validation stage to be
performed before the final analysis stage. This is explained in section 2.9.5. Within
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each stage, a proportion of the dataset is used to set up the system before the final
analysis and so, as the program progresses through the stages, the pool of data points
is reduced. In figure 3.7, within the nodular group, the correlation between the single
variables of |E*| and %ET shows a strong positive relationship (R=0.62). The next
figure, 3.8, shows a similar strong positive relationship between tan 8 and %ET
(R=0.74). If both morphometric (%ET and %SM) and mechanical (|E*| and tan 8)
datasets are used in the analysis, the relationship between these variables are further
strengthened (R=0.85).
The disadvantage of ANN is that it does not show the analysis pathway used to reach
its conclusion and therefore the system is unable to explain which parameters are the
most influential in its analysis. However, despite this, the statistical analyses suggest
that the viscoelastic model for the whole prostate does not follow a linear
relationship between the ET and SM components with its corresponding mechanical
measurement. Previous work on TURP chippings assumed the morphology of
prostatic tissue to be homogenous and isotropic [138], This work undoubtedly
demonstrates that the structure-property of TURP chippings does not apply to the
prostate when taken as a whole. Examination of a composite image of section of a
whole prostate as shown in figure 2.3 clearly demonstrates the heterogeneous nature
of the morphology. The histological parameters of %ET and %SM are unable to
fully represent the inherent complexity of the morphology when examining the
whole gland. Inspection of the simple linear correlation graphs between %ET and
%SM within nodular and stromal groups (see figures 3.1 and 3.2) show that there is a
significant amount of prostatic tissue unaccounted for. Within the stromal
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environment, it has been shown that collagen and fibroblasts can comprise up to 30-
35% of this compartment [33] and with advances in immunohistochemical
techniques, localisation of fibroblasts has recently become feasible [140]. Within the
glandular compartment, the basal cell layer is not stained. The epithelial cells are
stained with anti-PSA antibody whereas the basal cell layer can be localised with
stains for high molecular weight cytokeratins or p63 [152]. With these new
developments, it may be that once the morphology of the prostate can be
characterised fully, strong relationships between the mechanical properties can be
found.
Micro-point probing
In chapter 4, the mechanical studies were performed using a micro-sized probe
measuring 400pm x 500pm. The area of prostate tissue subjected to point probing
by the macro probe is 9.86mm2 compared with 0.2mm2 of the micro probe. The aim
of this work is to understand the effect of using a micro-indenter upon the
mechanical measurements obtained and to relate this to the underlying prostate
morphology. The rationale for micro testing resulted from a parallel project with a
micro-engineering facility to develop a micro-engineered palpation device for
measuring mechanical properties of biological tissues. The reduction in size of the
indenter allows for the study of mechanical properties at a scale that approaches
microscopic feature size.
The methodology used in the analysis of loco-regional morphology in the studies
presented in Chapter 3 is again used for the micro-point probing studies. The
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histological areas of interest were classified into stromal and nodular areas.
Significant differences were observed with the nodular areas containing a greater
amount of epithelial tissue compared with stromal areas, as shown in Table 4.1.
Within the nodular group, as the %ET increased within the nodule, the greater the
mean acinar area of the glands. The mechanical properties of nodular areas were
significantly different compared with stromal areas. The mean |E*| was found to be
significantly greater in the nodular group (p=0.03) but there was no significant
difference in tan 8 between the groups (p=0.31).
Simple linear regression analysis was used initially to examine the relationships
between morphology and mechanical properties. Within the nodular group, as
shown in figure 4.7, the relationship between the mean acinar area and tan 5 was the
strongest (R2=0.2 p<0.005). As mean acinar size of the glands increased, this was
paralleled with an increase in "viscosity" (tan 8). This correlation suggests that tan 8
is sensitive to gland size as measured using a micro-probe indenter. However, there
were weak linear correlations between %SM, %ET and ET:SM ratio with the
mechanical measurements. Multiple linear regression analysis was used to examine
the various parameters and their effect upon the mechanical properties. Furthermore,
the data was stratified based upon the %SM and %ET content. However, the
correlations between the remaining parameters with the mechanical properties were
weak.
Artificial neural networks were used to analyse the data from both the nodular and
stromal groups. There were no significant results from the analysis of the stromal
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group data. In figures 4.13 and 4.14, the ANN analysis of the relationship between
|E*| and the individual parameters of %ET and %SM yielded weak results. In
figures 4.15 and 4.16, the analysis of the relationship between tan 8 and the
individual parameters of %ET and %SM show that there is a strong positive
correlation between %ET (R2=0.625) but not between %SM (R2=0.226). The mean
results of both morphometric and mechanical data points were assessed together and
a strong positive relationship was seen (R2=0.697). It appears that tan 8 is a more
sensitive discriminator between stromal and nodular areas than |E*|.
The lack of correlation seen between the individual parameters of |E*| and %ET and
%SM; tan 8 and %SM demonstrate the difficulties in the comparison of loco-regional
morphology with the mechanical data generated from the use of micro-sized
indenter. The primary area of difficulty was to accurately pinpoint the area subjected
to mechanical testing. The area covered by the indenter is 0.2mm2 and modification
of the protocol described in 2.7 was explored. At the micro-level of histological
analysis, moving just 500 pm away from the "origin" of the site of point probing
may yield a result at the extreme ends of the scale. Use of a smaller matrix of
captured images, such as 3 x 3 or even individual high powered frames, has the
advantage of being closer in size to the actual area under the indenter. However with
a smaller matrix size, there was increased uncertainty that the area selected was truly
representative of the area tested. Initial attempts to represent the histological data as
a set of individual variables corresponding to different matrix sizes (e.g. 3x3 matrix
would yield 9 individual measurements) did not yield strong relationships with the
mechanical parameters using linear regression analysis. Therefore a mean value of
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the histological data from a matrix of 7 x 7 high powered fields per point probed was
used to describe a single point. The weak correlations from the linear, multivariate
and ANN analyses may be a reflection of the inaccurate localisation of
morphological area subjected to micro-point probing. A possible future solution
would be to use a laser fixed to the testing rig to mark a point adjacent to the tissue
tested ensuring that the resulting damage to the surface of the tissue will not interfere
with subsequent histological analysis. Lasers can penetrate to less than 1mm of the
tissue surface. The tissue marking will not be lost through the fixation and
embedding of the tissue.
The work presented here considers the prostate as a heterogenous organ, based upon
the studies by McNeal [9]. It cannot be accepted that prostate tissue examined in this
fashion is homogenous and isotropic. Instead, the results clearly demonstrate the
heterogeneity and anisotropy of whole sections of prostate tissue. Both the macro-
point and micro-point probing data show a significantly higher |E*| readings
compared to Phipps's work [127], These areas of increased |E*| are associated with
large glandular nodules as illustrated in figure 4.23. One may postulate that these
glands are under tension due to the constricting tension of the surrounding stroma.
These studies may indicate that nodules may contribute not only to the static element
of obstruction but also to the dynamic element. Recent in vivo studies have shown
that intracellular tissue pressure has a positive effect upon shear modulus as
measured using MR elastography [153]. In addition to further characterising the
morphology of the prostate, the measurement of interstitial tissue pressure may




The macro and micro-probing data presented here demonstrate that there are
measureable and quantifiable differences between the two methods of mechanical
testing. In the macro-point probing experiments, there were significant relationships
seen between the morphological parameters of SM and ET with the mechanical
parameters of |E*| and tan 8. However, these relationships were difficult to elucidate,
requiring the non linear analysis expertise of an ANN. This perhaps is a reflection of
the lack of histological description obtained from just two variables, ET and SM.
In the micro-point probing experiments, strong relationships between the
morphological and mechanical parameters were significantly more difficult to
elucidate. In addition to the problems encountered in the macro-probing
experiments, it was found to be very difficult to accurately pin point the area of
tissue that was subjected to mechanical testing. This factor may have added an
additional confounding element to the data analysis and is reflected in the weak
correlations seen in the ANN analysis.
These findings have implications for the consideration of a suitable sized remote
palpation device to conduct mechanical measurements in vivo. A micro sized probe
may be an ideal tool for the urologist to deploy within a cystoscope to obtain
mechanical measurements from the prostate. However, the average |E*| values in
micro-probing is 25,000 kPa compared with 220 kPa in the macro-probing
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experiments. This significant and exponential rise in |E*| values may preclude the
use of a micro-piston to assess tissue mechanics as the sensitivity in detecting
nodules and stromal areas is decreased [154], These findings will have a significant
impact upon the design and manufacture of a remote device capable of measuring
these high pressures. Based upon these findings, the recommendation would be to
utilise and develop the macro-point probing device for the measurement of
mechanical properties in prostate tissue.




Since the early work by Kyprianou, the current focus of research is to elucidate the
mechanisms by which quinazoline-based alpha blockers exert their pro-apoptotic
effects and recent reports show promising results [92, 155, 156]. To date, there are
no reports in the literature examining the potential class effect of pro-apoptotic
activity of alfuzosin, a quinazoline-based alpha blocker.
TURP tissues
The apoptotic indices were measured using a TUNEL assay and a Caspase-3 assay in
patients who have undergone a TURP. The treatment group was compared with a
control group and a group taking tamsulosin, a non-quinazoline based alpha blocker.
The results shown in figure 5.1 and 5.2 show a significant induction in apoptotic
activity in the alfuzosin group compared to the control and tamsulosin groups. There
was no significant difference between the tamsulosin and control groups. These
results confirm that alfuzosin share this class-related effect of apoptotic induction in
prostatic tissue.
Morphometric analysis, to determine the proportion of SM and ET, was performed
on all three groups. In figure 5.3, there is a significant reduction in smooth muscle
content in the alfuzosin group compared with the control and tamsulosin groups.
There was no significant difference in %ET between all three groups. The
mechanical properties, |E*| and tan 8 were assessed for all specimens. Figure 5.5
demonstrate that |E*| is significantly reduced in the alfuzosin group compared with
the control and tamsulosin groups. There is no significant difference in tan 8 seen
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between the groups. This may be explained by the observation that apoptotic activity
is reduced within the glandular epithelial compartment [141].
The results presented here confirm that in patients treated with alfuzosin, there is an
increase in apoptotic activity which is associated with a reduction in smooth muscle
composition of the tissue. The reduction in %SM causes a significant and
measureable change in the mechanical properties of the tissue. This is reflected in a
lower |E*| value seen within in the alfuzosin group. These results represent the first
evidence of the pro-apoptotic ability of alfuzosin. Early studies examining the
quinazoline based agents, doxazosin and terazosin, show that these agents exhibit
pro-apoptotic qualities which is associated with smooth muscle regression [87, 88].
This data from this study are in accordance with this early work, and confirm that
alfuzosin shares this class-related effect of apoptotic induction in prostatic tissue.
RRP tissues
Patients treated with alpha blocker therapy who subsequently underwent RRP for
localised prostate cancer were retrospectively identified. The aim of using RRP
tissue was two-fold. One was to increase our study numbers as the TURP cohort had
only 4 patients treated with alfuzosin. Secondly, it was to assess whether there were




The experimental methodology to assess apoptotic activity and morphometric
analysis in RRP tissue is similar to that used in TURP tissues. No mechanical
measurements were available as these patients were retrospectively identified. The
results from the apoptotic experiments shown in figures 5.7 and 5.8, demonstrate no
significant difference in the apoptotic indices of treated and non-treated prostates.
The low rate of apoptosis within both smooth muscle and epithelial compartments
may be explained by different cellular kinetics, i.e. the rate of cell death versus
proliferation, exhibited by the RRP group. The mean %ET in the RRP cohort is 57%
compared with 16% in the TURP cohort. The mean %SM is 17% in the RRP group
compared with 37% in the TURP group. The tissue composition between the two
groups is significantly different and may explain the difference in response to
alfuzosin. Studies have shown that epithelial and secretory cells exhibit an increase
in expression of the anti-apoptotic factor bcl-2. This is an important proto-oncogene
that has a role in blocking apoptosis [10, 28, 143, 144], Therefore, it would be
important not only to study the apoptotic activity within the tissue but to quantify the
anti-apoptotic activity.
The tissue was selected under the guidance of a uro-pathologist to mirror as close as
possible to the tissue that would be resected at TURP. However, the tissues used in
the RRP cohort are composed mainly of glandular tissue and therefore, most likely,
represent larger prostates than the TURP group. In future work, if RRP tissues are to
be utilised in studies with TURP tissues, prostate size and weight must similar as




The work presented here comprises the initial step in the understanding of the pro-
apoptotic effects of alfuzosin in BPH tissues. In future work, measurements of the
apoptotic activity should be performed in tandem with measurements of cell
proliferation to fully understand the cellular dynamics within the tissue studied. This
then may offer an explanation as to the observed low rate of apoptotic activity within
the RRP cohort. Further studies are required to elucidate the mechanisms involved
in the pro-apoptotic effects of alfuzosin. Based upon the initial studies presented
here, alfuzosin is an agent that researchers should examine more closely, as it may




The results from this work have highlighted several areas for improvement and
further research. Further work and refinement of the techniques used for
morphometric analysis is required. With the advent of laser micro-dissection of
tissues, similar techniques may be used to increase the accuracy in localisation of
areas of interest within the tissue, whether the tissue is a prostatic chipping from
TURP or a whole mount prostate from open surgery. Improvements in the
sophistication and automation of morphometric analysis systems may decrease user
workload and improve accuracy.
Improvements in the antibodies available for immunohistochemical analysis of the
glandular and stromal components of prostate tissue will enable a richer and more
complete description of prostate morphology than is otherwise available using just
anti-PSA and anti-smooth muscle myosin. This work has suggested that other
components of the prostate stromal matrix may well be important in further
understanding the morphological make-up of the prostate.
This work is only just beginning to understand the complex relationships between
structures such as glandular nodules and their mechanical properties. The studies
demonstrate that nodules are stiffer than surrounding stromal areas. The studies are
really two-dimensional in nature and to fully understand the role these nodules play
in the dynamics of bladder outflow obstruction, an appreciation and understanding of
its three-dimensional structure is required. Parker et al have utilised
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sonoelastography to examine the viscoelastic properties of prostate tissue. Recent
work from this unit have combined the quasi-static measurements obtained from
sonographical Doppler images with quantitative stress relaxation measurements to
characterise prostate tissue [126, 157], The value of elastography is that the 3-D
image of the whole prostate that is available and combining modalities, the structural
make-up of the prostate may be elucidated.
This work presented here is the first evidence that alfuzosin exhibits pro-apoptotic
activity within prostate tissue. Continued work in the scientific community in
understanding the pathways in which these quinazoline-based alpha blockers act,
may provide novel therapies in the treatment of prostate diseases. Further work in
this area would be to study the cellular kinetics of patients treated with alfuzosin to
fully understand its effect upon prostate tissue. Archival material could be utilised in
this future work with careful selection.
The framework and ultimate aim of this research is to develop a tactile remote
palpation device that can be passed via the urethra to obtain mechanical
measurements within the prostatic urethra. In order to replicate the testing conditions
in vivo, the apparatus used to measure mechanical properties should be modified so
that it can be deployed within a prostate. Work is continuing with mechanical
engineers within this project to fabricate a device suitable to be used within the
urethra or passed through a cystoscope. In the development of this device, various
techniques of sensing pressure e.g. using hydraulic actuation or piezoelectric
actuation, remains to be fabricated and tested. Once these tools are available, further
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dynamic mechanical testing within a whole prostate will examine the relationships
between regional morphology and local mechanical measurements and thereby
expanding our knowledge of the structure-property relationship of this heterogeneous
organ. Understanding these relationships may be useful in the further diagnosis and
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Patient No Age PSA Duration of medication (months)
Tamsulosin Group
25 61 3.4 6
28 57 6.5 8
31 59 2.6 12
54 58 5.5 3
55 76 7.6 6
67 61 6 12
Alfuzosin Group
3 71 3 6
30 75 5 12
74 80 1.8 36
76 68 8.9 3
Control Group
24 68 2.3 No medication
51 71 6.3 No medication
53 71 5.6 No medication
56 60 1.2 No medication
63 62 6.2 No medication
75 72 10 No medication
Clinical characteristics of the TURP group
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Patient No Age PSA Duration ofmedication (months)
Tamsulosin Group
12907 76 4.9 12
3800 76 n/a 10
799 68 7 8
1070 69 7.8 6
8324 77 6 14
Alfuzosin Group
524 76 4.7 10
105719 72 1.2 7
17962 65 5 15
13566 69 15 9
3574 56 3.5 18
Control Group
8489 64 n/a No medication
5359 74 8.9 No medication
4559 64 12.3 No medication
2153 78 n/a No medication
16921 71 n/a No medication
11442 74 6.4 No medication
Clinical characteristics of the RRP control group
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Appendix II
Appendix II. Raw data for morphological analysis
Point % Myo (7x7) %PSA (7x7) Histology
P70 Q1 Ptl 28 60 Nodule
P70 Q1 Pt2 21.00 35.00 Stroma
P70 Q1 Pt3 20.00 57.00 Stroma
P70 Q1 Pt4 15 73 Nodule
P70 Q1 Pt5 11 55 Nodule
P70 Q2 Ptl 22 37.119 Stroma
P70 Q2 Pt2 11.00 37.796 Nodule
P70 Q2 Ot3 8.00 36.83 Nodule
P70 Q2 Pt4 21 52.007 Stroma
P70 Q2Pt 5 27 40.981 Stroma
P70 Q3 Ptl 20 45 Nodule
P70 Q3 Pt2 32.00 33.00 Stroma
P70 Q3 Pt3 28.00 48.00 Nodule
P70 Q3 Pt4 12 49 Nodule
P70 Q4 Ptl 12 50 Nodule
P70 Q4 Pt2 14.00 45.00 Nodule
P70 Q4 Pt3 19.00 23.00 Stroma
P70 Q4 Pt4 21 18 Stroma
P77 R Ptl 21 53.296 Stroma
P77 R Pt2 23.00 64.533 Stroma
P77 R Pt3 29.00 43.732 Stroma
P77 R Pt4 11 36.525 Nodule
P77 R Pt5 23 38.833 Nodule
P77 L Ptl 14 53.296 Nodule
P77 L Pt2 24.00 64.533 Nodule
P77 L Pt3 11.00 43.732 Stroma
P77 L Pt4 44 52 Nodule
P77 L Pt5 28 45 Nodule
P79 L Ptl 35.1 43 Nodule
P79 L Pt2 31.4 69.00 Nodule
P79 L Pt3 28.1 68.00 Nodule
P79 R Ptl 21.1 58 Nodule
P79 R Pt2 20.6 77.00 Nodule
P79 R Pt3 31.0 57.00 Nodule
P81 L Ptl 31 28 Stroma
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Point % Myo (7x7) %PSA (7x7) Histology
P81 L Pt2 20.00 35.00 Nodule
P81 L Pt3 21.00 37.00 Nodule
P81 L Pt4 23.1 55.31 Nodule
P81 L Pt5 40.46 63 Nodule
P81 R Pt6 27.33 43 Nodule
P81 R Pt7 13.66 45.00 Nodule
P81 R Pt8 30.22 56.00 Nodule
P81 R Pt9 15.7 55 Nodule
P81 RPtlO 29.08 14 Stroma
P81 RPtll 26.98 10 Stroma
P82 R Ptl 11 40.66 Nodule
P82 R Pt2 23.00 66.00 Nodule
P82 R Pt3 15.00 45.00 Stroma
P82 R Pt4 21.00 41.424 Stroma
P82 R Pt5 40 4 Stroma
P82 R Pt6 22.00 11 Stroma
P82 R Pt7 40 6 Stroma
P82 R Pt8 22.00 47.972 Stroma
P82 L Pt9 22 56.255 Stroma
P82 L PtlO 38.00 23.083 Stroma
P82 LPtll 30 0.119 Stroma
P82 L Ptl2 32 22.003 Stroma
P82 L Ptl3 38 12.89 Stroma
P82 L Ptl4 29.00 25.1 Stroma
P82 L Ptl 5 24.00 31.1 Stroma
P82 L Ptl6 27 16.864 Stroma
P82 L Ptl 7 30.00 24.1 Stroma
P82 L Ptl8 23 26.238 Nodule
83-1 Ptl 31.25 25.9 Nodular
83-1 Pt2 19.92 43.46 Nodular
83-1 Pt3 36.01 5.16 Stroma
83-1 Pt4 30.02 12.84 Stroma
83-2 Pt5 19.61 64.23 Nodular
83-2 Pt6 23.74 27.84 Stroma
83-5 Pt7 38.4 22.03 Stroma
83-4 Pt8 11.69 60.31 Nodular
83-4 Pt9 15.64 60.27 Nodular
83-4 PtlO 17.67 69.25 Nodular
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Point % Myo (7x7) %PSA (7x7) Histology
83-3 Ptll 8.81 78.14 Nodular
83-3 Ptl2 8.77 78.3 Nodular
83-5 Ptl3 36.8 18.68 Stroma
84-3 Pt2 25.21 39.31 Stroma
84-3 Pt3 8.9 59.36 Nodular
84-4 Pt4 17.13 31.91 Nodular
84-3 Pt5 23.58 35.45 Stroma
84-4 Pt6 10.61 24.41 Nodular
84-3 Pt7 28.14 15.96 Stroma
84-4 Pt8 32.57 14.63 Stroma
84-3 Pt9 23.5 16.96 Stroma
84-2 PtlO 24.83 58.86 Nodular
84-2 Ptll 30.26 43.54 Nodular
84-1 Ptl2 21.52 43.6 Stroma
84-2 Ptl3 22.91 20.12 Stroma
85-1 Ptl 15.98 62.29 Nodular
85-1 Pt2 35.61 51.49 Nodular
85-1 Pt3 34 46.43 Nodular
85-2 Pt4 32 44.34 Stroma
85-2 Pt5 28.5 48.2 Nodular
85-2 Pt6 21.59 51.25 Stroma
85-3 Pt7 16.2 48.91 Nodular
85-3 Pt8 30.78 34.45 Nodular
85-4 Pt9 33.14 17.49 Stroma
85-4 PtlO 26.89 50.89 Nodular
85-4 Ptll 19.83 55.16 Stroma
85-3 Ptl2 25.63 37.64 Nodular
86-1 Ptl 14.77 29.37 Stroma
86-1 Pt2 30.44 28.67 Stroma
86-2 Pt3 11.53 72.16 Nodular
86-1 Pt4 22.64 23.01 Stroma
86-2 Pt5 20.07 49.84 Nodular
86-2 Pt6 19.97 36.74 Nodular
86-2 Pt7 19.36 51.75 Nodular
86-4 Pt8 16.34 40.96 Stroma
86-4 Pt9 10.21 40.54 Nodular
86-4 PtlO 19.06 53.17 Nodular
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Point % Myo (7x7) %PSA (7x7) Histology
86-3 Ptll 20.56 37.3 Stroma
86-3 Pt 12 32.55 25.26 Stroma
87-1 Ptl 18.67 Stroma
87-1 Pt2 22.87 Nodular
87-1 Pt3 24.71 Nodular
87-2 Pt4 27.99 35.13 Stroma
87-2 Pt5 29.75 37.48 Nodular
87-2 Pt6 25.09 46.6 Nodular
88-1 Ptl 16 31.95 Stroma
88-1 Pt2 16.05 17.62 Stroma
88-1 Pt3 21.26 41.45 Nodular
88-1 Pt4 23.29 46.95 Nodular
88-2 Pt5 22.98 39.26 Stroma
88-2 Pt6 23.04 42.5 Stroma
88-3 Pt7 20.53 55.25 Nodular
88-3 Pt8 30.7 51.12 Nodular
89-2 Ptl 32.71 12.55 Stroma
89-1 Pt2 26.75 30.16 Stroma
89-2 Pt3 26.87 18.86 Nodular
89-1 Pt4 15.32 60.13 Nodular
89-1 Pt5 26.78 51.94 Nodular
89-3 Pt6 22.98 38.57 Stroma
89-3 Pt7 22.4 35.42 Stroma
89-4 Pt8 29.17 59.92 Nodular
89-4 Pt9 38.06 41.18 Stroma
89-3 PtlO 20.4 51.13 Nodular
89-4 Ptll 31.78 19.36 Stroma
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Appendix III - Raw data for the capase-3 analysis of apoptosis in prostate tissue
TURP Patients taking Tamsulosin
% Apoptotic Apoptot
Total Cells Apoptotic Cells Cells Intensity Score
25-7
1 170 58 0.34 2 0.68
2 147 96 0.65 1 0.65
3 244 148 0.61 1 0.61
4 260 135 0.52 1 0.52
5 230 132 0.57 1 0.57
6 149 66 0.44 1 0.44
7 306 120 0.39 1 0.39
8 245 177 0.72 1 0.72
9 114 86 0.75 2 1.51
10 49 38 0.78 1 0.78
25-8
1 172 136 0.79 2 1.58
2 221 79 0.36 2 0.71
3 136 116 0.85 2 1.71
4 179 121 0.68 3 2.03
5 151 127 0.84 2 1.68
6 42 24 0.57 2 1.14
7 165 116 0.70 3 2.11
8 234 120 0.51 3 1.54
9 162 82 0.51 3 1.52
10 201 155 0.77 2 1.54
28-1
1 229 103 0.45 1 0.45
2 253 109 0.43 1 0.43
3 284 184 0.65 1 0.65
4 240 190 0.79 1 0.79
5 211 121 0.57 1 0.57
6 213 141 0.66 1 0.66
7 281 108 0.38 1 0.38
8 207 160 0.77 1 0.77
9 223 98 0.44 2 0.88
10 272 77 0.28 3 0.85
28-2
1 251 106 0.42 2 0.84
2 193 78 0.40 2 0.81
3 171 81 0.47 3 1.42
4 254 56 0.22 1 0.22
5 163 52 0.32 1 0.32
6 159 43 0.27 1 0.27
7 175 42 0.24 1 0.24













% Apoptotic Apoptotic Cells/10 Apoptotic
Total Cells Apoptotic Cells Cells Intensity Score fields Cells Apoptotic Score
1497 1319 1.39
9 251 35 0.14 1 0.14
10 263 83 0.32 1 0.32
31-2
1 179 172 0.96 1 0.96
2 173 151 0.87 2 1.75
3 129 106 0.82 2 1.64
4 149 124 0.83 2 1.66
5 172 152 0.88 2 1.77
6 138 129 0.93 1 0.93
7 168 141 0.84 1 0.84
8 144 138 0.96 1 0.96
9 118 102 0.86 2 1.73
10 127 104 0.82 2 1.64
31-5
1 292 278 0.95 2 1.90
2 151 0 0.00 0 0.00
3 158 0 0.00 0 0.00
4 164 0 0.00 0 0.00
5 132 91 0.69 1 0.69
6 173 98 0.57 1 0.57
7 180 46 0.26 1 0.26
8 135 0 0.00 0 0.00
9 172 0 0.00 0 0.00
10 211 17 0.08 1 0.08
54-1
1 138 0 0.00 0 0.00
2 153 0 0.00 0 0.00
3 194 0 0.00 0 0.00
4 240 0 0.00 0 0.00
5 231 0 0.00 0 0.00
6 261 0 0.00 0 0.00
7 197 0 0.00 0 0.00
8 198 0 0.00 0 0.00
9 161 0 0.00 0 0.00
10 145 0 0.00 0 0.00
54-3
1 220 93 0.42 2 0.85
2 87 55 0.63 2 1.26
3 165 113 0.68 2 1.37
4 193 64 0.33 2 0.66
5 222 141 0.64 1 0.64
6 154 104 0.68 1 0.68
7 216 138 0.64 3 1.92
8 143 62 0.43 3 1.30







%Apoptotic Apoptotic Cells/10 Apoptotic
Total Cells Apoptotic Cells Cells Intensity Score fields Cells Apoptotic Score
1928 819 0.66
10 113 38 0.34 2 0.67
55-5
1 278 181 0.65 1 0.65
2 234 70 0.30 2 0.60
3 232 93 0.40 2 0.80
4 118 83 0.70 1 0.70
5 172 75 0.44 1 0.44
6 211 51 0.24 2 0.48
7 191 105 0.55 2 1.10
8 200 87 0.44 2 0.87
9 115 43 0.37 2 0.75
10 177 31 0.18 1 0.18
55-6
1 148 85 0.57 2 1.15
2 105 71 0.68 1 0.68
3 83 64 0.77 1 0.77
4 78 33 0.42 1 0.42
5 98 75 0.77 1 0.77
6 87 58 0.67 2 1.33
7 115 92 0.80 1 0.80
8 102 82 0.80 1 0.80
9 88 79 0.90 2 1.80
10 109 93 0.85 2 1.71
67-3
1 124 87 0.70 1 0.70
2 96 82 0.85 1 0.85
3 177 96 0.54 1 0.54
4 179 87 0.49 2 0.97
5 136 100 0.74 2 1.47
6 155 89 0.57 1 0.57
7 216 138 0.64 2 1.28
8 240 125 0.52 2 1.04
9 182 73 0.40 2 0.80
10 188 148 0.79 2 1.57
67-5
1 176 92 0.52 1 0.52
2 326 87 0.27 1 0.27
3 302 119 0.39 1 0.39
4 289 98 0.34 2 0.68
5 269 79 0.29 2 0.59
6 216 134 0.62 1 0.62
7 211 97 0.46 1 0.46
8 139 116 0.83 2 1.67
9 151 68 0.45 2 0.90










Total Apoptotic Apoptotic Apoptotic
1 1
Cells Cells Cells Intensity Score
J I
1 229 90 0.393013 2 0.786026
2 119 82 0.689076 1 0.689076
3 228 58 0.254386 1 0.254386
4 191 103 0.539267 2 1.078534
5 197 152 0.771574 2 1.543147
6 206 118 0.572816 2 1.145631
7 115 53 0.46087 2 0.921739
8 250 0 0 0 0
9 211 81 0.383886 2 0.767773
10 198 139 0.70202 2 1.40404
.0-2
1 171 150 0.877193 2 1.754386
2 178 143 0.803371 2 1.606742
3 124 119 0.959677 2 1.919355
4 186 0 0 0 0
5 189 172 0.910053 2 1.820106
6 198 164 0.828283 2 1.656566
7 158 148 0.936709 2 1.873418
8 169 102 0.60355 2 1.207101
9 203 149 0.73399 2 1.46798
10 226 118 0.522124 2 1.044248
10-3
1 92 65 0.706522 2 1.413043
2 89 62 0.696629 2 1.393258
3 114 96 0.842105 2 1.684211
4 125 105 0.84 2 1.68
5 112 102 0.910714 2 1.821429
6 79 58 0.734177 2 1.468354
7 108 86 0.796296 2 1.592593
8 74 61 0.824324 2 1.648649
9 79 59 0.746835 2 1.493671
10 103 82 0.796117 2 1.592233
'4-3
1 112 73 0.651786 3 1.955357
2 124 75 0.604839 3 1.814516
3 199 171 0.859296 3 2.577889
4 167 105 0.628743 3 1.886228
5 169 75 0.443787 3 1.331361
6 151 102 0.675497 2 1.350993








Total Apoptotic Apoptotic Apoptotic
Cells Cells Cells Intensity Score
7 118 81 0.686441 2 1.372881
8 144 121 0.840278 2 1.680556
9 179 142 0.793296 2 1.586592
10 178 94 0.52809 2 1.05618
74-4
1 204 168 0.823529 1 0.823529
2 144 108 0.75 1 0.75
3 233 173 0.742489 1 0.742489
4 113 61 0.539823 2 1.079646
5 124 70 0.564516 2 1.129032
6 116 78 0.672414 2 1.344828
7 189 107 0.566138 2 1.132275
8 155 76 0.490323 2 0.980645
9 180 143 0.794444 2 1.588889
10 161 91 0.565217 1 0.565217
76-5
1 184 52 0.282609 1 0.282609
2 213 139 0.652582 1 0.652582
3 137 0 0 0 0
4 158 92 0.582278 1 0.582278
5 256 69 0.269531 1 0.269531
6 226 0 0 0 0
7 248 0 0 0 0
8 251 72 0.286853 1 0.286853
9 185 153 0.827027 1 0.827027
10 235 78 0.331915 1 0.331915
76-8
1 138 124 0.898551 2 1.797101
2 186 139 0.747312 2 1.494624
3 177 96 0.542373 2 1.084746
4 167 119 0.712575 3 2.137725
5 117 81 0.692308 2 1.384615
6 137 95 0.693431 2 1.386861
7 115 58 0.504348 2 1.008696
8 94 71 0.755319 2 1.510638
9 164 112 0.682927 2 1.365854
10 128 112 0.875 2 1.75







TURP Patients not receiving
medication
%
Total Apoptotic Apoptotic Apoptotic
Cells Cells Cells Intensity Score
>4-2
1 82 0 0 0 0
2 69 0 0 0 0
3 134 0 0 0 0
4 105 0 0 0 0
5 126 92 0.730159 1 0.730159
6 136 121 0.889706 1 0.889706
7 124 91 0.733871 1 0.733871
8 94 58 0.617021 1 0.617021
9 82 51 0.621951 1 0.621951
10 1 18 71 0.601695 1 0.601695
>1-5
1 130 116 0.892308 1 0.892308
2 187 137 0.73262 1 0.73262
3 251 58 0.231076 1 0.231076
4 238 153 0.642857 1 0.642857
5 179 108 0.603352 1 0.603352
6 146 91 0.623288 2 1.246575
7 151 124 0.821192 2 1.642384
8 114 90 0.789474 1 0.789474
9 159 109 0.685535 1 0.685535
10 195 171 0.876923 2 1.753846
>3-4
1 143 59 0.412587 1 0.412587
2 115 75 0.652174 1 0.652174
3 120 106 0.883333 1 0.883333
4 176 102 0.579545 2 1.159091
5 159 68 0.427673 1 0.427673
6 129 98 0.75969 1 0.75969
7 86 63 0.732558 2 1.465116
8 91 83 0.912088 2 1.824176
9 172 159 0.924419 1 0.924419
10 204 0 0 0 0
>6-4
1 194 78 0.402062 1 0.402062
2 144 91 0.631944 1 0.631944
3 177 143 0.80791 1 0.80791
4 164 121 0.737805 1 0.737805
5 156 106 0.679487 1 0.679487
6 218 108 0.495413 1 0.495413
7 224 98 0.4375 1 0.4375
8 154 0 0 0 0
















Total Apoptotic Apoptotic Apoptotic
Cells Cells Cells Intensity Score
10 155 131 0.845161 0 0
53-3
1 112 94 0.839286 2 1.678571
2 202 96 0.475248 1 0.475248
3 190 72 0.378947 2 0.757895
4 139 89 0.640288 2 1.280576
5 89 71 0.797753 2 1.595506
6 201 83 0.412935 2 0.825871
7 212 81 0.382075 2 0.764151
8 166 70 0.421687 2 0.843373
9 135 119 0.881481 2 1.762963
10 126 102 0.809524 2 1.619048
33-4
1 163 79 0.484663 2 0.969325
2 178 98 0.550562 2 1.101124
3 150 119 0.793333 1 0.793333
4 243 216 0.888889 1 0.888889
5 181 126 0.696133 2 1.392265
6 118 73 0.618644 2 1.237288
7 158 94 0.594937 2 1.189873
8 93 71 0.763441 2 1.526882
9 142 68 0.478873 2 0.957746
10 167 108 0.646707 2 1.293413
75-1
1 67 46 0.686567 2 1.373134
2 189 59 0.312169 1 0.312169
3 88 72 0.818182 2 1.636364
4 72 51 0.708333 3 2.125
5 159 105 0.660377 3 1.981132
6 106 58 0.54717 2 1.09434
7 146 115 0.787671 2 1.575342
8 154 120 0.779221 2 1.558442
9 129 112 0.868217 2 1.736434
10 132 78 0.590909 2 1.181818
75-4
1 205 0 0 0 0
2 153 0 0 0 0
3 176 0 0 0 0
4 205 0 0 0 0
5 241 0 0 0 0
6 137 64 0.467153 1 0.467153
7 227 175 0.770925 1 0.770925
8 165 122 0.739394 1 0.739394
9 223 108 0.484305 1 0.484305


























































Radical Prostatectomy Patients taking Tamsulosin
Total Total
Total Apoptotic % Apoptotic Apoptotic Cells/10 Apoptotic Apop
Cells Cells Cells Intensity Score fields Cells Score
139 83 0.597122 2 1.194245
143 119 0.832168 2 1.664336
163 123 0.754601 1 0.754601
147 102 0.693878 2 1.387755
154 125 0.811688 2 1.623377
158 134 0.848101 2 1.696203
152 131 0.861842 2 1.723684
139 114 0.820144 2 1.640288
179 154 0.860335 2 1.72067
173 86 0.49711 3 1.491329
131 122 0.931298 1 0.931298
152 114 0.75 1 0.75
150 120 0.8 2 1.6
136 85 0.625 1 0.625
154 142 0.922078 2 1.844156
125 95 0.76 1 0.76
142 102 0.71831 1 0.71831
136 98 0.720588 1 0.720588
148 118 0.797297 2 1.594595
181 149 0.823204 2 1.646409
76 76 1 1 1
109 78 0.715596 1 0.715596
160 114 0.7125 1 0.7125
120 76 0.633333 2 1.266667
98 54 0.55102 2 1.102041
131 102 0.778626 1 0.778626
101 38 0.376238 1 0.376238
119 88 0.739496 2 1.478992
108 72 0.666667 2 1.333333
105 81 0.771429 2 1.542857
163 101 0.619632 2 1.239264
180 152 0.844444 2 1.688889
124 81 0.653226 2 1.306452
188 153 0.81383 2 1.62766
158 125 0.791139 2 1.582278
176 121 0.6875 2 1.375
168 0 0 0 0
125 93 0.744 1 0.744














































Apoptotic % Apoptotic Apoptotic
Cells Cells Intensity Score
82 0.635659 1 0.635659
63 0.663158 1 0.663158
94 0.810345 1 0.810345
69 0.71134 2 1.42268
0 0 0 0
0 0 0 0
89 0.872549 1 0.872549
119 0.922481 0 0
86 0.434343 2 0.868687
74 0.544118 2 1.088235
84 0.435233 2 0.870466
81 0.870968 1 0.870968
75 0.842697 1 0.842697
129 0.969925 1 0.969925
42 0.893617 1 0.893617
64 0.810127 1 0.810127
65 0.747126 2 1.494253
81 0.778846 1 0.778846
61 0.693182 1 0.693182
112 0.868217 2 1.736434
64 0.477612 1 0.477612
75 0.789474 2 1.578947
0 0 0 0
168 0.965517 1 0.965517
0 0 0 0
98 0.695035 1 0.695035
0 0 0 0
0 0 0 0
0 0 0 0
75 1 1 1
112 0.854962 1 0.854962
86 0.895833 2 1.791667
71 0.845238 2 1.690476
138 0.873418 2 1.746835
119 0.862319 2 1.724638
92 0.821429 2 1.642857
88 0.838095 2 1.67619
146 0.752577 2 1.505155
81 0.852632 1 0.852632
154 0.911243 1 0.911243



































Apoptotic % Apoptotic Apoptotic
Cells Cells Intensity Score
0 0 0 0
0 0 0 0
0 0 0 0
152 0.808511 1 0.80851 1
23 0.127072 1 0.127072
0 0 0 0
0 0 0 0
0 0 0 0
0 0 0 0
0 0 0 0
42 0.446809 2 0.893617
138 0.775281 2 1.550562
154 0.797927 2 1.595855
119 0.643243 1 0.643243
64 0.397516 1 0.397516
72 0.433735 1 0.433735
154 0.706422 1 0.706422
72 0.507042 2 1.014085
142 0.78453 2 1.569061









Radical Prostatectomy Patients taking Alfuzosin
Total % Apoptotic Apoptotic
Cells Apoptotic Cells Cells Intensity Score
524L
1 168 0 0 0 0
2 151 0 0 0 0
3 118 0 0 0 0
4 169 0 0 0 0
5 128 38 0.296875 1 0.296875
6 171 0 0 0 0
7 165 0 0 0 0
8 185 0 0 0 0
9 124 102 0.822581 1 0.822581
10 138 121 0.876812 1 0.876812
524M
1 138 124 0.898551 2 1.797101
2 241 38 0.157676 1 0.157676
3 217 16 0.073733 1 0.073733
4 133 121 0.909774 1 0.909774
5 227 10 0.044053 1 0.044053
6 232 24 0.103448 2 0.206897
7 213 39 0.183099 2 0.366197
8 188 53 0.281915 2 0.56383
9 190 49 0.257895 2 0.515789
10 118 24 0.20339 1 0.20339
35741
1 203 152 0.748768 1 0.748768
2 142 69 0.485915 1 0.485915
3 165 102 0.618182 2 1.236364
4 172 6 0.034884 1 0.034884
5 224 0 0 0 0
6 239 0 0 0 0
7 183 121 0.661202 3 1.983607
8 173 0 0 0 0
9 161 0 0 0 0
10 114 74 0.649123 1 0.649123
3574L
1 150 124 0.826667 2 1.653333
2 162 139 0.858025 1 0.858025
3 169 145 0.857988 2 1.715976
4 146 131 0.89726 1 0.89726
5 131 94 0.717557 2 1.435115
6 134 102 0.761194 2 1.522388
7 114 98 0.859649 2 1.719298
8 122 109 0.893443 2 1.786885
9 142 114 0.802817 2 1.605634



































































































Apoptotic Cells/10 Apoptotic Apop
Score fields Cells Score










































































































% Apoptotic Apoptotic Cells/10 Apoptotic Apop
Apoptotic Cells Cells Intensity Score fields Cells Score
0 0 0 0
0 0 0 0
0 0 0 0
0 0 0 0
92 0.681481 1 0.681481
118 0.802721 1 0.802721
132 0.795181 1 0.795181
0 0 0 0
78 0.609375 1 0.609375
122 0.890511 1 0.890511
132 0.846154 1 0.846154
81 0.663934 1 0.663934
79 0.897727 1 0.897727
78 0.644628 1 0.644628
39 0.47561 2 0.95122
116 0.935484 1 0.935484
92 0.968421 2 1.936842
71 0.855422 2 1.710843
124 0.832215 1 0.832215





Radical Prostatectomy Patients no medication
Total % Apoptotic Apoptotic
Cells Apoptotic Cells Cells Intensity Score
114420
1 142 0 0 0 0
2 150 92 0.613333 2 1.226667
3 148 113 0.763514 1 0.763514
4 154 116 0.753247 1 0.753247
5 143 92 0.643357 2 1.286713
6 151 53 0.350993 1 0.350993
7 195 43 0.220513 2 0.441026
8 120 42 0.35 2 0.7
9 145 52 0.358621 2 0.717241
10 162 82 0.506173 1 0.506173
16921N
1 80 0 0 0 0
2 160 112 0.7 1 0.7
3 122 110 0.901639 1 0.901639
4 66 0 0 0 0
5 104 0 0 0 0
6 117 62 0.529915 1 0.529915
7 180 0 0 0 0
8 159 54 0.339623 2 0.679245
9 129 78 0.604651 2 1.209302
10 176 84 0.477273 2 0.954545
2153G
1 120 0 0 0 0
2 129 84 0.651163 2 1.302326
3 125 72 0.576 2 1.152
4 244 81 0.331967 1 0.331967
5 141 0 0 0 0
6 197 110 0.558376 1 0.558376
7 88 51 0.579545 2 1.159091
8 99 40 0.40404 2 0.808081
9 153 97 0.633987 1 0.633987
10 124 81 0.653226 1 0.653226
4559N
1 165 58 0.351515 1 0.351515
2 112 55 0.491071 2 0.982143
3 147 81 0.55102 1 0.55102
4 185 86 0.464865 2 0.92973
5 156 52 0.333333 1 0.333333
6 109 43 0.394495 2 0.788991
7 102 64 0.627451 2 1.254902
8 133 46 0.345865 2 0.691729
9 121 33 0.272727 2 0.545455
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Appendix IV - Raw data for the TUNEL assay analysis of apoptosis in prostate
tissue
TURP patients taking Tamsulosin
Total Total
Cell Apoptotic Cell Apoptotic Cells/10 Apoptotic Apop






1 236 2 0.008475
2 167 13 0.077844
3 237 10 0.042194
4 187 4 0.02139
5 176 11 0.0625
6 187 7 0.037433
7 129 1 0.007752
8 421 0 0
9 415 2 0.004819
10 178 8 0.044944
1 126 10 0.079365
2 118 19 0.161017
3 218 95 0.43578
4 222 63 0.283784
5 196 82 0.418367
6 176 0 0
7 197 1 0.005076
8 259 1 0.003861
9 159 31 0.194969
10 106 14 0.132075
1 223 2 0.008969
2 269 12 0.04461
3 149 33 0.221477
4 204 70 0.343137
5 325 23 0.070769
6 262 14 0.053435
7 169 12 0.071006
8 308 30 0.097403
9 287 31 0.108014
10 157 6 0.038217
1 215 0 0
2 255 0 0
3 251 0 0
4 218 0 0
5 283 0 0
6 233 0 0







Cell Apoptotic Cell Apoptotic Cells/10 Apoptotic Apop





8 279 0 0
9 260 0 0
10 459 0 0
1 213 4 0.018779
2 221 12 0.054299
3 169 6 0.035503
4 246 13 0.052846
5 121 9 0.07438
6 228 10 0.04386
7 143 3 0.020979
8 228 6 0.026316
9 224 7 0.03125
10 416 11 0.026442
1 181 15 0.082873
2 214 12 0.056075
3 222 14 0.063063
4 197 1 0.005076
5 215 0 0
6 253 3 0.011858
7 176 0 0
8 224 3 0.013393
9 176 2 0.011364
10 195 1 0.005128
1 319 14 0.043887
2 269 25 0.092937
3 426 15 0.035211
4 195 0 0
5 209 0 0
6 207 1 0.004831
7 138 0 0
8 234 8 0.034188
9 275 5 0.018182
10 314 11 0.035032
1 163 26 0.159509
2 134 39 0.291045
3 150 32 0.213333
4 94 23 0.244681
5 67 51 0.761194
6 82 34 0.414634
7 105 21 0.2








Cell Apoptotic Cell Apoptotic Cells/10 Apoptotic Apop





9 119 8 0.067227
10 149 14 0.09396
1 87 0 0
2 142 0 0
3 118 0 0
4 199 0 0
5 269 0 0
6 167 0 0
7 129 0 0
8 226 0 0
9 151 0 0
10 125 0 0
1 361 0 0
2 364 0 0
3 331 1 0.003021
4 394 0 0
5 361 0 0
6 379 0 0
7 348 0 0
8 296 0 0
9 421 0 0
10 148 0 0
1 165 0 0
2 169 0 0
3 118 0 0
4 146 0 0
5 134 0 0
6 150 0 0
7 166 0 0
8 156 1 0.00641
9 49 0 0
10 113 0 0
1 279 0 0
2 189 0 0
3 289 0 0
4 228 0 0
5 290 0 0
6 268 0 0
7 223 0 0
8 237 0 0







10 262 0 0
TURP patients taking Alfuzosin
Image
3







fields Cells % Apoptosis
1 120 0 0
2 269 42 0.156134
3 140 67 0.478571
4 143 74 0.517483
5 268 87 0.324627
6 178 13 0.073034
7 262 0 0
8 146 0 0




1 163 41 0.251534
2 145 86 0.593103
3 147 73 0.496599
4 260 25 0.096154
5 265 36 0.135849
6 191 72 0.376963
7 190 62 0.326316
8 179 21 0.117318





1 238 95 0.39916
2 197 98 0.497462
3 135 112 0.82963
4 221 86 0.38914
5 182 159 0.873626
6 171 109 0.637427
7 181 54 0.298343
8 239 63 0.263598





1 124 43 0.346774
2 39 10 0.25641
3 94 29 0.308511
4 54 12 0.222222
5 161 1 0.006211
6 167 0 0








Cell Apoptotic Cell Apoptotic Cells/6 Apoptotic
Image Total Total Index fields Cells % Apoptosis
8 67 19 0.283582
9 133 35 0.263158
10 84 31 0.369048
74-4
1 204 42 0.205882
2 165 89 0.539394
3 230 124 0.53913
4 192 94 0.489583
5 178 92 0.516854
6 206 89 0.432039
7 209 102 0.488038
8 145 111 0.765517
9 163 59 0.361963
10 200 56 0.28
76-5
1 238 14 0.058824
2 200 7 0.035
3 236 6 0.025424
4 149 0 0
5 202 0 0
6 232 2 0.008621
7 195 4 0.020513
8 212 0 0
9 128 2 0.015625
10 189 16 0.084656
76-8
1 216 3 0.013889
2 203 0 0
3 232 6 0.025862
4 209 2 0.009569
5 234 8 0.034188
6 179 3 0.01676
7 183 12 0.065574
8 131 37 0.282443
9 128 0 0






TURP patients taking no medications
Total Total
Apoptotic Cell Cells/6 Apoptotic %
Image Cell Total Total Apoptotic Index fields Cells Apoptosis
24-2
902 15 0.021 101 1 0.009901
2 95 0 0
3 58 0 0
4 101 3 0.029703
5 62 0 0
6 94 0 0
7 53 0 0
8 93 1 0.010753
9 135 5 0.037037
10 110 5 0.045455
5
l 266 0 0
2 182 0 0
3 171 0 0
4 168 0 0
5 243 0 0
6 198 0 0
7 135 0 0
8 228 0 0






2 207 0 0
3 176 0 0
4 127 0 0
5 184 0 0
6 179 1 0.005587
7 245 0 0
8 238 0 0




l 268 0 0
2 212 0 0
3 227 0 0
4 147 0 0
5 215 0 0
6 168 0 0
7 145 0 0
8 162 0 0
9 169 0 0







Apoptotic Cell Cells/6 Apoptotic %




1 226 0 0
2 106 0 0
3 132 0 0
4 141 0 0
5 218 0 0
6 188 0 0
7 172 0 0
8 206 0 0





1 90 4 0.044444
2 231 0 0
3 167 1 0.005988
4 209 5 0.023923
5 173 5 0.028902
6 168 90.053571
7 176 3 0.017045
8 225 1 0.004444





l 176 2 0.011364
2 144 20.013889
3 226 0 0
4 236 1 0.004237
5 122 2 0.016393
6 239 0 0
7 153 2 0.013072
8 150 3 0.02





1 158 0 0
2 156 0 0
3 224 0 0
4 202 0 0
5 214 0 0
6 239 0 0
7 198 0 0
8 324 0 0
9 247 1 0.004049






RRP patients taking Tamsulosin
Apoptotic Cell






















1 203 3 0.014778
2 238 3 0.012605
3 205 2 0.009756
4 237 0 0
5 228 0 0
6 158 0 0
7 174 1 0.005747
8 201 0 0
9 162 0 0
10 109 0 0
1 155 1 0.006452
2 181 3 0.016575
3 111 0 0
4 235 9 0.038298
5 141 3 0.021277
6 210 2 0.009524
7 182 2 0.010989
8 216 6 0.027778
9 190 3 0.015789
10 97 2 0.020619
1 168 0 0
2 199 0 0
3 227 0 0
4 256 15 0.058594
5 218 7 0.03211
6 171 3 0.017544
7 191 1 0.005236
8 264 6 0.022727
9 273 0 0













Image Cell Total Total Apoptotic Index
8324E
1 124 0 0
2 127 0 0
3 144 0 0
4 124 0 0
5 115 0 0
6 161 0 0
7 131 0 0
8 119 1 0.008403
9 102 1 0.009804
10 125 1 0.008
83241
1 153 0 0
2 168 0 0
3 179 0 0
4 198 2 0.010101
5 227 2 0.008811
6 142 0 0
7 113 0 0
8 149 1 0.006711
9 164 0 0
10 57 0 0
1070J
1 208 0 0
2 214 0 0
3 209 0 0
4 164 0 0
5 113 0 0
6 115 0 0
7 151 0 0
8 144 0 0
9 133 3 0.022556
10 118 0 0
12097J
1 123 0 0
2 146 0 0
3 155 0 0
4 185 1 0.005405
5 219 6 0.027397
6 198 2 0.010101
7 175 1 0.005714
8 143 0 0
9 136 0 0





































Apoptotic Index fields Cells % Apoptosis






















RRP patients taking Alfuzosin
Total







1 131 1 0.007634
2 74 3 0.040541
3 113 0 0
4 114 0 0
5 144 4 0.027778
6 197 0 0
7 143 0 0
8 147 0 0
9 217 1 0.004608
10 185 0 0
13566J
1 161 0 0
2 168 0 0
3 128 0 0
4 195 0 0
5 151 0 0
6 126 0 0
7 115 1 0.008696
8 130 0 0
9 136 0 0
10 128 0 0
13566K
1 126 1 0.007937
2 158 0 0
3 124 1 0.008065
4 140 0 0
5 166 0 0
6 195 0 0
7 179 0 0
8 181 0 0
9 148 0 0
10 119 0 0
179620
1 98 1 0.010204
2 226 3 0.013274
3 205 6 0.029268
4 195 3 0.015385
5 138 0 0
6 128 0 0
7 81 0 0
8 79 0 0
9 189 2 0.010582



















1 202 0 0
2 235 2 0.008511
3 167 1 0.005988
4 236 0 0
5 149 1 0.006711
6 104 0 0
7 76 1 0.013158
8 109 0 0
9 159 0 0
10 170 2 0.011765
1 193 1 0.005181
2 224 0 0
3 243 0 0
4 137 0 0
5 119 0 0
6 206 0 0
7 207 0 0
8 198 1 0.005051
9 185 1 0.005405
10 143 0 0
1 131 2 0.015267
2 83 0 0
3 129 2 0.015504
4 151 1 0.006623
5 143 0 0
6 135 1 0.007407
7 157 0 0
8 133 1 0.007519
9 154 0 0
10 137 0 0
1 192 0 0
2 268 4 0.014925
3 253 6 0.023715
4 265 3 0.011321
5 84 0 0
6 175 0 0
7 109 0 0
8 157 0 0
9 128 2 0.015625












Cell Apoptotic Cell Apoptotic Cells/6 Apoptotic %
Image Total Total Index fields Cells Apoptosis
105719J
1 119 1 0.008403
2 107 3 0.028037
3 121 2 0.016529
4 134 0 0
5 145 1 0.006897
6 101 1 0.009901
7 123 0 0
8 112 0 0
9 159 0 0
10 160 0 0
3574L
1 152 0 0
2 172 1 0.005814
3 179 0 0
4 174 1 0.005747
5 170 0 0
6 152 0 0
7 224 3 0.013393
8 203 2 0.009852
9 178 0 0
10 176 0 0
261
Appendix IV
RRP patients taking no medications
Cell Apoptotic Cell Apoptotic
Image Total Total Index
114420
1 130 3 0.023077
2 188 1 0.005319
3 86 0 0
4 304 1 0.003289
5 156 0 0
6 170 4 0.023529
7 196 1 0.005102
8 118 0 0
9 94 1 0.010638
10 139 1 0.007194
16921N
1 186 3 0.016129
2 145 0 0
3 134 0 0
4 161 3 0.018634
5 130 4 0.030769
6 141 0 0
7 143 2 0.013986
8 120 0 0
9 112 0 0
10 143 0 0
2153G
1 108 0 0
2 171 3 0.017544
3 170 4 0.023529
4 135 3 0.022222
5 199 1 0.005025
6 173 2 0.011561
7 110 0 0
8 110 0 0
9 125 2 0.016





1 238 1 0.004202
2 227 0 0
3 134 0 0
4 195 1 0.005128
5 161 1 0.006211
6 69 0 0
7 174 0 0
8 200 0 0
9 135 1 0.007407
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Appendix V - Presentations arising from this work
April 2006 "Morphometric analysis of the prostate demonstrates the importance of the
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European Association ofUrology Annual Meeting, Paris
April 2006 "The relationship between loco-regional morphology and the mechanical
characteristics of benign prostate tissue"
Scottish Urological Society, Edinburgh
June 2006 "Structure-property relationships for assessing tissue quality to aid diagnosis
of prostate disease"
Postgraduate Research Conference, Heriot-Watt University, Edinburgh
Sept 2006 "The relationship between the mechanical and morphological characteristics
of hyperplastic glandular nodules and stroma
British Prostate Group, Cardiff
Oct 2006 "The differences in morphological and mechanical characteristics between
glandular nodules and stroma in benign prostate tissue"
The Royal College of Surgeons of Edinbugh and the College of Surgeons
Hong Kong, Cojoint Scientific Congress, Hong Kong
May 2008 "The relationship between alpha blocker therapy, apoptosis and the
morphometric and mechanical properties of prostate tissue"
American Urological Association Annual Meeting, Florida
